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Abstract: 
Pharmaceuticals and personal care products (PPCPs) have emerged in recent years as 
a new class of chemical and biological pollutants in our environment.  In the search 
for suitably sensitive and specific techniques for detection of these compounds at 
very low concentrations, liquid chromatography-tandem mass spectrometry (LC-
MS/MS) has emerged as the new technique of choice.  This work describes methods 
for screening and quantification of various pharmaceutical and illicit drug residues in 
solid and liquid environmental and biological matrices.  Particular focus was given to 
efficiency of chosen stationary phase, sample preparation procedures and matrix 
effects which seriously affect the accuracy of LC-MS/MS measurements. 
An analytical method was developed for the analysis of a range of illicit 
drugs in hair samples.  The solid phase extraction procedure was optimised by 
comparison of the extraction efficiency of a range of commercially available 
cartridges.  The method was validated and applied to the detection of cocaine traces 
in the hair of a recreational drug user.  
 In the area of high performance liquid chromatography (HPLC) the 
advantages of new monolithic stationary phases over traditional particle packed beds 
is becoming apparent.  In this work, the performance of a half-metre monolithic 
column was characterised using van Deemter plots.  The separation efficiency of the 
monolith was compared to that of a conventional particulate column with promising 
results.  Investigations into loading capacity and peak capacity of the half-metre 
monolith also highlighted the suitability of the long monolith for the screening of 
large numbers of pharmaceutical compounds. 
The half-metre monolithic column was applied to the analysis of 
pharmaceuticals and personal care products (PPCPs) in complex environmental and 
biological samples.  The effects of ion suppression on mass spectrometric sensitivity 
for detection of pharmaceuticals in extracts of both soil and sludge were quantified 
for the long monolithic column and a particle packed column.  The half-metre 
monolith demonstrated less ion suppression for the majority of analytes.  The 
monolith was then applied to the determination of PPCPs in urine samples with 
minimal sample preparation. 
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1.1 Introduction: 
In the late 1990’s pharmaceuticals and personal care products (PPCPs) began to receive 
attention as a newly emerging group of chemical pollutants which had previously been 
overlooked.  These substances are of environmental interest as they are designed to have 
a biological effect and not enough is known about their fate after excretion from humans 
and animals.  One of the earliest references to introduce pharmaceuticals as potential 
environmental pollutants was presented in 1985 by Richardson and Bowran.  Here the 
presence of pharmaceuticals in human and industrial waste entering aquatic 
environments was introduced.1  In the 1990’s improved analytical instrumentation and 
techniques led to greater sensitivity meaning that the detection of trace levels of 
chemicals in environmental samples was no longer out of reach.  The advent of these 
modern technologies such as soft ionisation interfaces for mass spectrometry e.g. 
electrospray (ESI) and atmospheric pressure chemical ionisation (APCI) resulted in an 
exponential increase in publications dealing with the analysis of PPCPs from 2000 
onwards.  Originally most research was focused on identification and monitoring of the 
compounds particularly in aquatic environments.2  More recently the scope of research 
has broadened to cover the treatment and fate of the organic pollutants in the 
environment.  Other areas of interest include methods of PPCP removal as well as the 
analysis of more complex sample matrices such as soil and sludge.3 
The term PPCP was first introduced in 1999 in a publication by Daughton and 
Ternes.4  From this publication the term PPCP covered all pharmaceuticals either for 
human and veterinary use which are prescription or over the counter (OTC) products.  
The term also includes both licit and illicit drugs, active pharmaceuticals added to 
personal care products such as soaps, shampoo, sun block and perfumes, and 
nutraceuticals.4  Endocrine disrupting chemicals (EDCs) are not included under the 
heading of PPCP in this work although it should be noted that some PPCPs are known to 
have EDC properties e.g. phthalates.5  Pesticides are also excluded, however it should be 
noted that some compounds classified as pesticides e.g. triclosan and triclocarban are 
commonly present in everyday consumer products.6  Metabolites of parent compounds 
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must also be considered as relevant.  During the metabolism and treatment of animal and 
human waste products, conjugates and transformation products are formed.  These 
metabolites can have heightened solubility, increased, decreased or alternative biological 
effect and could also provide information regarding the total concentration of the parent 
drug reaching being excreted by a population.7  
Drug development and usage is increasing all the time with pharmaceutical 
marketing consultants IMS Health reporting global prescription sales growth of 6.4% to 
712 billion dollars in 2007.8  In 2005, Germany reported 9,000 drug preparations 
approved for use in the EU.  These pharmaceutical preparations were marketed in a total 
of 35,000 products.9  Consumption of prescription medicines by humans represents a 
small fraction of total PPCP utilisation.  Unapproved drug use and consumption of OTC 
remedies as well as cosmetics and other PPCPs which contain harmful compounds must 
also be considered.  In addition to human medicines, veterinary medicines (e.g. growth 
promoters and those used for breeding purposes) and food supplements (e.g. 
nutraceuticals) employed in agriculture must be included.6  From these origins a cocktail 
of potentially harmful chemicals is being released into the environment. 
PPCP residues in environmental samples can originate from both anthropogenic 
and natural sources.  Many of the most effective medicinal products are produced by 
microorganisms (e.g. antibiotics) or modelled on endogenous molecules (e.g. 
hormones).  Pseudo-hormones are designed to mimic the action of naturally occurring 
molecules and so it is difficult to assign an environmental effect to one compound in 
particular.  Ideally, all man-made PPCPs would be completely metabolised within the 
body or would be eliminated after excretion.  However, pharmaceuticals are designed to 
be robust, stable molecules and it is now well known that metabolism is often 
incomplete and that these compounds are surviving wastewater treatment processes.7  
Environmental science has typically dealt with point source contamination where a large 
concentration of a pollutant is released e.g. in industrial effluent or as an industrial 
accident.  This unfortunately is not the case with PPCPs which are continuously 
introduced into the environment in trace quantities by often large populations.  In this 
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way the origins of PPCP accumulation differs from more conventional pollutants in that 
their primary origin is impossible to define.6   
The ‘Oslo Paris Convention for the Protection of the Marine Environment of the 
North East Atlantic’ (OSPAR) provides the current European legislation on the 
protection of the North East Atlantic marine environment.  The convention regulates 
standards on eutrophication, release of hazardous and radioactive substances and oil and 
gas industries.  OSPAR provides a list of priority chemicals that are considered harmful 
to the environment due to their persistence, accumulative abilities and environmental 
toxicity.  Pharmaceuticals such as clotrimazole, (a common antifungal agent) and 
diosgenin, (steroid) were added to the above list in recent years.  Additives to personal 
care products including xylene (a synthetic scent found in perfumes) and certain 
phthalates, dibutylphthalate (DBP) and diethylhexylphthalate (DEHP) were also labelled 
as priority chemicals.10  These compounds are used to such a large extent in so many 
products that it is accepted that they are now almost ubiquitous.11  Recently, research 
into the effects of pthalates on humans and animals has led to disturbing discoveries, 
such as adverse effects on the male sexual reproductive system and associations between 
phthalates and asthma.12, 13  Other studies have revealed that children are particularly at 
risk.14 
Daughton reported in a recent publication that approximately 100 PPCPs have 
been identified in a range of environmental matrices.6  This figure may seem small when 
considering the extent and volume of PPCP consumption and use around the world.  
Several of these methods focus on a small quantity of structurally related compounds to 
allow for sensitive and robust determinations in a range of matrix types.  When using 
broad screening approaches it is often the case that analytical methods are not sensitive 
enough to detect all target compounds.  Furthermore, other PPCPs may not be consumed 
in sufficient quantities to produce a concentration detectable in environmental samples.  
In addition, these substances may be subjected to further transformation as they are 
excreted and treated in sewage treatment plants.  The obvious upshot of this is the 
possibility for harmful metabolites and transformation products being present but 
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undetected.6  The aim of this Chapter is to provide an overview of origins, fate and 
effects of pharmaceuticals and other bioactive compounds in the environment.   
 
1.2 Sources of PPCPs in the Environment: 
Recent studies reporting worrying levels of a wide range of pharmaceuticals in ground 
and surface waters have stimulated interest in the sources and pathways by which these 
compounds reach the external environment.  Conventionally, environmental concerns 
stemmed from contamination at point sources such as industrial processes, 
manufacturing and waste disposal sites.  However it is now accepted that PPCPs are 
primarily introduced to the environment by the mass population.15  Agricultural 
medicines such as antimicrobial compounds, growth promoters and drugs used in animal 
husbandry are metabolised by animals and excreted onto farmland. Manure is often 
applied as fertiliser resulting in possible exposure of sorbed PPCPs which may enter the 
soil or ground water environments through rain events.7  Agricultural sources also 
include aquacultural processes including fish farming. 
There are two main pathways by which the consumer introduces PPCP to the 
exterior environment.  These pathways were defined as ‘involuntarily’ and 
‘purposefully’ by Daughton.6  Involuntary introduction occurs by excretion and washing 
of topical medicines or PCP’s via the sewage system.  Many medicines are not fully 
metabolised within the body and are sometimes only slightly modified when they enter 
the sewage system.  Purposely polluting refers to the disposal of out of date or 
unfinished medications into rubbish or sewage systems.  By these routes bioactive 
PPCPs enter wastewater treatment plants (WWTPs) and landfills.6  Not all PPCP 
residues are eliminated within the WWTP leading to contaminated effluents from these 
treatment plants flowing into surface waters.  Landfill leachate is also an important point 
source as the products dumped at landfill sites have not been metabolised and arrive 
there chemically intact.16  There are, however, some point sources which must be 
considered as sources of PPCP pollution such as leachate from landfill dumps, hospital 
effluent and accidental spills during manufacture.  Drug production is no longer 
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considered to be a significant source of the pollution due to Good Manufacturing 
Practice (GMP) regulations and the enormous costs associated with loss of active 
pharmaceutical ingredient (API).7  The numerous routes of entry for PPCPs are outlined 
in Figure 1.1. 
 There are a number of factors that affect the introduction of PPCPs into the 
environment.  These include the volume of the drug or compound produced and the 
amount consumed (dosage, regularity of consumption), the extent to which the parent 
drug is metabolised within the body and how readily it and its metabolites are excreted.  
Also the extent of metabolism within the WWTPs and finally the ability of the parent 
drug and its metabolites to adsorb onto soil and sludge.3  The problem of 
environmentally persistent is exemplified by the common pharmaceutical clofibric acid 
which is alarmingly stable in aquatic environments and has even been detected in 
drinking water.17, 18   
It is necessary to examine the many degradation pathways of PPCPs within 
animal bodies in order to understand their chemical structure when entering the 
environment.  Studying the metabolic pathways of these compounds in the environment 
is difficult due to the cascade of metabolites originating from a single parent molecule.  
To predict the behaviour of PPCPs in the environment, physical and chemical properties 
need to be studied.  Attributes such as the sorption coefficient (Kdsolid), the, octanol/water 
partition coefficient (Kow) and the organic carbon normalisation coefficient (Koc) can 
provide information on the hydrophobic tendencies of a pharmaceutical.  However, it 
has been shown that sorption of pharmaceuticals to solids is a complex process and that 
other interactions such as cation exchange, bridging mechanisms and hydrogen bonding 
must also be considered.3, 19  While there have been a number of publications detailing 
the fate and effects of PPCPs in aquatic environments2, 4, 20, more focus is required in the 
field of solid matrices such as soil and digested sludge. 
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Figure 1.1: Primary sources and routes of human and veterinary pharmaceuticals into the environment, adapted from ref. 3
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1.3 Drug Metabolism: 
The topic of pharmaceutical metabolism is relevant to the understanding of the fate and 
effects of PPCP in the environment for a number of reasons.  Study of metabolic 
pathways can yield information on the extent to which the parent drug is metabolised, 
the quantities of parent drug and metabolite that are formed and excreted and also the 
structure and bioactivity of the new metabolites can be discovered.  Pharmacokinetics is 
the branch of pharmacology that deals with drug uptake, distribution, modification and 
excretion.21  Drug metabolism takes place mainly in the liver where a series of 
enzymatic reactions alter the chemical structure of the drug, preparing them for 
excretion in urine. 
 In order for a drug to produce the desired effect, it must first travel to the site of 
action within the body.  Manufacturing a drug to achieve this goal is one of the major 
challenges in drug design. The drug must partition through both hydrohilic and 
hydrophobic bodily compartments.  In many cases the lipophilicity of a pharmaceutical 
is increased in order for it to cross lipid cell membranes.  Lipophilic drugs are not easily 
excreted by the body and so they are transformed into more hydrophilic, (polar) 
metabolites that are more suited to elimination by the kidneys.22   
 The transformation of the drug molecule for excretion usually takes place in two 
steps known as the Phase I and Phase II reactions.  The Phase I reaction serves to 
functionalise the drug structure by adding a reactive group to the molecule in preparation 
for the Phase II step.  In Phase II, conjugation of the drug to a large bulky polar moiety 
occurs which labels it for excretion by the kidneys.21   
Phase I reactions include oxidation, reduction, hydroxylation, deamination, 
dealkylation and hydrolysis.21  Phase II reactions include glucuronidation, glycosidation, 
sulfation, methylation and acetylation.  The polar conjugates employed in Phase II 
include sugars, amino acids, fatty acids, acetyl groups and sulphates.  The Phase II 
reactions are controlled by a complex system of enzymes with each type of reaction 
requiring specific co-factors e.g. acetylation of sulfanilamides requires the enzyme 
acetyltransferase and co-factor acetyl-CoA.21  The cytochrome P450 system is the most 
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important group of metabolising enzymes and are located on the endoplasmic reticulum 
of cells particularly in cells of the liver, kidney and intestine.21  An example of the Phase 
I and Phase II steps is presented in Figure 1.2.22 
 
OCOCH3
COOH
OH
COOH
Phase 1
Hydroxylation
Aspirin
Derivative Phase II
Conjugation
Salicyclic Acid Glucuronide
O
COOH O
OH
OH
COOH
OH
 
Figure 1.2: The Phase I and Phase II metabolism of aspirin, adapted from ref. 22 
 
The metabolic reactions and pathways of many pharmaceuticals and commonly 
consumed medicines are well known, as depicted in Figure 1.2.  However, within 
human populations, there are significant variations in metabolic enzymes, including 
cytochrome P450 enzymes.22  This means that even if pharmacokinetic data has been 
obtained for a pharmaceutical, it cannot be universally applied to all individuals.  
Tracking metabolic processes become more complex when inhibiting and inductive 
factors are considered.  Inducing substances cause an increase in the activity of 
metabolising enzymes resulting in increased elimination of the inducing drug itself or 
rapid biotransformation of other pharmaceuticals in the body.  This is exemplified by 
ethanol which increases the activity of microsomal oxidase with repeated consumption.22  
Inhibition of metabolism is exemplified by the anti-ulcer drug cimetidine which binds to 
cytochrome P450, halting the enzymes activity.21  All of these factors must be 
considered when answering the questions listed at the start of this section.  Inhibiting 
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agents will cause retention of therapeutics and medicines within the body while inducers 
will promote elimination of the compounds at an increased rate 
PPCPs excreted from the body after metabolism as a pharmacologically inactive 
species are not of great concern.  However, excreted drug metabolites are not always 
inactive.  Pharmaceuticals may be designed to only become active after metabolism to 
overcome drug delivery issues e.g. prodrugs.  Prodrugs are pharmaceuticals that are 
administered in an inactive form which produces an effect once metabolised.  Human 
use of a prodrug is exemplified by the immunosuppressant azathioprine.  Other 
pharmaceuticals produce more potent or toxic metabolites which are harmful to the body 
and may exert a toxic effect in the environment also.  These harmful metabolites are 
exemplified by the hepatotoxic derivative of paracetamol N-acetyl-p-benzo quinine 
imine.22  Also the immunosuppressant cyclophosphamide produces the toxic metabolite 
acrolein.22 
 
1.4 The Wastewater Treatment Process: 
Wastewater treatment plants receive polluted water from many different sources 
including domestic sewage from towns, industrial discharges or agricultural and landfill 
run-off.  The chemical and biological composition of these wastewaters varies greatly.23  
Domestic wastewater is composed of 99.9% water with only 0.1% consisting of solid 
matter.24  However, the composition of the wastewater that arrives from a range of 
sources at the WWTP will depend greatly on the industrial, agricultural and landfill 
catchment area.23  Other components of wastewater include bacteria, organic matter, 
inorganic species containing nitrogen and phosphorous and pollutants such as pesticides, 
insecticides and heavy metals.23 
 The legislation in Ireland pertaining to wastewater treatment and management 
was entered into Irish law under the EU Directive 91/271/EEC.25  This directive 
included the Environmental Protection Agency Act, 1992 and the Urban Waste Water 
Treatment Regulations, 1994 which provide the policies and standards that must be 
upheld in the treatment of wastewater.25  The treatment plant itself is protected under the 
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1992 Act which ensures monitoring of influents so the performance of the plant is not 
affected.25 
 The wastewater treatment process is actually composed of a series of individual 
processes which each have different functions, but all are designed to reduce the 
concentration of pollutants in the water and prepare it for reintroduction to the 
environment.  An outline of a WWTP is depicted in Figure 1.3.  Preliminary treatment 
is the first step and involves mechanically removing debris and other floating material 
from the influent.  The raw sewage arriving at the plant may contain wood, rags, paper, 
grit, large suspended matter and faecal matter.23  These materials are removed so as not 
to damage machinery or cause blockages by filtering the water through screens or 
strainers.23  The strained wastewater passes into large settlement tanks where it is left for 
an appropriate length of time to allow settleable solids (0.05-10 mm) to accumulate at 
the bottom of the tanks.23  The settled sewage can then be physically removed from the 
bottom of the tank before the wastewater passes onto the next stage. 
 The secondary treatment of wastewater is most commonly called the activated 
sludge process.  Activated sludge consists of numerous co-inhabiting microorganisms, 
that are added to the wastewater to consume organic colloidal and dissolved matter.  The 
organic matter is removed mainly by heterotrophic and autotrophic bacteria but also 
some fungi.26  The bacteria found in the sludge can include individuals from the genera 
pseudomonas, bacillus, athrobacter, nocardia, acinetobacter and achromobacter. The 
sludge also contains protazoa belonging to three main groups: flagellates, ciliates and 
amoebae.  Some of these eukaryotes feed off the organic matter in similar ways to the 
bacteria, but their main function is to prevent the stationary phase of the bacterial life 
cycle by grazing on the prokaryotes.26  An activated sludge reactor consists of a mixture 
of aerated wastewater and activated sludge containing a high microbial population.  The 
wastewater is supplied to specially designed tanks which are constantly aerated so as to 
provide optimum conditions for respiration to occur.  The rate of microbial respiration in 
the tanks is increased and the amount of organic matter due to its metabolised to form 
CO2, H2O and new microbial biomass.23 
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Figure 1.3: Outline of a waste water treatment plant, adapted from ref. 27 
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Another characteristic of secondary treatment is the formation of flocculated 
agglomerations (flocs) within the aeration tank.  It is hypothesised that filamentous 
bacteria form the skeleton of the flocs and bacteria which produce slime layers form the 
bulk of the structure.  The bacterial slime layer is composed of substances called 
exopolysaccharides which allow attachment to the filamentous backbone.  The flocs 
expand and envelope other microorganisms and organic matter.23  The flocs are an 
essential component of the treatment as they represent biological microcosms where the 
removal of organic matter is promoted by a number of mechanisms.  Colloidal and 
suspended matter within the flocs is easily broken down into simple molecules by 
extracellular enzymes and transported into bacterial cells for metabolism.  Other more 
complex substances are absorbed through the bacterial membrane.  Respiratory 
pathways occur inside the bacterial cells resulting in the production of energy which is 
converted to new cellular matter.26  Cellular matter is accumulated in the flocs which can 
be easily removed from the tanks.  At the end of the treatment the sludge-wastewater 
mixture is passed into secondary settlement tanks to allow the solid flocculated material 
to be separated from the water.  One of the most crucial functions of the floc is its ability 
to increase the rate of settlement within secondary settlement tanks.23  The wastewater is 
then subjected to tertiary treatment while the sludge has a number of possible fates.  
These include reintroduction to the activated sludge process, inactivation and utilisation 
as an agricultural fertiliser or disposal through landfills or incineration.25 
 Tertiary treatment of wastewater deals with the removal of nutrients (nitrogen 
and phosphorous containing compounds) and elimination of any residual microbes via 
disinfection techniques.  Nutrient removal is an essential process as it prevents 
eutrophication causing compounds reaching environmental waters and increasing the 
risk of excessive algal and aquatic plant growth.25  A number of techniques are available 
for removal of nitrogen from wastewaters.  Air stripping of ammonia involves lowering 
the pH of the water to form volatile ammonia gas which can be eliminated by aerating 
the tank.  Aluminium based minerals called zeolites can be employed as ion exchangers 
for the removal of ammonium ions while the addition of chlorine to water converts the 
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ions to nitrogen gas.  Biological nitrification and denitrification are alternatives to the 
physical and chemical methods described above but require expensive alterations to the 
treatment plant.25  A biological technique has also been developed for the removal of 
phosphates but the more common method of elimination involves the redox reaction of 
phosphate with metal ions (e.g. iron and aluminium) to produce an easily disposable 
precipitate.25 
 Disinfection is the final step and is carried out to eliminate any harmful, disease 
causing pathogens remaining in the water before its release to the environment.  
Disinfection techniques fall under three headings: chemical, physical and irradiation.  
Chemical techniques involve the addition of chlorine, ozone or hydrogen peroxide.  
Ozone is particularly effective against non-biodegradable organic matter.  Physical 
techniques are mainly based around membranes with pore sizes for retention of bacteria, 
viruses and even ions.  Finally irradiation with UV light can be employed to eliminate 
any remaining organic compounds.25   
 
1.5 The Behaviour of PPCPs During the treatment Process: 
Many different types of pharmaceutical compounds have been detected in WWTPs 
including blood-lipid regulators, antibiotics, antiepileptics, and tranquilisers.4, 28, 29  The 
presence of these potentially damaging compounds in effluent entering environmental 
waters poses questions as to the efficiency of the treatment processes in the plant.  
Previous studies have indicated variations in removal of pharmaceuticals from 
wastewater with both high and low concentrations being released into the 
environment.30, 31 
 There are a number of operational factors which may affect the removal of PPCP 
from wastewater during its treatment.  These include the biochemical oxygen demand 
(BOD), quantity of suspended solids (SS) loading, solids retention time (SRT), pH, and 
temperature.32  The SRT is particularly important as a longer period of sludge treatment 
promotes the growth of microorganisms with a wider range of metabolising and 
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transforming abilities.  This can possibly lead to increased removal of PPCPs before the 
water is released back to the environment.32   
 The physical and chemical properties of each PPCP govern its fate within the 
WWTP.  If the compound is biodegradable then its concentration in effluents may be 
lower.  Important properties include hydrophobicity and volatility.  Hydrophilic 
compounds such as acid, basic and neutral pharmaceuticals may be more likely to 
remain in aqueous media and therefore may be more difficult to eliminate from influent 
streams.  Hydrophobic compounds may be more susceptible to adsorption onto sludge 
particles during treatment.32   
 There are numerous mechanisms by which pharmaceuticals could be degraded, 
however the most likely include: aerobic and anaerobic biodegradation, (during 
secondary treatment), chemical degradation, volatilisation and adsorption onto solid 
particles.32  The more hydrophobic pollutants removal pathways may be predictable 
using the octanol-water partition co-efficient as previously reported by Rogers.33  Those 
compounds with a higher log KOW value could be more likely to adsorb onto solid 
matrices.33   
 Studies to date have indicated relatively low removal of pharmaceuticals, 
antibiotics and diagnostic agents used in x-rays from WWTPs.34  Ternes et al. reported 
no affinity of acidic drugs for sludges during primary treatment processes using the 
solid-water distribution co-efficient (Kd).35  Some removal of diclofenac and the 
fluoroquinolone antibiotics (e.g. ciprofloxacin and norfloxacin) was reported during 
primary treatment in separate studies.35, 36  Some antibiotics exhibit high log Kow values 
as does diclofenac, which may partly explain the higher levels of removal during 
primary processes.32   
 Many studies based on detecting pharmaceuticals in WWTPs have focused on 
acidic pharmaceuticals with concentrations in influent and effluent ranging from 300-
23,400 ng/L and 24-2400 ng/L, respectively, (Ibuprofen being highest in both cases).37-39  
Other studies have focused on determining the amount of adsorption onto sludge which 
occurs during treatment.  In 2001, removal of pharmaceuticals including diclofenac and 
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carbamazepine were reported after just 15 minutes of contact with activated sludge.40 
Activated sludge treatment plants with low SRTs have demonstrated low levels of 
pharmaceutical removal and in some cases none at all in a number of publications.39, 41  
It is becoming increasingly clear that the length of the SRT within the plant influences 
the removal of PPCPs.  This indicates that sorption of pharmaceuticals to solids is an 
equilibrium process which is highly dependent on time and independent of properties 
such as Kow and Kd.  Clara et al. reported an increase in elimination of ibuprofen from 0 
% to 98 % by extending the SRT to 48 days.39  Similar results have been reported by 
Buser et al. for WWTP that employ longer SRTs.42  The theory that operational aspects 
of wastewater treatment affect the removal of drugs has also been investigated with 
activated sludge plants and oxidation ditch systems both reporting relatively high 
removals of acidic pharmaceuticals.34, 37, 38  A WWTP employing a trickling filter 
treatment bed was less successful in the elimination of pharmaceutical residues.37  
However, some compounds do not adhere to these theories, discrepancies have been 
reported in removal data for diclofenac from wastewaters subjected to similar SRT 
periods.  The concentration of the anti-inflammatory removed during treatment has 
varied from slight amounts to more than 70 %.28, 39, 42  Investigations into the 
degradation of clofibric acid in a range of WWTPs with differing treatment techniques 
were also contradictory.  Wide ranging levels of biodegradation were reported for 
conventional activated sludge plants, trickling filter establishments and plants with 
additional tertiary treatments.37, 43  These contradictory findings indicate that the 
performance of sludge in WWTPs varies quite a lot as it cannot be reproducibly 
produced. 
An important study carried out by Jones et al. in 2007 investigated the sorption 
of pharmaceuticals paracetamol, ibuprofen, propranolol, mefenamic acid and salbutamol 
to biosolids in a UK WWTP.  Although elimination rates were high (~90%) for all target 
analytes, ng/L concentrations were still detected in effluent except for propranolol.  The 
conclusion drawn from this study was that sorption of the selected analytes to sludge 
was not the primary mechanism of removal and that microbial metabolism was more 
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likely.44 More recently several PPCPs from a wide range of therapeutic classes were 
detected in the influent and effluent of Irish WWTPs.45 
 Antibiotic residues have been detected in the influent and effluent waters of a 
number of WWTPs across Europe, Canada and the USA.46-48  The antibiotics detected 
included sulfonamides, tetracyclines, macrolides, and fluoroquinolones.48  Influent and 
effluent concentrations of five antibiotics ranged from 0.04-1.30 µg/L in American 
WWTPs,48 and sulfamethoxazole concentrations as high as 400 ng/L have been reported 
in Germany.46  Overall, activated sludge treatments have shown relatively successful 
removals of antibiotics.41, 48  A study of wastewater samples taken during different 
seasons demonstrated that lower concentrations of antibiotics were detected in the early 
spring and summer representing the months receiving the most precipitation.48, 49  These 
results are in agreement with earlier studies which highlighted reduced removal of 
pharmaceuticals during period of high rainfall.28  Similar concentrations of the 
fluoroquinolones have been detected at WWTP sites in Switzerland and Canada.47, 50  
Sorption to sewage sludge is thought to play an important role in the removal of 
antibiotics from wastewater.  Tetracyclines are prone to complexation with metal ions 
forming stabilised complexes which could bind to suspended matter in the sludge.32  
This may explain low concentrations of tetracycline in some German WWTPs,46 while 
other studies with particularly short SRTs reported median concentrations of ~ 150 
ng/L.47  This result suggests that biodegradation is also an important factor in removal of 
antibiotics and should not be ignored.  However, recent studies into the antibiotic 
removal from the Pearl River Delta in South China have indicated that fluoroquinolones 
are eliminated due to adsorption to sludge.51  This was demonstrated by direct analysis 
and detection of fluoroquinolones in sludge biomass.  Macrolides and sulfonamides 
were found to survive the treatment process.51  One possible future problem associated 
with antibiotic presence during the activated sludge process is inhibition of bacterial 
function as demonstrated by Dokianakis et al.52 
 Diagnostic chemicals are another branch of PPCPs which have been detected in 
municipal influents and effluents.  Six diagnostic chemicals employed for x-rays were 
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detected at particularly high levels in a German WWTP where the maximum level 
exceeded 3000 ng/L.53  Once again the SRT was judged to play an important role in 
removal of these compounds as concentrations removed increased with increasing SRT 
in a study by Kreuzinger et al.41  Tertiary treatments in WWTPs such as ferric chloride, 
lime and aluminium sulphate coagulation were shown to remove less than 25% of 
PPCPs from drinking water.54  Tertiary treatments involving oxidation with chlorine and 
ozone showed better results, however, this study focused mainly on endocrine disrupting 
chemicals and hormones, further work is required to investigate the effects of these 
processes on pharmaceuticals.54   
 New techniques are being developed to improve the quality of wastewater before 
it is released back to the environment.  These include membrane bioreactor technology 
(MBR) and advanced oxidation processes such as ozonation and photocatalysis.55  MBR 
has already showed promising results for the removal of acidic, neutral and basic 
pharmaceuticals, however there are still issues with some persistent compounds such as 
carbamazepine.41, 56  These new techniques will be expanded upon in a later section of 
this review. 
 
1.6 PPCP Disposal and Leaching from Landfill Sites: 
The consumer is often unsure what to do with unused or expired medications.  
Traditionally discarding the drugs to the sewage system was common practice and is still 
common as it avoids any risk of children reaching them.57  However concern is 
mounting about the concentrations of pharmaceuticals being detected in aquatic 
environments and some governments are advising their public to dispose of the unused 
medications with household waste.  In an attempt to prevent further contamination of 
water systems, the United States White House Office of National Drug Control Policy 
released a statement in 2007 advising consumers to avail of any possible drug take-back 
programs or to add the medicines to their household waste.58  As a result of this, any 
hazardous materials are transported to landfill sites to join the rest of the municipal solid 
waste (MSW).  In many modern landfill sites, leachates are collected and treated in 
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WWTPs resulting in many pharmaceuticals entering the aquatic environments, which 
these new guidelines were aiming to protect.  A recent survey conducted by Musson et 
al., indicated that almost 50 % of consumers are disposing of pharmaceuticals as solid 
waste and not using the sewage system route.59   
Hazardous substances can be released from landfill sites in a number of ways 
including gaseous emissions of volatile compounds, airborne particulate matter and 
leachate of liquid seepages into land around or below the site.60  Landfill leachate is a 
complex matrix composed of organic and inorganic elements including xenobiotic 
organic compounds and toxic heavy metals.  These substances pose a risk to the 
environment and to humans when they seep from landfills into ground and surface 
waters.  This occurs despite recent advances in landfill design such as barrier systems.60  
The chemical composition of landfill leachate has been studied by Schwarzbauer et al. 
between two studies in 2002 and 2004.61  Over 180 individual organic compounds were 
identified within the seepage water of a landfill facility in Germany.  Common 
degradation products of carbohydrate, peptides and other biological molecules were 
identified but xenobiotic compounds were also present including pharmaceuticals, 
pesticides and halogenated aromatics.61  Among the detected compounds were the 
pharmaceuticals ibuprofen, propylphenazone, clofibric acid and many of the 
sulphonamide antibiotics.  In the second study certain organic compounds were chosen 
and monitored within the seepage as markers of pollution originating from the landfill 
site.  It was noted that the concentrations of the compounds decreased with increasing 
distance from the waste facility.62  It is obvious that landfill leachates are an important 
source of PPCPs within the environment.  Greater efforts need to be taken in future to 
update landfill sites with barrier systems, treat leachate as it is produced using proven 
methods or organise separate collection of pharmaceuticals for incineration.57 
 
1.7 Fate of PPCPs and Environmental Risk Assessment: 
The fate of pharmaceuticals once released into the environment it is difficult to predict.  
There are several processes that can occur: photochemical conversion to form other 
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compounds, dilution and transportation within the aquatic environment and sorption 
onto solid matrices such as soil and sewage sludge which is of particular importance in 
this work.  PPCPs enter sewage sludge as already discussed, in the WWTPs and are 
often applied within the biosolid as agricultural fertilisers.  The PPCPs may enter and 
persist within the soil or leach into water systems depending on a number of factors.   
 The sorption and persistence of a pharmaceutical in solid matrices depends on its 
capacity for sorption, its resistance to photo-degradation and its affinity for water, which 
if high will cause seepage from the solid to surface waters.3  Natural waters may also 
also act as a semi-solid matrix due to a high dissolved organic matter (DOM) load, 
allowing sorption to occur.  The distribution of a drug between a solid and a liquid is 
described by calculating the ratio of drug concentration in solid and liquid at 
equilibrium, known as the distribution co-efficient, (Kd).  This is the simplest method 
available, however it has been shown to vary for some highly hydrophobic compounds 
perhaps due to its dependance on pH.63  The variation in data can be reduced by the 
calculation of the normalised sorption coefficient, (Koc) which is a ratio of Kd to the 
organic carbon content of the solid.63  Koc can be easily calculated using the octanol-
water partition co-efficient which is an easily obtained physiochemical parameter, 
making Koc the preferred tool for investigation of environmental risk.64  However, these 
co-efficients still vary quite considerably for a given compound in different types of 
solid sample.65  These variations cannot be simply explained by the differing organic 
content of the soil samples.  There are other mechanisms of binding at work such as 
complexation, ion-exchange and hydrogen bonding.65   
A recent study of digested sludge from a WWTP and soil which had been 
enriched with the resulting biosolid from the WWTP were analysed for traces of 27 
PPCPs.66  Significant levels of triclosan, warfarin and carbamazepine were identified in 
the digested sludge samples, while lower but still relevant concentrations of triclosan 
were found in the fertilised soil.66  These results confirm earlier studies which reported 
triclosan at ~1200 ng/g in digested sludge from a WWTP in Germany.67  Soil column 
studies have also been conducted to determine if drugs remain sorbed to soil or leach 
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into water systems.  Oppel et al. determined that diazepam, carbamazepine and 
ibuprofen were all highly retained on the soil while clofibric acid seeped out in 
leachate.68 
 It is important to assess the toxicological effects that PPCPs have on the 
environment and on individual species.  Pharmaceuticals are designed to exert a specific 
effect on an individual, however when released into the environment they could affect 
other organisms.  The use of medicinal products in the EU is regulated by the European 
Medicines Evaluation Agency (EMEA). 69  An environmental risk assessment (ERA) 
must be carried out under EU Directive 93/39/EEC to investigate any toxicological risks 
associated with a drug before it can be licensed for human or veterinary use.69 
 
1.8 Sample Preparation Techniques: 
 
1.8.1 Introduction: 
In recent years technological advances have allowed scientists to detect analytes at lower 
concentrations than was ever possible before.  Modern interface technologies altered the 
standard analytical techniques used for pharmaceutical analysis by linking liquid 
chromatography (LC) to mass spectrometry (MS) for the first time.  This new technique 
has replaced gas chromatography-mass spectrometry (GC-MS) as the ‘work-horse’ of 
analytical science particularly with respect to PPCPs in the environment.  GC-MS is not 
suitable for determining many pharmaceuticals and requires complex derivatisation 
steps.  Modern environmental analysis concerning PPCPs generally consists of three 
procedures, sample preparation, liquid chromatographic separation, mass selective 
detection and data interpretation.  The theory of LC and MS were discussed in Chapter 1 
of this work.  This section aims to describe the theory and processes involved in modern 
sample preparation techniques and review the analytical techniques which have been 
used by scientists to date for the analysis of pharmaceutical and illicit drugs in solid 
environmental matrices and biological matrices such as hair and urine. 
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1.8.2 The goals of sample preparation: 
The function of the sample preparation step of an analytical procedure is to separate the 
analyte of interest from the sample matrix components.  In the case of environmental 
samples, the matrices are often very complex, but also the target analytes may be present 
at very low concentrations, a fact which is particularly true for PPCPs.  The same 
challenges are faced with biological samples such as urine and hair.  These samples 
contain high levels of organic matter which can contaminate equipment such as 
chromatographic columns or interfere with detection.  Therefore, sample preparation 
must not only increase the concentration of the target analyte to a level detectable by 
modern instruments, but it must selectively increase only the target analyte 
concentration and and to a certain degree eliminate the matrix components.  This is 
known as sample clean-up in which the analyte is extracted from very ‘dirty’or complex 
sample types to reduce matrix interference and improve method sensitivity.70  During 
sample preparation, analytes may also be transferred to a solvent which is more 
amenable to the next step of the procedure, e.g. the analytical separation.  Techniques 
such as GC require volatile samples and nuclear magnetic resonance (NMR) requires 
deuterated sample environments.  Additionally, the sample preparation technique should 
not render the sample highly acidic or basic as this can also spoil chromatographic 
columns.71  The clean-up procedure should be relatively inexpensive, rugged, easy to 
perform and result in minimal analyte loss. 
 
1.8.3 Solid phase extraction (SPE): 
Solid phase extraction (SPE) is a sample preparation technique that involves passing a 
gas or liquid over a solid sorbent, which has an affinity for the target analyte within the 
sample.  The analyte is retained on the sorbent while matrix components pass through to 
waste.  The analyte is then retrieved by elution in a suitable solvent or by thermal 
desorption.72  SPE fulfills the requirements previously outlined in Section 2.8.2, as it can 
enrich the sample, can minimise most of the matrix content and allows the transfer of 
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analytes to a suitable solvent for analysis.  These attributes have made SPE one of the 
most common preparation techniques in many scientific fields including pharmaceutical, 
environmental and biological analysis.72  However SPE was not always the technique of 
choice and there are alternative techniques also employed such as LLE. 
 SPE was first introduced as a replacement for the then popular preparation 
technique of liquid-liquid extraction (LLE).  LLE is a type of solvent extraction that 
involves two immiscible liquids, usually aqueous phase and an organic solvent.  The 
analytes partition into each phase based on their solubilities, hydrophobic molecules will 
be distributed in the organic solvent while polar and ionic species will partition into the 
aqueous phase.73  LLE was the standard method of sample preparation up until the 
1980’s when SPE became a widely used laboratory technique.  There are a number of 
drawbacks associated with LLE, large volumes of expensive solvents are consumed 
which are difficult to dispose.  Emulsions can be formed during the procedure 
particularly with biological samples such as urine which lead to ruination of the sample.  
Additionally LLE produces low preconcentration factors when compared to SPE.  It is 
not feasible to extract a large volume of sample with a small volume of organic solvent 
in LLE, an essential step in environmental analysis as the analytes are present at such 
low concentrations.73   
 In the early 1950’s activated charcoal was employed for the preconcentration of 
organic compounds in large volumes of water.74  However, this technique did not 
become popular due to irreversible adsorption for groups of analytes and a weak affinity 
for others.74  The late 1960’s and early 1970’s saw the advent of porous polymer 
sorbents based on polystyrene and polyacrylate polymer beads.  These types of sorbent 
were very successful in the analysis of organic compounds in water samples.74  During 
the 1970’s bonded phases employing a silica back-bone became of interest with the 
increasing popularity of LC.  Soon after, disposable cartridges were introduced which 
improved the ease and availability of the technique.  In the 1990’s automation of SPE 
was developed along with mixed-mode sorbents, immunosorbents, restricted access 
sorbents and multi-well plate formats for multiple samples.72  
 42 
 SPE techniques have their own drawbacks which cannot be ignored.  
Manufacture of the sorbents is not always a reproducible process and leads to variations 
in retention of compounds.  Also the small amount of sorbent within the column or tube 
can become overloaded when extracting large volumes of sample and lead to loss of 
analytes due to breakthrough.  Impurities introduced during manufacture can also affect 
the sample preparation process and the sorbents can also become blocked leading to low 
recoveries.72  
 
1.8.4 The practice and theory of SPE: 
All SPE procedures are composed of four steps regardless of samples and sorbent type.  
These steps involve sorbent conditioning, sample loading, washing and analyte elution.  
Figure 1.4 below outlines the four steps of the SPE technique.  Firstly, the sorbent is 
washed usually with an organic solvent such as methanol or acetonitrile to remove any 
contaminants from manufacturing and to allow ‘wetting’ of the sorbent functional 
groups.  Other conditioning steps involving acidic or basic solutions may also be 
employed to ionise functional groups.  Equilibration is carried out by passing an aqueous 
solvent through the SPE column.75   
A vacuum is generally employed to allow more rapid sample loading, especially 
for large sample volumes.  The sample is passed through the solvent at a constant rate, 
without allowing the sorbent to dry out, to allow sufficient time for the analytes to 
interact with the sorbent.  During this step the analyte is either retained on the sorbent as 
matrix components flow through or the analyte is eluted while the matrix species are 
retained.  The washing procedure is carried out using a suitable solvent to remove any 
interfering matrix components and to dry the sorbent more quickly.  Finally the analytes 
can be eluted in a suitable solvent.75  the volume of eluting solvent used should be as 
small as possible to maximise the preconcentrating effect of the technique while 
ensuring that all of the analyte is removed.72  
 
 43 
Barrel
Sorbent
Conditioning 
solvent added
Sample 
Loading
Washing off 
persistent matrix 
components
Elution of 
analytes
Solvent
Analyte
Matrix 
component 1
Matrix 
component 2
Direction of Flow
 
Figure 1.4: Diagram outlining the four steps of SPE, adapted from ref. 76 
 
The theoretical processes that occur during SPE are comparable to those in liquid 
chromatography as bothcan be described as frontal techniques.  Large volumes of 
sample are usually loaded due to the low concentrations of analyte within them.  The 
amount of analyte that can be isolated depends on the breakthrough volume (VB) of the 
sorbent.72  The breakthrough volume can be determined by passing sample through the 
sorbent continuously until analyte is detected coming through the sorbent without being 
retained. At this point during the technique the analyte is no longer being quantitatively 
retained on the sorbent.72  The point at which the concentration of analyte entering the 
barrel and the concentration leaving it are equal indicates that the retention capacity is 
saturated.  This means that sorbent adsorption sites are saturated with analyte or matrix 
components or its retention capacity has been exceeded.  The point of inflection on the 
curve is known as the retention volume (VR).72 
 The breakthrough volume can be calculated using the following equation.72 
 
VRB VV σ3.2−=    (Eqn. 1.1) 
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Where σV is the standard deviation of the axial dispersion of the analyte through the SPE 
sorbent.72  The volume of eluting solvent required to achieve 99% analyte recovery (VE) 
is given by: 
 
[ ] ( )[ ]NkVV ME 3.211 ++=    (Eqn. 1.2) 
 
Where VM is the interparticle volume of the sorbent, k is the retention factor and N is the 
number of theoretical plates.72 
 
1.8.5 Types of SPE sorbent and retention of analytes: 
A large selection of SPE sorbents are commercially available today, which is testament 
to the popularity and success of the technique.  The type of retention mechanism 
involved depends on the sorbent chosen.  Reversed-phase sorbents are the most 
universally used, however ion-exchange, normal phase and mixed-mode are also 
common.  The choice of sorbent is based on the nature of the analyte and the sample.  
The type of sample matrix (organic/aqueous), the nature of the analyte, (polar, non-
polar, ionised) the type of ionisation, (strong/weak or acidic/basic) must all be 
considered.72  The stationary phase chosen should also be porous and allow sufficient 
interaction between analytes and active groups.  The interaction between the analyte and 
the functional group of the sorbent should be reversible so the analyte can be eluted but 
suitably strong to allow retention.   
 Normal phase adsorbents are made up of the inorganic oxides such as silica gel, 
alumina and Florisil, which is a magnesium silicate.  The advantages of normal phases 
are their highly active groups and large surface area.  Careful buffering of solutions 
allow for ion-exchange applications.72  Analyte preconcentration occurs due to hydrogen 
bond and dipole interactions.  Unfortunately these sorbents are subject to irreversible 
retention and catalytic degradation of analytes.72  Applications of normal phase sorbents 
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include fractionation of different lipid types,77 preconcentration of herbicides78 and 
clean-up of complex matrices before analytical separation.79 
 Reversed-phase sorbents include the bonded silicas and porous polymers 
sorbents, both of which have been used extensively for the preconcentration of organic 
compounds in aqueous matrices.80  Retention of analytes on reversed-phase sorbents 
occurs due to pi- pi interactions and van der Waals forces.  The silica backbone is most 
commonly functionalised with long alkyl chains e.g. C8 and C18 groups.  Longer chains 
promote retention of smaller molecules while shorter chains are employed for 
macromolecule retention.80  Other silica functionalising groups include 3-cyanopropyl 
and 3-aminopropyl which selectively extract analytes due to polar interactions.  Despite 
their success, silica based sorbents suffer from pH sensitivity and low breakthrough 
volumes for small polar compounds.  Silanol sites that remain uncapped can irreversibly 
retain basic compounds causing low recoveries.80  Porous polymers hold solutions to 
both of these problems as they contain no residual silanol groups and they can withstand 
the full pH range.  The polymers are most commonly manufactured from styrene and 
divinylbenzene monomers which demonstrate stronger pi- pi interactions and exhibit a 
higher surface area.81  One disadvantage associated with polymer sorbents is low level 
of interaction with aqueous samples due to their hydrophobicity.  This problem is being 
addressed by surface modification with polar groups such as sulfonates or addition of a 
polar monomer to the polymerisation process.81  This approach is exemplified by the 
commercially available Oasis HLB product which is easily water-wettable.82 
 Inorganic and organic ions can be removed from an array of matrices (usually 
aqueous) using ion-exchange sorbents.  As with many other types of compound specific 
stationary phases in SPE, e.g. molecular recognition, restricted access and 
immunoaffinity sorbents, ion-exchange SPE is based on modification of the normal and 
reversed-phase sorbents.80  Both silica and polymer backbones can be employed once 
modified with a cation or anion exchanging group.  Retention occurs due to electrostatic 
interaction between analyte and sorbent functional group.  Some of the most common 
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functional groups include tertiary and quaternary amines for anion exchange and 
carboxylic or sulphonic acid groups for cation retention.72   
 Mixed-mode sorbents consist of ion-exchange functionalities combined with 
hydrophobic alkyl chains for retention of ionisable compounds that also exhibit a non-
polar character.  These types of sorbents have found particular use for pharmaceutical 
and clinical analysis due to the acidic and basic functional groups ofeten found in 
pharmaceuticals and illicit drugs.83  Preconcentration of pharmaceuticals in biological 
and environmental matrices using this type of phase results in excellent reduction of 
matrix components, providing extracts suitable for chromatographic analysis.80 
 
1.8.6 Pressurised liquid extraction: 
The inherent homogeneity of solid samples renders it difficult to reproducibly extract 
and detect pharmaceutical residues.  The high organic load of matrices such as hair, soil 
and sludge mean matrix effects are a particular problem in the development of analytical 
techniques.  Generally, an extraction process coupled with SPE clean-up and 
preconcentration is required to allow accurate qualitative and more importantly 
quantitative information about drug residues in environmental and biological matrices to 
be obtained. 
 Pressurised liquid extraction (PLE) or accelerated solvent extraction (ASE) was 
introduced in 1995 by Dionex Inc. as a new extraction technique for organic compounds 
from solid or semi-solid environmental, food and industrial matrices.84  The principle of 
the technique is that high temperature solvents at elevated pressures should produce 
improved extraction efficiency due to faster kinetics than at ambient temperature and 
atmospheric conditions.85  There are two processes that occur during the extraction 
process that should lead to improved extraction of organic compounds, solubility and 
enhanced mass transfer coupled with distortion of equilibria.85 
 At high temperatures the solvents used in ASE have a higher solubilising 
capacity and dissolve more organic compounds within the sample.  Mass transfer or 
diffusion rates are improved due to the higher temperatures and introduction of fresh 
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solvent also improves extraction rates as the concentration gradient between the solvent 
and the sample matrix is increased.85  Surface equilibria within the sample can be 
disrupted by both the elevated temperatures and pressures.  Increased thermal energy can 
disturb intermolecular forces such as hydrogen bonding and van der Waal’s forces 
between matrix adsorption sites and target analytes.  Additionally, the decreased 
extraction solvent viscosity results in more efficient diffusion into the solid matrix, both 
of these effects result in improved analyte extraction.85  Elevated temperatures would not 
be possible if high pressure did not allow the solvents to remain in the liquid phase.  
High pressure is also an important factor in the penetration of sample matrix.85 
 A description of the ASE setup is given in Figure 1.5.  The sample (1-30 g) is 
measured into a stainless steel extraction cell and tightly sealed.  The extraction solvent 
(e.g. 50 : 50 methanol : water) is pumped into the cell and extraction takes place at 
temperatures up to 200 oC and pressures of up to 3000 psi.  The solvent remains 
stationary in the cell for a short period and is then purged using firstly fresh solvent and, 
secondly, a gas (N2).  The extract is collected in a glass sample vial.84  Sample extraction 
times and volumes of solvent used are smaller than those employed in other more 
conventional techniques such as Soxhlet extraction.85  ASE has been approved by the 
US EPA as an extraction technique for organic compounds such as polychlorinated 
biphenyls (PCB’s), polyaromatic hydrocarbons (PAH’s) and pesticides from soil.86   
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Figure 1.5: Diagram of accelerated solvent extraction apparatus, adapted from ref. 84 
 
1.9 Analysis of PPCPs in Complex Environmental Matrices: 
 
1.9.1 Introduction: 
PPCPs have attracted much interest in recent years as an emerging class of contaminants 
due to their extensive human and veterinary usage and their numerous entry routes into 
the environment.  The need to study the distribution, occurrence and fate of these 
compounds in environmental matrices has led to numerous analytical methodologies 
being proposed for their analysis.  These proposed procedures however have focused 
 49 
almost exclusively on sample clean-up usually involving SPE coupled to either LC or 
GC with single or tandem mode MS.87  Detecting pharmaceutical residues in 
environmental matrices is particularly challenging for a number of reasons.  The 
concentration of the compounds is generally very low.  Furthermore, many of the 
compounds are thermally unstable and may also interact with components of the 
environmental matrix making extraction even more difficult.88  To date, the majority of 
research has focused on drinking, surface and ground waters, as well as influent and 
effluent of WWTPs with a number of review papers being published solely on this 
topic.29, 89, 90  It is challenging to quantitatively extract trace residues from aquatic 
samples, however new advances in SPE technologies have improved recoveries of 
analytes and allowed for multi-residue analysis of different families of drugs 
simultaneously.87   
The extraction and detection of PPCPs from solid environmental matrices (e.g. 
soil, sediment, sludge) is of great importance, particularly as antibiotics reaching the 
environment may lead to drug-resistant bacteria.  The effects of PPCPs in the 
environment have been reported particularly in the fish farming industry due to 
contaminated sediments.3  Additionally, sludge applied in agriculture and the receiving 
soil are subject to accumulation of persistent PPCPs leading to a possible detrimental 
effect on plant life.91, 92  Leaching of PPCPs from soil may also be responsible for 
deleterious effects on aquatic organisms.3  Solid environmental matrices require more 
selective extraction and sample-preconcentration due to variable composition and high 
organic content.  The aim of this section is to discuss the analytical techniques for 
analysis of PPCPs in complex environmental matrices with emphasis on solid samples 
such as sludge and soil.  Particular attention is to be given to sample preparation, LC-MS 
and LC-MS/MS. 
 
1.9.1 Analytical techniques for determination of PPCPs in the aquatic environment: 
Modern analytical techniques for determination of PPCP traces in aquatic samples 
involve sample preconcentration, gas or liquid chromatographic separation and selective 
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detection using MS.  Today, with the advent of new polymeric, multi-mode SPE 
sorbents along with improvements in liquid chromatography-mass spectrometry (LC-
MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) technologies, 
multi-analyte determinations are possible.93  These, so called ‘multi-residue methods, are 
in demand due to the continuously growing number of PPCPs being identified in the 
aquatic environment.  An analytical method that allows detection of a range of analytes 
reduces analysis time, sampling time, costs less and provides an overall picture of the 
state of the environment.87   
 Concentrations of PPCPs in environmental samples are generally in the ppm to 
ppb range depending on the type of sample.88  Sample preparation techniques therefore 
must involve a high enrichment factor if the target analytes are to be detected.  In recent 
years, pre-treatment of aqueous samples has moved away from traditional LLE, with 
solid phase microextraction (SPME) and SPE becoming the commonly used 
preconcentration techniques.  SPME is particularly useful when employed with GC-MS.  
Very small volumes of sample are required and there are no solvents involved providing 
high concentration factors of organic compounds.  The pharmaceuticals can also be 
desorbed directly from the SPME fibre into the GC instrument which further simplifies 
the sample preparation.94, 95  GC is only applicable to separation of volatile analytes 
which limits its use in multi-residue analysis, particularly for larger analytes such as 
antibiotics.  Additionally, SPME can suffer from low sorption capacity of fibres leading 
to incomplete extraction of analytes.96 
 A wide range of SPE sorbents have been applied to the detection of different 
categories of pharmaceuticals and other medicinal products in recent years.  Reversed-
phase C18 cartridges have been used to extract antibiotics, analgesics and non-steroidal 
anti-inflammatory drugs (NSAID’s).97  Ion exchange sorbents have been employed for 
extraction of antiobiotics, analgesics, beta-blockers and blood-lipid regulators.98  
Polymeric sorbents have been used for enrichment of analgesic, anti-epiletics and 
NSAID’s in surface waters.99  One of the main challenges facing the analyst when 
developing a multi-residue method is extraction of all analytes simultaneously.  The 
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physico-chemical properties of pharmaceuticals determine their extraction efficiency for 
a given sorbent.87  Analytes with a wide range of properties such as pKa and Log KOW 
will have differing levels of enrichment. Often when conducting multi-residue analytical 
methods, mixed-mode sorbent types are needed or two types of extraction cartridges are 
placed in sequence for extraction of all analytes however, this may lead to high levels of 
matrix components also being enriched.87   
 New polymeric sorbents such as Waters Oasis are distinguishable from other 
types by their use for molecules with a wide range of polarities, which allow for 
improved interaction with analytes in aqueous samples.  These characteristics are due to 
a hydrophilic pyrrolidone monomer being included at manufacture.87  This sorbent has 
been used for extraction of acidic and neutral pharmaceuticals simultaneously.100, 101  
The extraction can be carried out at a neutral pH with a lesser need for acidification.100  
Elimination of the acidification step means no risk of hydrolysis of analytes within the 
sample.102 
A number of studies have been carried out to compare the extraction efficiencies 
of different types of sorbent for a diverse group of PPCPs.99, 103  Lin et al. investigated 
the extraction efficiency of a C18 reversed-phase sorbent and two polymeric sorbents 
(including Oasis HLB) for pharmaceuticals in WWTP effluent and riverwater.99  The 
Oasis HLB cartridges reported higher and more reproducible extraction efficiencies than 
the other sorbents at neutral pH.99  Alternative sample preparation techniques which 
have been applied to PPCP analysis in aqueous matrices are membrane assisted solvent 
extraction (MASE) and hollow fibre liquid phase micro-extraction (LPME). Both 
methods demonstrated good detection limits but reported that method precision needed 
improvement.104, 105 
Similar results were obtained by Gros et al. who compared two polymeric, one 
hydrophobic reversed-phase and one mixed mode cartridge with cation exchange and 
reversed-phase properties (Oasis MCX).103  In this study, 29 pharmaceutical analytes 
were chosen with a range of pKa values from 4-9.  The extractions were carried out at 
neutral pH in order to identify the best extraction method without sample pre-treatment.  
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The mixed-mode cartridge reported high recoveries of the acidic pharmaceuticals at 
neutral pH, but the basic analytes were not retained.103  This cartridge is generally 
employed at low pH where basic compounds are protonated and can be retained due to 
cation exchange. The acidic and neutral compounds are enriched by the reversed-phase 
groups.  The second polymeric sorbent (Lichrolut ENV) performed badly and is also 
generally employed at low pH.  The C18 sorbent demonstrated good retention of most 
analytes but was still inferior to the Oasis HLB sorbent which was subsequently chosen 
as the optimum sorbent for the analysis of surface waters and WWTP influent and 
effluent.103 
 The majority of pharmaceutical analysis in aquatic environmental matrices has 
been carried out on C18 or C8 reversed-phase high performance liquid chromatography 
(HPLC) columns.88  MS detection provides excellent selectivity so that complete 
resolution of analyte peaks is not a requirement for detection, however, if possible, it 
does increase sensitivity by reducing ion suppression effects.93  Mobile phases 
commonly consist of an aqueous phase (water) and organic phase (usually methanol or 
acetonitrile).  The aqueous phase often contains a mobile phase additive to stimulate ESI 
ionisation or to achieve consistent retention times.93  Analytical separations of acidic 
pharmaceuticals and anti-inflammatory drugs generally employed volatile additives e.g. 
formic acid, ammonium acetate and ammonium formate.106-108  Analysis of antibiotics 
sometimes requires mobile phase additives to increase sensitivity of the mass 
spectrometric detection.  This has previously been achieved by the addition of 
ammonium acetate, ammonium formate, oxalic acid and formic acid.46, 92, 109  More basic 
drugs such as beta-blockers are usually analysed using a more neutral mobile phase.110  
More complex separation techniques such as ion-pair liquid chromatography (IP-LC) 
have been employed for the analysis of NSAID’s and triclosan in surface and 
wastewaters.  Quintana et al. added ion-pairing agent tri-n-butylamine (TrBA) to the 
mobile phase and achieved increased signal intensities and stable retention times.111  
Ultra performance liquid chromatography (UPLC) has also been applied to these 
complex environmental samples.112, 113  These analytical methods reported separations of 
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up to 29 analytes in 10-15 minutes and reductions in peak width when compared to 
conventional HPLC analysis.  Detection limits were in the low ng/L level which is 
comparable to HPLC analysis methods, although despite the shorter analysis times 
UPLC still has only seen limited application in this area.88, 112, 113 
Mass spectrometry has been the detection technique of choice for analysis of 
pharmaceutical residues in aqueous sample for many years.  In single mode MS, 
molecular ions isolated at a single m/z in positive or negative ion modes are measured in 
a process known as single ion monitoring (SIM).  Over the past two decades, LC-MS 
technologies have greatly advanced in reliability, sensitivity and selectivity.  In modern 
day laboratories, detection limits in the ng/L range and lower are commonplace.87  LC-
MS/MS is now the standard detection technique for pharmaceuticals in environmental 
matrices.93  Selected reaction monitoring (SRM) allows unequivocal identification of 
compounds in complex samples.  The triple quadrupole (QqQ) mass analyser is the most 
frequently used mass analyser with popular interface technologies being ESI and 
APCI.114, 115  These soft ionisation techniques suffer from matrix effects particularly 
when analysing a complex sample such as wastewaster of WWTP influent and 
effluent.87  These matrix effects can lead to enhancement or suppression of signal 
intensity.89  A number of strategies have been introduced in recent years to minimise 
these effects.  A combination of adding of internal standards (e.g. stable isotope 
surrogate standards) and standard addition calibration are most commonly used although 
it has also been demonstrated that reducing the flow of solvent and sample entering the 
ion source can increase signal intensities and reduce matrix effects by up to 60% for 
many PPCPs including the NSAID’s.116, 117  Another common mass analyser is the 3D 
ion-trap allows for easy identification of compounds in multiple reaction monitoring 
(MRM) modes.  This instrument has been successfully applied to the determination of 
20-30 pharmaceuticals in river and wastewater simultaneously with detection limits in 
the ng/L range.45, 118 
 Advanced hybrid mass spectrometers have now become widely available such as 
the quadrupole time-of-flight (q-TOF) and the orthogonal acceleration time-of-flight 
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(oa-TOF) mass analysers.87  These are useful in quantification of environmental PPCP 
residues due to their high resolution and ability to provide accurate mass measurement 
data for precursor and product ions.88  The elucidation of the metabolic pathways of 
PPCPs in the environment is of crucial importance to toxicological studies.  Some 
metabolites may have even more potent biological effects than the parent compound and 
must be identified and removed from the aquatic environment.87  Eichorn et al. 
employed the q-TOF analyser to identify antibiotic metabolites which had been formed 
due to biodegradation activities of sludge on trimethoprim.119  Stolker et al. also reported 
the excellent capability of the q-TOF to provide improved qualitative information and 
improved selectivity over the more conventional triple quadrupole.98   
 
1.9.2 Analytical techniques for determination of PPCPs in the solid environmental 
matrices: 
The analysis of solid matrices for antibiotics and pharmaceuticals is important mainly 
due to the development of antibiotic resistant bacteria, which are exposed in soils, 
sludges and sediments.  If these microorganisms develop resistance there is a possibility 
they will no longer be eliminated when treated with antibiotics and in this way may be 
more harmful to humans.120  PPCPs in solid matrices however are particularly 
challenging to isolate and enrich without co-extraction of matrix components and 
usually require laborious, time-consuming extraction and analysis techniques.  The 
analytical methods designed for this purpose were reviewed by Diaz-Cruz et al. in 2003 
and Xia et al. in 2005.3, 121  In this work, recent advances in this field will be discussed.  
A list of analytical techniques, their operating procedures and validation information is 
provided in Table 1.1 
 55 
Table 1.1: Analytical techniques employed for the extraction, sample clean-up and determination of PPCP residues in solid 
environmental matrices. 
Compounds Matrix Extraction 
procedure 
Clean-up 
procedure 
LC 
column 
Mobile 
Phase 
Detection %Relative/ 
Absolute 
Recovery 
LOQ Detected 
levels 
Ref 
Amphetamine Activated 
sludge 
Ultrasonic 
solvent 
extraction 
(USE) 
Oasis HLB C18-RP 50 mM 
formic acid + 
MeOH  
API-IT ~90% 2 
µg/Kg 
5-300 
µg/Kg 
122
 
Pharmaceuticals, 
and ICM 
Activated 
+ digested 
sludge 
USE Oasis MCX 
C18 SPE 
C18-RP 5 mM 
NH4Ac or 
acetic acid + 
MeCN 
ESI + 
API-QqQ 
~40-119% 
(all 
analytes 
incl.) 
20-50 
µg/Kg 
<1mg/Kg 123 
Antibiotics-
fluoroquinolones, 
trimethoprim, 
sulfamethoxazole 
Anaerobic 
digested 
sludge 
Two step 
USE 
Filtration 
through 
membrane 
syringes 
C18-RP 0.1% formic 
acid + MeCN 
ESI-IT 14-86%  0.1-4.4 
mg/Kg 
124
 
Antibiotics-
sulfonamides, 
macrolides, 
trimethoprim. 
Activated 
sludge 
PLE Oasis HLB C18-RP 1% formic 
acid + MeOH 
ESI-QqQ 78-142% 3-41 
µg/Kg 
12-197 
µg/Kg 
125
 
Antibiotics-
fluoroquinolones 
Municipal 
sewage 
sludge + 
sediment 
USE Chromabond 
Tetracycline 
C18-RP 50 mM 
formic acid + 
MeOH 
API-IT 80-105% 1-7 
ng/L 
30-510  
µg/Kg 
126
 
 
Antibiotics-
fluoroquinolones 
Activated 
+ digested 
sludge + 
soil 
PLE Mixed phase 
cation disk 
SPE 
RP-
Amide 
C16 
25 mM o-
H3PO4 + 
MeCN 
FLD  75-94% 0.18-
0.45 
mg/Kg 
1.4-2.4 
mg/Kg 
127
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Table 1.1: Contd. 
Acidic 
pharmaceuticals, 
antibiotics + 
ivermectin 
River 
sediment 
USE Oasis MCX, 
Lichrolute 
En + C18 
C18-RP 20 mM 
oxalic acid + 
MeCN 
APCI + 
ESI-QqQ 
80-110% 0.4-8 
µg/Kg 
 
107
 
Carbamazepine, 
metabolites + 
caffeine 
WWTP 
biosolid 
PLE Oasis HLB C8-RP 10 mM 
NH4Ac with 
0.1% formic 
acid + 
MeOH/ 
MeCN 
ESI-QqQ 80-92% 0.2-
1.7 
µg/Kg 
2-258 
µg/Kg 
128
 
Tetracyclines + 
tylosin 
Fertilised 
soil 
Liquid-
solid 
extractrion 
(LSE) 
none C18-RP 0.5% formic 
acid with 1 
mM NH4Ac 
+ 
MeCn/MeOH 
ESI-IT ~40-70% ~5 
µg/Kg 
Up to 
200 
µg/Kg 
92
 
Estrogens Digested 
+ 
activated 
sludge 
USE GPC and 
silica gel 
clean-up 
GC 
capillary 
n/a GC-IT 73-104% 2-4 
µg/Kg 
17-49 
µg/Kg 
129
 
Phenylureas, 
triazines + 
chloroacetanilides 
Soil PLE none C18-RP MeCN + 
water 
ESI + 
APCI-IT 
~60-120% 0.3-22 
µg/Kg  
 
130
 
Sulfonamides + 
trimethoprim 
Liquid 
manure 
LLE Aminopropyl 
SPE 
C18-RP 0.1% Formic 
acid, 1 mM 
NH4Ac + 
MeCN 
ESI + 
APCI-
QqQ 
77-91% 5 
µg/Kg 
10-270 
µg/Kg 
131
 
Synthetic musks 
 
 
Biosolid PLE GPC and 
silica gel 
clean-up 
GC 
capillary 
n/a EI-IT >80% 0.2-
1.9 
µg/Kg 
409-7897  
µg/Kg 
132
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Table 1.1: Contd. 
Insecticide + 
pesticides 
Soil and 
digested 
sludge 
PLE Florisil SPE HP5MS 
GC 
capillary 
 
n/a GC-IT >92% 3-62 
µg/Kg 
38-210 
µg/Kg 
133
 
Sulfonamides, 
tetracycline + 
tylosin 
Pig 
manure 
PLE LLE + anion 
exchange 
SPE 
C18-RP Formic acid, 
water + 
MeOH 
ESI-QqQ ~70% 10-
100 
µg/Kg 
2-30 
mg/Kg 
134
 
Estrogens + 
progestrogens 
River 
sediments 
USE Sep-Pak Plus 
C18 SPE 
C18-RP MeCN + 
water 
ESI-MS 64-100%  Low 
µg/Kg 
range 
135
 
Multi-residue Biosolid 
+ 
enriched 
soils 
PLE Oasis HLB C18-RP 10 mM 
NH4Ac + 
MeCN 
ESI-IT ≥60% ~50 
µg/Kg 
5-20 
mg/Kg 
66
 
Antibiotics, 
macrolides + 
ionophores 
Soil PLE Diol SPE C18-RP 100 mM 
NH4Ac + 
MeCN 
APCI-
QqQ 
43-118% 0.6-
5.3 
µg/Kg 
0.7 
µg/Kg 
136
 
Tetracyclines, 
macrolides and 
sulfonamides 
Soil PLE Isolute SAX 
+ Oasis HLB 
C18-RP Formic acid, 
water + 
MeOH 
ESI-QqQ 50-100% 1.5-5 
µg/Kg 
10-55 
µg/Kg  
137
 
Triclosan + 
triclocarban 
Municipal 
sewage 
sludge + 
biosolid 
PLE Oasis HLB C18-RP Water + 
MeOH 
ESI-QqQ 90-103% 5 +0.5 
µg/Kg 
0.62-
11.55 
mg/Kg 
138
 
Sulfonamides Aged soil PLE PVDF 
filtration 
C18-RP 1 mM acetic 
acid in water 
+ MeCN 
ESI-QqQ 41-93% >15 
µg/Kg 
>50 
µg/Kg 
139
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 Sample extraction techniques for solid matrices must be efficient and selective 
for the target analytes due to their low concentration and the high organic load present in 
the sample.  Low recoveries will result from inefficient extraction of analytes or co-
extraction of matrix components.  From Table 1.1, PLE has become the most commonly 
used extraction technique for soils.  However, Hamscher et al. employed liquid-solid 
extraction with no SPE clean-up step for the determination of tetracyclines in soil.92  
Method recoveries were calculated at a range of spiking concentrations and were 
generally in the 60-70% range for all analytes except tetracycline.  This study provides 
evidence that tetracycline is a stable pharmaceutical pollutant which may have an 
affinity for soil particles.92  The last three studies described in Table 1.1 employed PLE 
for the extraction of antibiotics from soil however very different extraction solvents and 
clean-up techniques were employed.136, 137, 139  Schlüsener et al. employed ammonia in 
methanol, Jacobsen et al. used citric acid buffer and methanol with tandem SPE and 
Stoob et al. extracted with acetonitrile : water at pH 8.8.  The tandem SPE involving an 
anion exchanger (SAX) and a hydrophilic-lipophilic polymer (HLB) has also been 
termed ‘mixed-mode SPE’ and worked to remove negatively charged organic material 
and preconcentrate the analytes on the polymer sorbent.137  Despite the differences in 
analytical procedure, the recoveries and limits of quantitation for the three methods are 
quite comparable.  PLE has also been applied to the extraction of pharmaceuticals from 
soil to determine the effect of recycled wastewater being used for irrigation.140  Kinney 
et al. also employed water : acetonitrile as an extraction solvent and determined acidic 
and neutral compounds e.g erythromycin, carbamazepine and fluoxetine.140 
 Sludges are generally analysed directly from the WWTP (activated sludge) and 
have >95% water content, or in a processed form known as dewatered sludge or 
biosolid.141  Activated sludges are sometimes treated as liquids and subjected to LLE 
followed by gel permeation chromatography (GPC) and SPE clean-up, particularly for 
the analysis of polycyclic and nitro-aromatic musks.142  The traditional preparation 
technique for solid samples such as the digested sludges was soxhlet extraction which is 
still commonly used.142  However, the thermal instability of many pharmaceutical 
 59 
residues as well as laborious lab work and higher solvent usage also renders this 
technique outdated when compared to more modern techniques such as USE and PLE.143  
It is evident from Table 1.1, that ultrasonic solvent extraction (USE) and PLE are now 
the most commonly used extraction techniques for liquid and solid sludges.  Both 
sludges are filtered and lyophilised (freeze-dried) prior to extraction to give them solid 
sample characteristics.129  Elimination of excess moisture in the biosolids has also been 
performed using diatomaceous earth to absorb the water before extraction.128  In the case 
of PLE, extraction temperature plays a big role in the efficiency of the technique.  This 
was exemplified in the work of Barron et al. where a decrease in extraction efficiency 
was noted for a range of pharmaceuticals above and below 60 oC.66 
Miao et al. extracted carbamazepine and its metabolites (10,11-dihydro-10,11-
epoxycarbamazepine, 11-dihydro-10,11-epoxycarbamazepine, 2-
hydroxycarbamazepine, 3-hydroxycarbamazepine and 10,11-dihydro-10-
hydroxycarbamazepine) from raw and treated WWTP biosolid using acetone and water 
followed by SPE on Oasis HLB cartridges with excellent recoveries of 80-92%.128  This 
study helped to elucidate the degradation pathways of carbamazepine within the WWTP.  
The study showed that carbamazepine was not effectively removed from wastewater 
during treatment and that it and its metabolites distribute within the aqueous phase rather 
than the solid phases during WWTP treatment 128 
PLE was also applied to the removal of antibiotics in lyophilised sludge by 
Göbel et al. in 2005 and reported good recoveries for macrolides, sulfonamides and 
trimethoprim.125  A study of extraction solvent including methanol, acetonitrile and 
acetone indicated that the most efficient mixture was 50 : 50 methanol : water.  A study 
of pH also indicated that hydrophobic interaction may be responsible for sorption of 
macrolides to sludge.125  The optimised PLE method was also compared to a USE 
method for extraction of the same analytes at two different operating pHs.  Both 
methods provided efficient extraction, however, under both conditions the PLE method 
reported higher recoveries with Oasis HLB as an SPE sorbent.  The recoveries at pH 7 
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and pH 4 were comparable but at pH 7 were more reproducible illustrating that extracts 
can be directly enriched after PLE on the polymer cartridges.125 
 Golet et al. employed a phosphoric acid and acetonitrile PLE extraction solvent 
in the analysis of zwitterionic fluoroquinolone antibiotics including ciprofloxacin and 
norfloxacin.127  An acidic solvent provided the best extraction because at low pH both 
the anionic binding sites on the sludge and the antibiotics were protonated causing 
electrostatic repulsion and better extraction.  USE was tested initially as an alternative 
pre-treatment technique but reported poor recovery data.  Clean-up was performed using 
a mixed-phase cation exchange SPE disk and resulted in overall good method recoveries 
from sludge and sludge treated soil.127  Synthetic musks have also been identified in 
biosolids using PLE in sample treatment with n-hexane and ethyl acetate as extraction 
solvents.132  GC-MS is still employed for the analysis of these compounds due to their 
volatile nature.  However, a more complex sample clean-up involving GPC and silica 
gel columns is required prior to analysis.  The GPC step serves to separate the musk 
fraction for co-extracted compounds.  The synthetic fragrances were found to 
accumulate in biosolids rather than aqueous sludges and were also identified in soil that 
had been treated with the biosolid.132   
 Ternes et al. designed an analytical method for the determination of acidic and 
neutral pharmaceuticals, musks and iodinated contrast media (ICM) in activated and 
digested sludges.123  USE was employed for the extraction of all analytes with 100% 
methanol while PLE was also used to withdraw the polycyclic aromatic musks using 
methanol mixed with acetone.  A range of clean-up techniques were employed including 
cation exchange (for acidic drugs) and reversed-phase SPE sorbents.  The PLE and USE 
methods demonstrated comparable extraction efficiency for two musks (galaxolide and 
tonalide) from both sludge samples.123  Relative recoveries greater than 70% were 
reported for the acidic pharmaceuticals using USE while extraction of the neutral drugs 
was less reproducible.  Although effective, this method involved many different 
extraction techniques to detect a wide range of analytes.123  More recently, Barron et al. 
developed a multi-residue procedure for the analysis of 27 acidic and basic 
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pharmaceuticals and antibiotics in biosolid and biosolid treated soils.66  The method 
involved PLE extraction with Oasis HLB clean-up and reported recoveries ≥60% for 20 
of the analytes in both soil and sludge matrices.  High concentrations of the antibacterial 
triclosan were identified in environmental samples and were even present 3-4 months 
after fertilisation of soil with the contaminated biosolid.66 
 Acidic pharmaceuticals along with antibiotics and parasiticide ivermectin were 
extracted from river sediments using USE.107  Acetone and acetic acid was employed for 
the removal of acidic drugs with clean-up on Oasis MCX at reduced pH to ensure 
ionisation.  The USE method was reported to extract up to 92% of the ibuprofen from 
spiked sediment and the method recoveries for the entire USE-SPE procedure ranged 
from 80-110%.107  The exception to this was bezafibrate which also demonstrated low 
recoveries for Ternes et al.123  Alternative extraction techniques include microwave 
assisted extraction (MAE) which was employed for the extraction of triclosan from 
sludge and sediments by Morales et al. in 2005.144  The target analytes were extracted in 
acetone and methanol under the influence of a microwave field, method recoveries 
ranged from 78-106%.  Recently, Xia et al. reviewed analytical techniques used for 
extraction of PPCPs from solid environmental samples and deemed PLE to be the most 
efficient method in terms of extraction time and solvent consumption.121 
 GC-MS and gas chromatography-tandem mass spectrometry (GC-MS/MS) have 
been the standard methods of analysis in environmental studies for years.  However, 
with the emergence of this new group of pharmaceutical pollutants that includes 
thermolabile, non-volatile and highly polar compounds, LC has become more 
suitable.120  GC is however still employed for the analysis of synthetic musks, pesticides 
and hormones in solid environmental samples as depicted in Table 1.1.129, 132, 133  The 
application of biological assays has also been limited in this field perhaps due to 
insufficient sensitivity and specificity.  Radioimmunoassays (RIA) were applied to the 
detection of anti-microbial residues in animal manure.  The results indicated that when 
compared to a more conventional LC-ESI-MS technique, the RIA had insufficient 
sensitivity to detect low levels of the residues.145   
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 Reversed-phase LC is by far the most popular chromatographic separation mode 
due to its versatility and applicability to a wide range of analytes.  The stationary phase 
of choice (from Table 1.1) is composed of C18 or C8 chains on a silica particle 
packing.120  Retention in reversed-phase chromatography is due to hydrophobic 
interaction between molecule and the alkyl chains of the stationary phase.  Octadecyl 
chains contain a higher hydrophobic organic load than C8 phases, which are also 
popular, and often result in more efficient separations.143  Low flow rates (0.1-0.5 
mL/min) are required with ionisation sources such as ESI and so narrow-bore columns 
(e.g. 2-3 mm i.d.) have become common for chromatographic separations.  Additionally, 
low flow rates have been shown to improve matrix effects.143   
Methanol and acetonitrile are the most commonly used mobile phases, 
particularly for the separation of acidic and neutral pharmaceuticals and are usually used 
individually. However; Miao et al. combined the two organic solvents for the analysis 
carbamazepine in sludges and reported good retention and separation.128  The pH of LC 
mobile phase plays a big role in the efficiency of the separation.  At high pH acidic 
pharmaceuticals are completely dissociated and may not be well retained by reverse-
phase sorbents.  Low pH is more suited to the separation of acidic analytes but for multi-
residue methods the pH must also be suited to basic analytes which require a higher pH 
to avoid ionisation and decreased retention.  In general the pH of the mobile phase 
should be approximately 2 units from the pKa of the analyte.143  Another factor in mobile 
phase composition is compatibility with the MS detector.  Volatile buffers such as 
ammonium acetate and ammonium formate can be added at low concentrations to 
produce reproducible retention times and encourage ionisation in the MS interface but 
can also result in suppression of the signal intensities.146  For acidic drugs ammonium 
acetate concentrations from 2-20 mM are preferred to achieve stable retention and 
acceptable levels of ion suppression.97  Tri-butylamine can also be added to mobile 
phases as an ion-pairing agent to increase sensitivity for anionic pharmaceuticals.  Other 
common mobile phase additives include formic acid and acetic acid which are employed 
for acidification of mobile phase in analysis of antibiotics.92, 125, 126, 131  Shortening of 
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analysis time is also an important factor in multi-residue analysis as long run times are 
often a problem when targeting so many analytes.147   
Analysts are constantly seeking to increase the speed of HPLC analysis without 
losing efficiency of separation.  There are several aspects of the HPLC method that can 
be considered when attempting to shorten analysis time.  Most obviously, increasing 
flow rates can achieve more rapid analyses.  However, higher flow results in higher 
column backpressures, which restrict the flow rate to one that is within the pressure 
limitation of the HPLC system, usually about 400 bar.  At higher flow rates there is less 
time for mass transfer processes to occur in the column and this can lead to a reduction 
in column efficiency. 
Another way of reducing run-time is to decrease the length of the analytical 
column.  Retention times can be cut using this method but unfortunately, less stationary 
phase means less plates and column performance suffers.  These short columns are 
usually packed with smaller particles (sub 2 µm) to overcome this problem.  The smaller 
particles provide a greater surface area and hence greater N values while enhancing mass 
transfer due to smaller diameters.  However, particle diameter is inversely proportional 
to column backpressures and so this approach also has its limits.  
Increasing the column temperature can also be advantageous.  Even though the 
range of temperatures that can be used is limited by stationary phase and solute stability, 
it is still useful.  Mobile phase viscosity is reduced at high temperatures which broadens 
the range of flow rates that can be employed.  Additionally, the rate of mass transfer is 
increased leading to advances in separation efficiency.  
Modern techniques known as ultra-fast LC or UPLC are now commonplace in 
analytical publications.  These new technologies employ expensive, ultra-high pressure 
pumps to produce high flow rates through columns containing sub 2 µm particles.  
Although high values of N have been recorded and analysis times are shorter due to high 
flow rates, these systems require specialised HPLC components, deal with excessively 
high column backpressure, allow only minute sample injection volumes and suffer from 
frictional heating.148  Petrovic et al. and Kasprzyk-Horden et al. have both developed 
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multi-residue techniques for almost 30 pharmaceuticals across a wide range of 
therapeutic classes using UPLC with promising results.112, 113   
Particle packed beds as stationary phases suffer from high operating 
backpressures and slow mass transfer rates.  From the evidence discussed in the section 
on fast HPLC it is obvious that a replacement is needed.  In recent years much attention 
has been focused on the production of columns from a single monolithic block of media 
of either an organic or inorganic material.  These monolithic columns are composed of 
cross-linked polymers or blocks of continuous silica that are porous in nature.148  
Monolithic columns are beneficial to HPLC analyses because they allow for faster flow 
rates and therefore more rapid analysis times due to their macroporous structure.  
Nakanishi et al. published one of the first papers on the production of silica monolithic 
rods which had a biporous structure of large pores in the micrometre range and smaller 
‘meso-pores’ in the nanometre range.149, 150  The monoliths rigid structure has enhanced 
permeability and so higher flow rates are permitted without the hindrance of high 
backpressures.  This porosity and large surface area have a second advantage, mass 
transfer kinetics occur more rapidly in the monolithic columns leading to less band 
broadening at high flow rates.  Additionally, capacity for large sample volumes is also 
increased by the presence of the miniscule meso-pores in the monolithic structure.148 
 UV and fluorescent detection have been employed for the analysis of PPCPs in 
solid matrices and up until a few years ago were still the detection techniques of 
choice.127, 135, 151  Kinney et al. applied LC-ESI-MS to the determination of acidic and 
neutral pharmaceuticals in soils.  The specificity of this technique can be improved to 
mimic that of an LC-MS/MS instrument by increasing the exit voltage across the needle 
in the electrospray chamber.  This increased energy causes the molecular ions to 
fragment and is known as collisionally induced dissociation (CID).143  This approach to 
increasing specificity was utilised by Cahill et al. for the analysis of drugs in water 
samples.152  However, CID can lead to co-extracted compounds and matrix components 
in the complex samples also fragmenting within the ion source which affect the 
sensitivity and accuracy of the measurement. 
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 The two most common interfaces used in LC-MS/MS of environmental solids 
are carried out at atmospheric pressure, i.e. ESI and APCI.  From Table 1.1 the 
electrospray technique has been used most often for analysis of solid samples but APCI 
is also common.153  For certain analytes such as the acidic pharmaceuticals, ESI has 
proven to be a more sensitive technique as demonstrated by Stolker et al.98, however, 
both ionisation procedures are suitable for analysis of neutral and basic analytes.106  The 
most commonly used mass analysers used in LC-MS/MS, from Table 1.1 are the triple 
quadrupole (QqQ) and the ion-trap (IT).  These instruments can be operated to fragment 
the parent drugs molecules and allow unequivocal identification of compounds.120  Even 
more advanced quadrupole-TOF instruments are now becoming widely available and 
provide high resolution analysis not possible on the aforementioned analysers.143 
 The limits of quantification (LOQ) for analysis of PPCPs in sludge samples 
using IT and QqQ mass analysers given in Table 1.1 demonstrate that both techniques 
provide comparable levels of sensitivity.  Methods using both instruments have reported 
LOQs of between 0.2 and 50 µg/Kg for pharmaceuticals, antibiotics and synthetic 
musks.  These results illustrate the versatility and specificity of tandem MS for 
pharmaceutical analytes even in complex matrices.  Table 1.1 also depicts the 
applicability of these techniques to the determination of a very diverse group of analytes 
analysis in real environmental samples, many of which were detected in the µg/Kg or 
ng/g range.  Although not yet demonstrated for solid matrices, the advantages of the new 
q-TOF mass analyser have already been demonstrated. Stolker et al. employed both a q-
TOF and QqQ for the analysis of acidic drugs and antibiotics in environmental water 
samples.98  The q-TOF allowed for all analytes to be screened and identified using the 
exact masses of the product ions in one run.98  Loffler et al. demonstrated that different 
ionisation techniques can be employed depending on the nature of the compounds.107  In 
this study, APCI-MS/MS was employed for acidic pharmaceuticals while the antibiotics 
were analysed using ESI-MS/MS.  Limits of quantification (LOQs) were comparable 
though slightly lower for the pharmaceuticals.107  Schlusener et al. employed APCI-
MS/MS in SRM mode for the analysis of macrolides (e.g. erythromycin) and ionophores 
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(veterinary antibiotics) in manure and reported very low limits of detection (LODs) of 
0.2-1.6 µg/Kg.136  There is growing concern in MS/MS analysis about the criteria for 
confirmation of pharmaceutical residues in environmental samples to avoid false 
positives being reported.  The European Commission Guidelines now state that at least 
two SRM transitions must be monitored for correct identification of a compound in an 
environmental matrix when using a conventional QqQ instrument.  Mass analysers such 
as the q-TOF are becoming increasingly popular as their ability to produce full scan 
product ion spectra simplifies analysis.147 
 One of the pitfalls of MS/MS analysis is the matrix effect.  It affects data quality 
in LC-MS, GC-MS, GC-MS/MS and LC-MS/MS.  The matrix effect leads to differences 
in analyte signal when compared to a standard solution.  In GC-MS and GC-MS/MS 
analysis matrix effects are most commonly caused by co-extracted material in the 
sample that elutes at the same time as the analyte or has a similar m/z value as the target 
compound.  This problem can also be seen in LC analysis and can be partially solved by 
improving the separation step.  In LC-MS and LC-MS/MS analysis, the major drawback 
is the susceptibility of API interfaces such as ESI and APCI to ion suppression or 
enhancement caused by interfering matrix components.  The co-extracted compounds 
can be organic or inorganic and interact with the analytes during sample preparation or 
during ionisation in the interface.88  The extracted interferences can vary between 
samples and so the matrix effect in a series of samples is not uniform or predictable.  
The signal suppression or enhancement that occurs can affect linearity, precision and 
accuracy of quantitative data from LC-MS/MS analysis.147  Ion suppression is probably 
the most common effect observed in environmental analysis and has become one of the 
most challenging issues for analytical scientists.  It is caused by interfering compounds 
in the ion source which reduce the efficiency of desolvation and desorption processes 
resulting in a varying amount of charged analyte reaching the detector.147  
Environmental samples such as soil and sludge pose a severe risk of matrix effects in 
reversed-phase liquid chromatography (RPLC) due to a higher organic load and are also 
very unpredictable due to inhomogeneity of the samples.88 
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 A number of studies have indicated that APCI is affected by matrix effects to a 
lesser extent than ESI.106, 154  Zuehlke et al. reported that highly polar pharmaceuticals 
were strongly suppressed when employing ESI whereas APCI reported recoveries close 
to 100%.154  Similar results were reported by Schlüsener et al. for the detection of 
steroid hormones and antibiotics in the influent and effluent of sewage plants.155  The 
two ionisation techniques were compared and a much higher matrix effect was reported 
for ESI even after extensive sample-clean-up with SPE and size exclusion 
chromatography (SEC).  Unfortunately, ionisation of all analytes was not possible when 
using APCI and so ESI had to be used for quantification.155  It is a well known fact that 
APCI is not as suitable ionisation technique for very polar compounds as ESI and so the 
matrix effect associated with ESI must be dealt with.143   
Matrix effects can also be caused by contamination of the internal parts of the 
instrument.  With ESI, the end plate of the source can become dirty, particularly when 
analysing complex samples such as sludge.  As analysis progresses, the matrix 
components that adhere to the end plate can enter the source resulting in suppression or 
enhancement.  The unpredictability of matrix effects is exemplified by another study 
conducted by Ingrand et al. for steroid hormones also in the effluents of a WWTP.156  In 
this study, APCI and ESI were compared in both positive and negative mode and ESI 
negative mode was chosen as the most sensitive technique for analysis.156  Pfeifer et al. 
employed both ionisation techniques for the analysis of antibiotics in manure.131  The 
ionisation efficiency of the two techniques was comparable.  Sodiated adducts were 
observed when using ESI and the intensity of signals varied with the amount of sodium 
in the sample.  Both enhancement and suppression were observed for analytes when 
using ESI while only enhancement was reported for APCI analysis.131  The increase in 
matrix effect with increasing complexity of sample matrix was exemplified in a study by 
Miao et al. which compared signal suppression in a range of sample matrices including 
influents, effluents, surface water and analytical grade water.157  LC-ESI-MS/MS 
analysis exhibited increasing ion suppression from surface water to effluent to influent 
while no effect was observed for the analytical grade water.157  High levels of ion 
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suppression have also been reported for more complex matrices such as soil and sludge.  
Barron et al. reported low levels of suppression, <5% for most target analytes in soil 
extracts but much higher levels were noted for the analytes extracted from sludge 
samples.  The average matrix induced suppression effect in sludge was 42 ± 20%, most 
likely due to the high organic load associated with sludge samples.  However, the 
analytes that eluted late were most highly suppressed perhaps due to the high percentage 
of organic solvent in the mobile phase flushing out hydrophobic matrix components.66  
Stoob et al. also reported ion suppression of sulfonamides in soil samples as high as 
63%.  This method did not include a SPE clean-up step but the sample was filtered 
through a PVDF membrane with a 0.45 µm pore size.139   
 A number of operational techniques have been applied to the task of eliminating 
matrix effects in LC-MS/MS analysis.  Improvement of chromatographic separation will 
generally reduce the signal suppression or enhancement.88  SPE methods can be 
designed to selectively enrich only the analytes, leaving interfering compounds behind.  
However, exhaustive sample clean-up can be time-consuming, laborious and there is a 
risk of losing some target analyte and it is also challenging to develop preparation 
methods applicable to a wide range of PPCPs.88  Size-exclusion techniques are a new 
method of removing high molecular weight interfering components from a sample.  
Restricted access materials (RAMs) and molecularly imprinted polymers (MIPs) may be 
the new generation of SPE sorbents for clean-up of environmental and biological 
matrices.  Koeber et al. have applied these new clean-up materials to the extraction of 
triazines from riverwater with excellent elimination of matrix components.158  This topic 
has also recently been reviewed.159  Kloepfer et al. applied ultrafiltration to removal of 
organic interferents from riverwater with less successful results indicating that much of 
the matrix effect could be caused by small organic compounds.117  In the same study, the 
flow of sample and mobile phase entering the interface was decreased using a column 
splitter.  This technique reduced matrix effects very effectively and increased method 
sensitivity with signal intensity increasing up to nine-fold.117  Dilution of samples has 
also been employed for a reduction in matrix effects.100 
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 When quantifying traces of pharmaceuticals in the environment there are a 
number accepted approaches to overcoming the effect ion suppression and enhancement 
have on the accuracy of the results.  External calibrations using matrix matched samples 
can be employed to obtain a calibration curve, however this technique requires an 
uncontaminated matrix which is not always easy to find.134, 136  The conventional method 
of standard additions is still employed but does involve time and effort especially with 
multi-residue methods.111  Addition of internal standards is now a widely used 
quantification technique in trace environmental analysis.  Structurally similar analogues 
of the analyte can be added to standards to eliminate matrix effects to some extent.  
However, matrix effects are not constant throughout a chromatographic separation and 
so one internal standard is not sufficient.  It can be difficult to source compounds that are 
structurally similar to all the analytes that will elute close to the analyte retention time 
and behave in a similar way in the ion source.124  The most successful method of 
eliminating matrix effects is the use of isotopically labelled standards.  These standards 
can be deuterated or contain C13, however heavier deuterated standards will have slightly 
different retention times than the target analytes.  However the commercial availability 
of these standards is limited and they can be quite expensive.143  The different 
approaches to quantification have been compared and contrasted for aqueous 
environmental samples.  Van de Steene et al. examined numerous methods to reduce 
signal suppression including structurally similar compounds as internal standards.160  It 
was reported than this technique partially compensated for the matrix effects, however 
standard additions were still employed for quantification to overcome the problem of 
varying matrix effect between samples.160  Gros et al. also investigated the ability of 
internal standards and matrix matched external calibration to reduce suppression effects 
in wastewater on 29 multi-class pharmaceuticals.103  The study concluded that addition 
of isotopically labelled internal standards was the most efficient method of correcting 
loss in signal intensity without being labour intensive.103  Internal standards have been 
applied in the analysis of more complex matrices such as sludge, biosolid and WWTP 
influent and effluent.125, 138, 155 
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 The analytical techniques available for the determination of PPCPs in 
environmental samples have advanced immensely over the past decade.  It is estimated 
that only approximately 5% of the approved medicinal compounds have been 
investigated in environmental samples.93, 107  It is important to analyse all types of 
matrices for these traces in order to comprehend the impact on the environment.  More 
sensitive, reliable and efficient methods of analysis are always needed in environmental 
analysis so that risk assessment data can be collected about these emerging pollutants.  
Further work is needed to solve the problems associated with the modern techniques 
such as matrix effects in LC-MS/MS and there is a need for more focus on the drug 
metabolites and not just the parent drugs entering our environment. 
 
1.10 Analysis of PPCPs in Complex Biological Matrices: 
 
1.10.1 Introduction: 
The presence of pharmaceuticals particularly hormones and antibiotics in food products 
and the environment is a topic of growing concern.  The exposure of healthcare and 
agricultural employees to harmful drugs is also receiving increased attention.2, 4, 161  
There is increasing concerns about the effects of occupational exposure to cytotoxic 
drugs and amended guidelines on the handling of these drugs have been introduced in 
many countries.162  Antibiotic resistance is another pressing issue and is known to be 
spread by chronic exposure to antimicrobial agents.163  The WHO has labelled the 
increasing rates of resistance to antibiotics as one of the most worrying health issues of 
the century.164  Because of these environmental and healthcare issues, there is always a 
demand for analytical techniques suitable for the detection of low concentrations of 
pharmaceuticals in biological matrices.   
There are many biological matrices that can be analysed for PPCPs and provide 
information about the fate and effects of PPCPs in the environment and in living 
organisms.  These complex matrices include blood (includes plasma and serum), urine, 
saliva, hair and tissue and a wide range of analytical techniques have been used to 
 71 
investigate them.  Biological samples are different to environmental matrices in their 
make-up but pose similar challenges for sample clean-up, sensitive analysis and 
elimination of matrix effects.  Tissue is probably the least commonly used type of 
biological sample employed for drug analysis as it is highly-invasive to obtain.  Recently 
fish tissues have been analysed using chromatographic techniques coupled to MS 
detection to investigate the bioaccumulation of PPCPs in living organisms.  Similar 
extraction and analysis methods as discussed for environmental samples were applied to 
these biological matrices.  Although matrix effects were problematic during the analysis, 
the studies indicated that bioaccumulation of drugs particularly anti-depressants in 
tissues of aquatic organisms does occur.165, 166   
Biofluidic matrices such as urine and blood have been analysed using 
immunoassays167, capillary electrophoresis168, micellar electrokinetic chromatography 
(MEKC)169 and more conventional chromatographic techniques such as GC and LC170.  
The advent of improved extraction procedures such as SPE and SPME along with easy 
access to selective MS detectors has resulted in increased use of GC-MS/MS and LC-
MS/MS in the analysis of pharmaceuticals in biological matrices particularly hair and 
urine.171, 172  Both hair and urine are non-invasive samples to collect and exposure to 
many different types of legal and illegal pharmaceutical compounds can monitored.170, 
171, 173
  These sample types can also provide an indication of any chronic exposure to 
chemicals or harmful drugs in the environment and are useful for monitoring the use of 
veterinary drugs.174, 175  This section aims to discuss the analytical techniques that are 
applied to the determination of PPCPs in biological matrices with particular focus on the 
use of chromatographic techniques for the analysis of hair and urine. 
 
1.10.2 Analytical techniques for determination of PPCPs in hair: 
Analysis of hair has received a lot of attention in the last three decades, since 
Baumgartner et al. used a radioimmunoassay (RIA) to detect opiates in hair strands at 
µg/g levels.176  Prior to this hair had been analysed to evaluate exposure to toxic heavy 
metals such as arsenic, mercury and lead.177  Baumgartner and co-workers demonstrated 
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that the concentration of drug along the shaft of hair corresponded to the time of drug 
use.176  The first chromatographic analysis of hair was conducted by Klug et al. in 1980 
and led to a surge of research in the area of hair analysis over the next thirty years.178  
Today, standardised analysis techniques for hair testing have been published to provide 
recommendations in forensic hair analysis.179, 180  In modern drug testing preliminary 
tests can be carried out for some drugs using immunoassys to determine any possible 
traces.181, 182  GC-MS is the method of choice for confirmatory analysis,183 however 
other hyphenated techniques such as LC-MS/MS are becoming popular.184 
The main advantages of hair analysis over other matrices such as plasma, serum 
or urine is the longer window of analysis, (months or even years depending on hair 
length), the non-invasive nature of sample collection, segmented hair analysis can 
provide information of time and length of drug use and repetitive use can also be 
documented.171  Applications of hair analysis include workplace drug testing, doping 
control in athletes, drug abuse history, exposure to environmental pollutants or food 
poisoning, post-mortem toxicology, drug-facilitated assaults and even determination of 
alcohol abuse.171 
 The anatomical and physiological properties of hair have been described in many 
publications, however the structure of hair and the incorporation of pharmaceuticals into 
the hair strand are still not fully understood.185, 186,187  Hair is heterogenous in nature, it is 
composed of keratinised cells held together by a cell membrane structure (composed of 
proteins and lipids) and can be divided into three individual sections known as the 
cortex, cutical and medulla. The structure of a hair is shown in Figure 1.6.171  Hair 
growth originates in the follicle below the surface of the skin.  The growth process 
occurs in cycles composed of the anagen, catagen and telogen phases.177  These phases 
last approximately 4-8 years, ~2 weeks and ~10 weeks, respectively.  The anagen step 
involves rapid growth when the follicle is actively producing new hair cells at a rate of 
0.6-1.4 cm/month.  The catagen phase involves transition from active to a state of resting 
which is the telogen phase.177  Axillary and pubic hair can also be employed for analysis 
as an alternative to head hair but obviously have differing growth rates. Studies have 
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found that drug concentrations in pubic and axillary hair vary significantly from those 
found in head hair.188-190  This variation could be explained by differing blood flow and 
the aforementioned differing growth rates.191 
 
Medulla
Cuticle
Cortex
 
Figure 1.6: Structure of hair strand, adapted from ref. 171 
 
Most models that describe the incorporation of drugs into hair propose external 
adsorption from the environment and passive diffusion from the blood during hair 
growth.  However, studies have shown that substances can be integrated into the hair 
structure by other routes such as diffusions from sweat and sebum into the shaft and 
incorporation from skin cells.171 A multi-compartment model such as this has been 
demonstrated by Henderson.192  There are three main factors that affect the integration 
of drugs into hair: the amount of melanin in hair, the acidic, basic and lipophilic nature 
of the drug itself.171  Hair samples with a lower melanin content or non-pigmented hair 
have been shown to incorporate a lower concentration of basic drugs than highly 
pigmented hair.  There was however no difference in the concentrations of neutral drugs 
such as carbamazepine.193  Drug molecules with a high degree of lipophilicity can easily 
pass through cell membranes.  However for hydrophilic or ionised molecules, cell 
 74 
membranes are an impermeable barrier.171  A study by van Erp et al. demonstrated that 
the intracellular pH of hair cells such as keratinocytes is acidic and in vitro studies by 
Claffey et al. confirmed that melanin has an affinity for basic drugs.194, 195  The 
combination of these factors results in the accumulation of basic and neutral drugs in 
hair such as cocaine and acidic drugs such as ∆9-tetrahydrocannabinol (THC).196  Once 
incorporated into the hair, the drugs exhibit high levels of retention and stability and 
have even been detected up to three years after drug consumption, however this analysis 
depends on the length of the sample.197 
 As already mentioned, immunoassays are commonly used as a preliminary 
screening method which if returning positive results, will lead to a confirmatory 
chromatographic analysis.182  Previously designed immunoassays for the analysis of 
urine were applied to detection of drugs in hair samples and suffered from lack of 
specificity and sensitivity.171  More recently, enzyme-linked immunosorbent assays 
(ELISA) kits have been developed which employ coated well technology and have 
demonstrated suitable sensitivity for use in hair analysis.198, 199  These ELISA test kits 
are also easily automated and are very useful for rapid and simple screening of hair 
samples in laboratories which handle many samples.200  Despite these recent advances 
all positive results reported from an immunological test must be verified by 
chromatographic analysis.171 
 Hair from the test subject is usually collected from the vertex posterior due to 
relatively uniform rate of growth in hairs at this point.  After collection, the hair should 
be stored at room temperature in dry, dark conditions preferably in a paper envelope,171 
however plastic containers have also been employed.201  The former are preferred as 
plasticisers in the latter may damage the sample.171  Figure 1.7 below describes the steps 
involved in collection, extraction and analysis of hair samples.171  There are sources of 
error associated with each step of the analytical procedure which will be discussed later 
in this Section.202 
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Segmentation
Sampling and storage
Decontamination by washing
Extraction or digestion
Cut into small pieces or grinding
Pre-test by immunoassayClean-up of extract
Confirmation analysis by GC-MS, GC-MS/MS 
or LC-MS/MS
Interpretation of results
 
Figure 1.7: Flow diagram of the steps involved in hair analysis, adapted from ref. 171 
 
Chromatographic techniques are the most commonly used methods of analysing hair 
samples but extensive extraction and clean-up procedures are needed to ensure the 
samples are compatible with the technique and to minimise matrix effects.  Table 1.2 
below lists details of some of the chromatographic techniques that have been applied to 
the analysis of drugs in hair samples. 
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Table 1.2: List of chromatographic methods developed for the analysis of drugs in hair samples. (SFE: supercritical fluid 
extraction, HCl: hydrochloric acid, CH2Cl2: dichloromethane, NaOH: sodium hydroxide, MeOH: methanol, DIH2O: distilled 
water) 
Year Analytes Preparation Extraction Clean-up LOD Recovery 
% 
Analysis Ref. 
1995 Opiates, cocaine, 
morphine, codeine, 
6-MAM 
CH2Cl2 + 50mg of 
pulverised hair  
Incubated in 0.1 
M HCl overnight 
at 56 oC 
LLE and 
derivatised 
ng/mg 68-86  GC-MS 203 
1995 Amphetamines CH2Cl2  + DIH2O 
washing + 30-50 
mg hair/sample 
Incubated in 1 M 
NaOH at 95 oC 
for 10 min 
LLE and 
derivatised 
ng/mg 76-82 GC-MS 190 
1995 Opiates CH2Cl2  wash + 50 
mg hair/sample 
SFE – with pure 
CO2 + modifier 
Evaporated to 
dryness + 
derivatised 
ng/mg 53-96 GC-MS 204 
1995 Cocaine +BEG MeOH wash + 
hair cut 
Incubated in 
MeOH for 18 hrs 
at 40 oC  
SPE and 
derivatised 
ng/mg  GC-MS 205 
1995 THC +THC-COOH CH2Cl2 wash + 
500 mg hair 
pulverised 
Incubated in 1ml 
1M NaOH 
10min @ 95oC 
LLE and 
derivatised 
ng/mg 75-80 GC-MS-
SIM 
189
 
1997 Benzodiazepines CH2Cl2 wash and 
pulverised 
Incubated in  
Sorensen buffer 
pH7.6 for 2 hrs 
at 40 oC 
LLE and 
derivatised 
pg/mg 
range 
48-90 GC-NCI-
MS 
206
 
1997 Amphetamine, 
MDMA, MDA 
 
CH2Cl2 wash + 30  
mg hair pulverized  
Incubated in 1 ml 
NaOH 10 mins 
@ 95 oC 
LLE and 
derivatised 
ng/mg   GC-MS 207 
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Table 1.2: Contd. 
1998 Cocaine, BEG and  
Cocaethylene 
 
 
CH2Cl2 and water 
washes + 100 mg 
of hair analysed 
Incubated in 0.1 
M HCl for 15 hrs 
@ 56 oC  
SPE  ng/mg 88-92 LC-ESI-
MS/MS 
208
 
2000 Methadone and 
EDDP 
DIH2O and 
acetone washes 
and 50 mg of cut 
hair 
DTT and Pronase 
extraction at 37 
oC for 12 hrs 
SPME  ng/mg 103-107 GC-MS 209 
2000 Lipophilic organic 
drugs 
 
DIH2O + acetone Alkaline hair 
digestion 
HS-SPME ng/mg  GC-MS 210 
2001 Methadone + EDDP 
 
 
 
DIH2O, CH2Cl2 + 
MeOH 
Incubated in 0.01 
M HCl overnight 
at 60 °C 
Automated 
SPE 
ng/mg 80-86 GC-IT-
MS 
211
 
2002 Cannabinoids 
including THC 
 
DIH2O, petroleum 
ether +CH2Cl2 
Alkaline 
hydrolysis 
HS-SPME ng/mg  GC-MS 212 
2003 Opiates, cocaine and 
BEG 
MeOH wash, 
pulverized + 20 
mg analysed 
Incubated in pH 
5 phosphate 
buffer at 45 oC 
for 18 hrs 
SPE and 
derivatised 
ng/mg 81-90 GC-MS  213 
2003 Tramadol Sodium 
dodecylsulfate + 
MeOH 
Incubated in 3 M 
HCl overnight at 
60 °C 
SPE ng/mg 87-94 GC-MS 214 
2004 Ethyl glucuronide + 
fatty acid ethyl 
esters 
 
n-heptane dimethyl 
sulfoxide/n-
heptane 
HS-SPME + 
SPE + 
derivatised 
ng/mg  GC-MS 215 
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Table 2.1: Contd. 
2004 Opiates + Cocaine 20 mg of hair 
pulverised  
MeOH 
sonication @ 37 
oC 3 hr 
SPE pg/mg 71-90 LC-
APCI-
MS/MS 
216
 
2004 Zoplicone CH2Cl2 wash, cut 
up + 20 mg 
analysed 
Incubated in pH 
8.4 phosphate 
buffer overnight 
LLE pg/mg 92 LC-ESI-
MS/MS 
217
 
2004 Bromazepam, 
clonazepam and 
metabolites 
CH2Cl2 washes, 
powdered or cut 
up + 20 mg 
analysed 
Incubated in pH 
7.6 Sorensen 
buffer for 14 hrs 
@ 56 oC  
LLE 
 
 
pg/mg  LC-ESI-
MS/MS 
218
 
2005 Fentanyl, sufentanil 
+ other opioids  
CH2Cl2 wash + 
50mg hair 
pulverised 
Phosphate buffer 
pH 8.4 overnight 
LLE and 
derivatised 
pg/mg >75 GC-
MS/MS-
SRM 
219
 
2005 Benzodiazepines CH2Cl2 wash, cut 
up + 20 mg 
analysed 
Incubated in 
Sorensen buffer 
at 56 oC for 14 
hrs 
LLE pg/mg  LC-ESI-
MS/MS 
220
 
2005 Benzodiazepines  CH2Cl2 wash, cut 
up + 20 mg 
analysed 
Incubated in pH 
8.4 phosphate 
buffer overnight 
LLE  LOQ 
0.5-5 
pg/mg 
32-76 LC-ESI-
MS/MS  
221
 
2006 Opiates, cocaine, 
BEG, methadone, 
EDDP and others 
CH2Cl2 + 
petroleum ether, 
washings + hair 
cut 
Incubated in 
methanol 
overnight at 40 
oC or alkaline 
hydrolysis 
SPE and HS-
SPME 
ng/mg  GC-MS 222 
2007 Amphetamines + 
analogues 
Ethanol + CH2Cl2 Incubated in 1 M 
NaOH for 15 
min at 80 °C  
LLE pg/mg 71-99 LC-ESI-
MS/MS 
223
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After sample collection, the next step of the analytical process is decontamination.  This 
is a very important part of the analysis for a number of reasons. Firstly, if personal care 
products, sweat and dust are not removed prior to analysis they can enhance matrix 
effects.  Secondly, external contamination of hair with drugs can occur without 
consumption of the compound.171  Studies have shown that individuals exposed to a 
drug vapour in order to mimic an environment where a drug is being smoked, results in 
significant contamination to hair.205  The ideal washing solvent should remove any 
interfering compounds completely without damaging the hair sample or extracting any 
drugs which maybe inside the matrix.171  From Table 1.2 there is a wide range of wash 
solvents employed for decontamination of hair samples.  These include surfactants such 
as sodium dodecylsulfate, dichloromethane, methanol, acetone, petroleum ether and 
distilled water. Non-protic solvents are advantageous as they do not promote extraction 
of drugs during the wash procedure however methanol and phosphate buffer can swell 
the hair structure resulting in removal of compounds from the hair matrix.  Choice of the 
incorrect solvent for decontamination could lead to false positives and inaccuracies 171 
 As there is not yet a direct method available for the detection of drugs in hair, the 
matrix must be degraded to release any compounds from within.  To aid in this process 
the sample is usually cut into small pieces or subjected to grinding or pulverizing.218, 220  
Before choosing an extraction method there are a number of factors to consider.  The 
structure of the drug being extracted, the extraction solvent and the length of the process 
all have to be optimised.  Incorrect extraction conditions could lead to insufficient 
extraction, drug decomposition or co-extracted impurities.  From Table 1.2 the most 
commonly used extraction solvents are methanol, aqueous buffers, and sodium 
hydroxide.  Methanolic extraction can be used for almost all types of drugs.  Extraction 
occurs due to swelling of the hair matrix and release of the drugs due to diffusion.  This 
approach allows for the extraction of neutral and lipophilic compounds and does not 
result in as much hydrolysis of analytes during extraction as with other solvents.213  
Extraction with methanol can also allow for direct injection of the extract into GC-MS, 
however this is only suited to analytes that are at high concentrations as co-extraction of 
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matrix components is inevitable and a clean-up step is almost always needed.224  
Aqueous buffer solutions such as phosphate buffers and dilute HCl extractions are 
particularly useful for the extraction of basic drug residues.  The extracts are cleaner 
than those from methanol extraction however, hydrolysis of certain analytes such as 
cocaine and the marker of heroin usage, 6-monoacetylmorphine, (6-MAM) to 
benzoylecgonine and morphine respectively is a major disadvantage.208, 211, 213  The most 
quantitative extraction method is sodium hydroxide extraction, which involves digestion 
of the hair matrix, however not all drugs are stable under such alkaline conditions, for 
example cocaine.224  This extraction technique has shown particular use for the removal 
of amphetamine and its analogues,207, 223 cannabinoids,189, 212 and can also be used in 
conjunction with headspace solid phase micro-extraction (HS-SPME) for multi-residue 
analysis.210  Enzymatic extractions have also been conducted using enzymes such as 
pronase which can hydrolyse the hair structure by reducing disulfide bonds.209  Finally, 
supercritical fluid extraction (SFE) has been applied to extraction of opiates, 
amphetamines and other illicit drugs.204, 225, 226  The supercritical fluid usually consists of 
CO2 plus a modifier however this technique is not commonly used due to high 
expense.171 
 Direct injection of extracts is only possible after SFE or with methanolic 
extraction, more commonly a clean-up step is needed.  LLE is still quite useful for 
elimination of matrix components as the samples are usually very small.  The extraction 
is carried out under alkaline conditions and organic solvents used include diethyl ether 
and dichloromethane.217-219  SPE is also a common method of sample enrichment as can 
be seen in Table 1.2.  It has become more popular in recent years due to improved 
sorbents and is also easily automated.171  Cartridges employed have generally been 
mixed-mode sorbents with hydrophobic and ion-exchange characteristics.  Clauwert et 
al. used a mixed-mode C8 and strong cation exchange functionalised silica for the 
extraction of basic drugs.208  A similar sorbent manufactured by Varian (Bond Elut 
Certify) has also been used for extraction of opiates, cocaine and benzoylecgonine and 
Cleanscreen cartridges which employ reversed-phase and sulfonic acid retention 
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mechanisms were used to enrich a similar group of analytes.213, 216  However, more 
recently, SPME has received a lot of attention as an analyte enrichment technique with 
advantages such as miniaturization, automation, no organic solvent use and direct 
thermal desorption from the fibre into the GC instrument.222, 227, 228  SPME can be used 
for direct extraction from the liquid extract which has previously described for 
methadone and its metabolite EDDP.209  Another approach is to use the headspace 
version of the technique.  HS-SPME has proven to be a simple and efficient method of 
enriching drug residues in hair extracts.  It employs a silica fibre coated in a polymeric 
stationary phase and can be suitable for lipophilic substances and even those with 
relatively low volatility.224  The analytes are adsorbed onto the fibre coating and can 
then be desorbed into the GC injection port directly.224  Apart from pharmaceutical 
extraction, this clean-up technique has also been employed for the enrichment of 
markers of alcohol abuse such as fatty acid ethyl esters.215  However if confronted with 
non-volatile solutes within a complex sample matrix, SPME may not be the most 
suitable extraction technique.  In addition, the extraction procedure takes more time than  
 Analytical methods for determination of drugs in hair must be suitable for 
unequivocal identification and quantification.  Difficulties in developing these methods 
are the small sample size and the low concentrations of drugs that are present.171  For 
years, GC-MS has been the method of choice for hair analysis.  The high resolution of 
the capillary separation coupled with the selectivity of MS detection results in specific 
and sensitive methods of analysis.  The use of SIM mode measurements and deuterated 
standards to minimise matrix effects can improve the accuracy of the technique.171  The 
limits of detection of recently developed GC-MS methods are in the low ng/mg or high 
pg/mg range.209, 213  However, as is well known, GC requires thermally stable, volatile 
analytes which means that derivatisation is often required and many drugs do not 
possess these physiochemical characteristics.  Particularly for multi-residue analysis in 
hair, this can be a problem as mixed derivatisation steps are needed for detection of all 
analytes.171  Cirimele et al. used negative chemical ionization as an alternative ionization 
technique and achieved lower LODs in the range of 1-20 pg/mg for benzodiazepines.206  
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Recent advances in technology have made GC-MS/MS more available.  This has 
resulted in the use of MRM mode where more than one fragment ion is monitored for 
each analyte.  This technique has increased the sensitivity and specificity with LODs in 
the low pg/mg range, and is increasingly used in hair analysis.219, 229-231   
 LC-MS/MS analysis of hair almost eliminates issues such as derivatisation, 
volatility or thermal stability from the analytical procedure.  LC-MS/MS has the ability 
to separate a diverse range of analytes often without derivatisation and even though it 
does not have the chromatographic resolution of GC, this is compensated for by the 
specificity of MS/MS detection.  LC-MS/MS has been particularly useful for the 
analysis of a range of benzodiazepines and zoplicone in hair samples.217, 221  However, 
the technique has also been applied to the analysis of medicinal drugs such as 
neuroleptics, psychotherapeutic drugs and markers of alcoholism.232-234  LC-MS/MS 
analysis offers LODs, often <1 pg/mg which are as low if not lower than GC-MS/MS 
techniques.217, 218  The most commonly used instrumental setups are ESI and APCI 
ionization coupled to QqQ or IT mass analysers operated in SRM or MRM modes.  The 
advent of new q-TOF instruments has not gone unnoticed and may be very useful in the 
future for the identification of unknown compounds.224  As already discussed, when 
analysing complex sample types using LC-MS/MS, the greatest challenge is the 
elimination of interfering components which can cause ion suppression or enhancement.  
Generally in hair analysis, deuterated standards or similarly structured analogues of the 
analytes are added as internal standards.208, 220, 221  During the development of an 
analytical method for hair analysis, matrix effects must be documented.235  Scheidweiler 
et al. quantified matrix effects observed during the analysis of opiates, cocaine and their 
metabolites.  It was reported that benzoylecgonine, morphine and 6-acetylmorphine 
were matrix enhanced while cocaethylene demonstrated ion suppression.216  Conversely 
Villain et al. reported no matrix effects from endogenous substances during the analysis 
of 16 benzodiazepines in hair after extraction in alkaline buffer and LLE clean-up.221 
 There are a vast number of applications for analysis of pharmaceuticals in hair 
and they have recently been comprehensively reviewed by Pragst.171  Briefly, drug 
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treatment programmes can use hair analysis as a tool to manage patients as it provides a 
window into their drug history.  Consumption of prescribed drugs as well as any illicit 
compounds can be monitored.222  Particularly in heroin treatment programmes, abuse of 
illicit heroin and consumption of prescribed pharmaceutical heroin can be 
distinguished.236, 237  Hair analysis is very useful in the prosecution of drug-facilitated 
crimes (DFCs) as it provides a longer window for analysis to be carried out.  Urine and 
blood analysis are useless unless analysed directly after an assault has taken place.  Hair 
analysis overcomes this obstacle and can also provide information as to the time of the 
assault from segmented analysis.224  A number of studies have been conducted to 
determine benzodiazepines and zolpidem in the hair of assault victims.217, 218, 220  Other 
applications of hair analysis include: determination of fetal drug exposure,238 monitoring 
drug abuse in the workplace,219 and detection of alcohol abuse.188, 215  To conclude, hair 
analysis is a valuable complementary technique to more conventional urine and blood 
testing.  Sensitive and specific analysis and detection techniques are needed and MS/MS 
instrumentation is becoming a prerequisite.224  Miniaturisation of the analytical process, 
application of more advanced instrumentation and further work in the area of segmented 
analysis should result in hair analysis becoming an even more valuable analytical 
technique.171 
 
1.10.3 Analytical techniques for determination of PPCPs in urine: 
Apart from blood, plasma and serum, urine is probably the most commonly analysed 
biological sample.  The number of publications in this area is large and many are beyond 
the scope of this review.  Therefore this Section will provide a brief review of sample 
preparation techniques, liquid chromatographic separation and mass selective detection 
of PPCPs in urine samples from recent years.  Urine is the sample of choice for the 
analysis of many compounds because drugs and metabolites are present in relatively 
high concentrations, the window for analysis is longer than for blood, the sample is not 
very invasive to obtain and sample pre-treatment is not as complex as for some other 
biological matrices.172  The limitations of urine analysis are the adulteration tactics, 
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excretion of metabolites that must be targeted instead of the parent drug.172  As with hair 
analysis, immunological techniques are commonly employed for initial screening of 
urine samples and if traces of a pharmaceutical compounds are reported, then 
chromatographic analysis is conducted.172 
 Certain analytes require a pre-treatment step prior to pre-concentration, e.g. 
Shima et al. added salts to precipitate protein from the sample matrix for the analysis of 
amphetamine and its conjugates in urine.239, 240  The pH of the sample can also be 
adjusted prior to LLE and SPE to improve extraction efficiency and enrichment.  Hirsch 
et al. and Tuerk et al., demonstrated lyophilisation for enrichment of antibiotics in water 
samples prior to LC-ESI-MS analysis.46, 173  However the same process is not applicable 
to biological matrices due to the complex sample matrix.173  LLE has been the traditional 
pre-concentration method for biological matrices, however SPE and SPME techniques 
are currently more common particularly for multi-residue analyte enrichment.170, 172  
Over the years LLE has been applied to the selective preconcentration of a wide range of 
analytes including analgesics, anti-epileptics, benzodiazepines, antidepressants, illicits 
and anticoagulants.170  Solvents employed in LLE for preconcentration of biological 
fluids include ethyl acetate,241 acetone and chloroform,242 dichloromethane and 
acetone,243 toluene and ethyl acetate243 and butyl acetate244 to name a few.  More 
recently LLE has been employed for the extraction of amphetamine-like ‘designer 
drugs’ from urine blood and post-mortem tissue.245  Johansen et al. also employed butyl 
acetate in the LLE of hallucinogen, LSD and related compounds in forensic samples.246 
 In a review of analytical methods by Drummer in 1999, many different SPE 
cartridges were reported as suitable extraction sorbents for pharmaceutical residues in 
urine, plasma, serum and even liver cells.170  However, mixed-mode sorbents 
particularly Bond Elut Certify,242, 247 Chromabond,248 and Cleanscreen249 cartridges were 
reported as particularly useful for retaining all types of functional groups and 
demonstrating good recoveries.170  More recently, both C18 and mixed-mode cartridges 
have remained popular for enrichment of drugs in urine with Chromabond C18 being 
applied to the extraction of both cannabinoids and basic drugs.250, 251  Dams et al. 
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employed weak cation exchange sorbents for the preconcentration of opiates in urine 
with relative recoveries in the range of 61-116%.252  Sixteen structurally different 
antibiotics were preconcentrated from urine using C18 SPE cartridges and reported 
recoveries >60 % in most cases at four different spiking concentrations.173 A strong 
eluting solvent such as tetrahydrofuran was employed to ensure elution of the 
fluoroquinolone antibiotics which are known to adhere to C18 material.253  For multi-
residue analysis with analytes across several therapeutic classes and varying functional 
groups, mixed-mode sorbents are most common.  Concheiro et al. employed the 
polymeric sorbent Oasis HLB for the extraction of opiates, amphetamines and cocaine 
simultaneously and reported all recoveries above 50%.  Marquet et al. employed Oasis 
MCX, mixed-mode phase extraction cartridges which contain hydrophobic polymers 
and sulfonic acid functional groups for the preconcentration of compounds from eight 
different classes including antibiotics, benzodiazepines, pesticides and anti-coagulants in 
serum.254  SPME and HS-SPME have also been employed for the extraction of drugs 
from biological fluids.  Kurecková et al. used SPME to preconcentrate steroids from 
urine samples with promising results.  HS-SPME has been employed for the extraction 
of amphetamines from urine with relative recoveries in the range of 50-104%.255, 256 
 A large number of GC-MS techniques for the determination of a diverse range of 
analytes were previously reviewed by Drummer.170  In this review, Drummer 
acknowledged LC-MS and LC-MS/MS techniques as the future technique for multi-
residue screening of pharmaceuticals and illicit drugs in biological samples.170  This was 
mainly due to the elimination of derivatisation steps during sample preparation and 
coupling of LC to MS and MS/MS instruments.  Additionally, LC methods allow for the 
detection of drug conjugates without the need for prior hydrolysis, a step that was 
required in many GC methods.172  In the late 1990’s, most LC methods applied to the 
analysis of drugs in urine employed DAD or UV detectors.257, 258  However, with 
modern atmospheric pressure interfacing instrumentation and wider availability of MS 
detection, the older detectors are no longer popular.  
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 The most commonly used stationary phases employed in the analysis of urine are 
reversed-phase C18 and C8 columns.173, 259  SynergiTM reversed phase columns have been 
employed for multi-residue analysis in conjunction with a phenyl-hexyl stationary phase 
for separation of basic drugs and cannabinoids respectively, with detection limits in the 
low ng/mL range for all analytes.250  Alternatively, pentafluorophenylpropyl (PFPP) 
bonded silica column was employed by Needham et al. for the separation of cocaine and 
its metabolites.  The method demonstrated good retention and peak shape while only a 
1/10 dilution of the urine sample was required as sample preparation.260  Mobile phases 
similar to those employed for hair and environmental analysis are employed for urine 
analysis.  Methanol and acetonitrile with additives such as ammonium acetate, formic 
acid and ammonium formate have been employed in most cases.173, 251, 259, 261  UPLC 
analysis of amphetamines and ketamine in blood was conducted by Apollonio et al.  
Nine forensically relevant compounds could be separated in 3 minutes indicating that 
this technique may have use for rapid screening of many compounds in one sample.262 
 MS/MS detection is now becoming a requirement in analytical methods in order 
to avoid false positive results.  Identification of compounds in biological and 
environmental samples must now be based on agreement of retention times, molecular 
ions and more than one product ion transition.172  SRM mode is still employed for 
biological analysis but there is no denying the advantages of MRM with tandem MS 
which has demonstrated much lower detection limits.173, 239  A trend is appearing 
towards the development of multi-residue analytical methods for pharmaceutical traces 
in biological and environmental samples.172  Bogusz has developed an analytical method 
applicable to different types of biological samples for quantification of many different 
groups of drugs.263  The method involved the use of two separation columns and two 
mobile phase of slightly different composition.  LC-APCI-MS-SIM was employed for 
quantification with deuterated standards to overcome matrix effects and LODs for all 
compounds were in the low ng/mL range.263  Dams et al. demonstrated direct injection 
of urine after only centrifuging to remove suspended material for determination 25 target 
analytes including opiates and cocaine.  The analysis was carried out on an IT mass 
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analyser with deuterated standards added for quantification and no matrix effects were 
reported despite the lack of sample preparation.264  Finally, Mueller et al. have recently 
developed a screening technique for 301 pharmaceutical residues in blood and urine 
samples using a hybrid quadrupole linear ion tap mass analyser (q-LIT).261  Information 
dependant acquisition (IDA) experiments were carried out using MRM and enhanced 
product ion (EPI) scans.  Identification of compounds is carried out using an MS/MS 
library.261 
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2.1 Introduction: 
The analysis of hair samples has received increasing attention in recent years due to an 
increasing number of applications, more sensitive analysis and detection techniques.  
Determination of pharmaceuticals in hair is now an important process for workplace 
testing, determining history of drug abuse, postmortem toxicology, gestational drug 
exposure and application to drug facilitated crimes (DFCs).1  Several recent publications 
have dealt with development of a method with application to actual evidential samples 
from an assault case, monitoring of doping in athletes and workplace testing of medical 
care professionals.2-6  Many of the applications of hair analysis are in the area of 
forensics and there is great focus on the illicit drugs as target analytes.   
 The advantages of hair as a sample for forensic analysis are a longer time period 
for drug detection, segmented analysis which can allow for the time of drug intake to be 
estimated and the non-invasive manner of sample collection.  Another advantage is that 
hair analysis can allow for the detection of illicit drugs in hair after a single dose which 
is often the case with a DFC.  Urine and blood analysis may not result in the detection of 
the drug particularly if the victim only reports the crime some days after consumption.3 
 Hair samples are generally obtained from volunteers by shaving an area or 
cutting several strands from the posterior vertex of the head.  Samples are stored at room 
temperature in plastic containers10 or paper envelopes.11  Numerous methods have been 
developed for the determination of illicit drugs in hair samples however most of them 
follow a similar process.  The first step involves decontamination usually with an 
organic solvent to remove oils, fats and any possible drug contamination from the 
outside of the hair strands.  This step is generally followed by extraction, sample clean-
up, chromatographic separation and mass selective detection.  The analytical methods 
developed for the extraction and analysis of drugs in hair samples have been reviewed in 
Chapter 1. 
 GC-MS was previously the method of choice for analysis of hair samples but 
LC-MS and LC-MS/MS have grown in popularity in recent years.  LC methods allow 
for the determination of large numbers of underivatised analytes from a range of 
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pharmaceutical classes with excellent specificity and sensitivity.  For these reasons, LC-
MS/MS is particularly applicable to new multi-residue methods.7  These multi-analyte 
techniques allow for screening of a large number of analytes in one run and are possible 
due to newly introduced SPE sorbents with mixed-mode retention characteristics and 
advances in LC-MS technologies.  A multi-residue method was recently developed by 
Villain et al. for 16 benzodiazepines and hypnotics in hair using LC-MS/MS with 
quantification limits in the low pg/mg range.8 
 This work presents a quick, multi-residue analytical method for the 
determination of twelve illicit drug residues in hair samples.  The analytes chosen are 
from a number of different pharmaceutical families including amphetamines, cocainics, 
benzodiazepines, opiates and hallucinogens.  A methanolic extraction was chosen for 
removal of drug residues from hair samples due to its applicability for different types of 
analytes and low levels of analyte hydrolysis.1, 9  A number of SPE sorbents were 
evaluated as preconcentration media for the analytes and the extracts were submitted for 
LC-MS/MS analysis using SRM mode for identification and quantification.  The 
validated method was then applied to the analysis of hair sample from a recreational 
drug user. 
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2.2 Experimental: 
 
2.2.1 Reagents and Preparation of glassware and standards: 
Analytical grade (all purity ≥ 97%) benzoylecgonine hydrate, cocaethylene, temazepam, 
diazepam, papaverine hydrochloride, 3,4-methylenedioxymethamphetamine 
hydrochloride (MDMA) and 2-ethylidine-1,5 dimethyl-3,3-diphenylpyrrolidine 
perchlorate (EDDP) were purchased under license from Sigma-Aldrich (Poole, UK).  
Cocaine hydrochloride, morphine sulfate salt pentahydrate, methadone hydrochloride, 
heroin and lysergic acid diethylamide (LSD), were purchased under license from Sigma-
Aldrich (St. Louis, MO, USA).  The chemical structure of each drug is provided in 
Table 2.1.  
All solvents used were HPLC grade or better.  Isopropanol, acetonitrile and 
methanol were obtained from Labscan (Dublin, Ireland).  Acetone, dichloromethane, 
dichlorodimethylsilane and ethyl acetate were purchased from Aldrich (Gillingham, UK) 
as was the mobile phase additive ammonium acetate.  Ammonium hydroxide (LC-MS 
additive grade) was purchased from Fluka (Steinheim, Germany).  Analytical reagent 
grade glacial acetic acid was received from BDH Chemicals (Poole, UK).  Ultra-pure 
water was obtained from a Millipore Milli-Q water purification unit (Millipore, Bedford, 
MA, USA) with specific resistance of 18.2 MΩ/cm or better.  All glassware utilised for 
storage of illicit drug stocks and standards were silanised prior to the preparation to 
prevent the drugs from adhering to glass surfaces.  This was carried out by rinsing the 
glassware with 10 % dichlorodimethylsilane in dichloromethane.  This was followed by 
rinsing with dichloromethane and rinsing with methanol twice each.  Stock solutions of 
the illicit drugs were prepared in methanol to a concentration of 1000 mg/L and were 
stored in a refrigerator at 4 oC.  Working standards were prepared freshly before analysis 
in ultra pure water. 
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Table 2.1: The chemical structure of each illicit drug 
Drug Structure Drug Structure 
Morphine 
 
Benzoylecgonine 
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2.2.2 Extraction of hair samples: 
The extraction procedure is summarised in Figure 2.1. Hair samples were obtained from 
volunteers by shaving an area or cutting several strands from the posterior vertex of the 
head and were stored in plastic containers at room temperature until analysis time.  
Before analysis, the hair was vortexed twice in 5 mL of dichloromethane to remove any 
external residues.  The hair was dried by pressing between two sheets of glass fibre filter 
paper.  The sample was then ground up using a mortar and pestle for approximately 5 
minutes and 25-50 mg of crushed hair was weighed out depending on the amount of 
sample available.  The samples were placed in silanised glass jars.  A volume of illicit 
drug standard prepared in milli-Q water was added to the samples at this point where 
required and samples were allowed to stand for 20 minutes at room temperature.  To 
each of the jars, 2.5 mL of methanol was added, the jars were capped and incubated in a 
water bath for 3 hours at 37 oC and shaken manually at regular intervals.  After 
extraction, the content of each jar was emptied into a 50 mL centrifuge tube and the jar 
was rinsed with 7.5 mL of ultra pure water.  The water rinsing was also added to the 
centrifuge tube.  The sample was then centrifuged at 6000 rpm for 15 minutes, the 
supernatant was removed into a silanised beaker and made up to 50 mL using ultra pure 
water.  This was done to reduce the methanol concentration in the sample to 5 % or less.  
The pH of samples was adjusted to pH 3.5 using acetic acid or ammonium hydroxide 
solutions.  SPE was carried out on Oasis MCX cartridges using 6 mL of methanol 
followed by 6 mL of water to pre-condition the sorbent.  After sample loading the 
cartridge was washed with 1 mL of 2% acetic acid and allowed to dry under vacuum for 
30 minutes.  The samples were eluted in 5 mL of 5% ammonium hydroxide in methanol, 
dried down under nitrogen at 50 oC and reconstituted in 100 µL of 90 : 10 v/v 10 mM 
ammonium acetate in H2O : acetonitrile.  
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Figure 2.1: Schematic diagram of hair extraction procedure
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2.2.3 Liquid chromatography –mass spectrometry: 
Chromatographic separations were performed on an Agilent 1100 series high 
performance liquid chromatograph with a vacuum degasser, binary pump, ALS 
autosampler, and diode array detector.  This LC was coupled to a Bruker Daltonics 
Esquire~LC ESI-ion trap mass spectrometer.  Agilent Chemstation version A.09.03 
(Agilent Technologies, USA) and Bruker Daltonics esquire control version 4.0 (Bruker 
Daltonics, UK) were employed to control the system and data analysis was performed 
using Bruker Daltonics Data Analysis 3.0 (Bruker Daltonics, UK).   
Separations were performed using a Waters Sunfire 150 x 2.1 mm i.d. 3.5 µm 
column.  A multi-step gradient was employed with mobile phases of (A) 90 : 10 and (B) 
20 : 80 10 mM ammonium acetate : acetonitrile.  Gradient conditions were 100% mobile 
phase A for 5 minutes, then an increase to 50% mobile phase B over 23 minutes 
followed by another increase to 100% B over the next 7 minutes.  This was held constant 
for 10 minutes and a re-equilibration of 15 minutes was applied giving an overall 
runtime of 1 hour.  Flow rate of 0.2 mL/min and injection volume of 10 µL were 
employed.  A longer multi-step gradient was also employed. 
In order to tune the mass spectrometer and determine the parent and precursor 
ions for each drug, individual 10 mg/L solutions of each drug made up in 100% 
methanol were infused directly into the mass spectrometer.  This was carried out using a 
Cole-Palmer syringe pump and a Hamilton micro-syringe.  Once the molecular ion was 
identified, it was fragmented to obtain the product ion for each drug in tandem MS 
mode.  During analysis definitive identification of drug residues was obtained by 
identifying the individual transitions between parent and product ions in tandem MS 
mode.  Quantitative measurements were achieved by integrating the most intense peak 
exhibited for each illicit drug.  The final MS parameters are given in Table 2.2. 
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Table 2.2: ESI-MS parameters employed for analysis. 
Parameter Positive Mode 
Capillary Voltage 4500 
End Plate Offset (V) -561 
Skimmer 1 (V) 28.1 
Skimmer 2 (V) 6.7 
Cap. Exit Offset (V) 63.7 
Octopole (V) 2.51 
Octopole RF (Vpp) 155.3 
Octopole Delta (V) 1.98 
Lens 1 -2.4; -37.8 
Trap Drive 34.7 
Dry Gas Flow (N2; L/min) 8 
Nebulizer Pressure (psi) 50 
Dry Gas Temp. (oC) 300 
 
2.2.4 Method Validation: 
Recovery data was obtained by spiking n=3 blank hair samples with illicit drugs to a 
concentration of 400 pg/mg and extracting under optimised conditions.  The spiked 
extracts were then dried down under nitrogen and reconstituted in 100 µL of 90 : 10 10 
mM ammonium acetate : acetonitrile giving a final 100% recovery concentration of 0.2 
mg/L.  The spiked extracts were then compared to a blank hair extract which had been 
dried down under nitrogen and reconstituted in 100 µL of a 0.2 mg/L standard solution 
of illicits in Milli-Q water.  A blank hair sample was also analysed with the recovery 
samples and background subtraction was performed were necessary.  Method precision 
data was obtained by calculating the standard deviation of peak height values for each 
drug in the three spiked hair extracts.  Suppression of analytes in hair was also 
investigated by comparing the samples spiked post extraction with a 0.2 mg/L standard 
in Milli-Q water.  Percentage suppression was calculated as loss of analyte recovery e.g. 
if the analyte had 60% recovery when compared to the standard then it was 40% 
suppressed. 
Linearity samples were prepared by spiking blank hair samples with 
concentrations of illicit drugs ranging from 50-1000 pg/mg.  The samples were extracted 
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as described and reconstituted in 100 µL of 90 : 10 10 mM ammonium acetate : 
acetonitrile.  Acceptable linearity was taken for correlation coefficients ≥0.95 for curves 
containing at least five data points. 
The concentrations at which the signal-to-noise ratio was closest to 10 : 1 and 3 : 
1 were calculated as the LOQ and LOD, respectively.  Instrumental retention time 
precision was determined by n=6 repeat injections of a 1 mg/L standard of illicits in 
milli-Q water and this data was also employed for the calculation of peak height 
precision. 
 
2.3 Results and Discussion: 
 
2.3.1 MS/MS detection of illicit drugs: 
 
Table 3.3: Precursor and product ions recorded for MS/MS monitoring of illicit drugs 
Analyte m/z Precursor ion m/z Product ion (m/z) 
Morphine 286 [M + H]+ 268 [M + H]+ – [H2O] 
Benzoylecgonine 290 [M + H]+ 168 [M + H]+ – [C6H5COOH] 
MDMA 194 [M + H]+ 163 [M + H]+ – [NH2CH3] 
Cocaine 304 [M + H]+ 182 [M + H]+ – [C6H5COOH] 
Heroin 370 [M + H]+ 268 [M + H]+ –[CH3CO]-[CH3CO2] 
LSD 324 [M + H]+ 223 [M + H]+ – [CO-N(C2H5)2] 
Cocaethylene 318 [M + H]+ 196 [M + H]+ – [C6H5COOH] 
Papaverine 340 [M + H]+ 202 [M + H]+ –[C6H4(OCH3)2] 
Temazepam 301 [M + H]+ 283 [M + H]+ – [H2O] 
EDDP 278 [M + H]+ 249 [M + H]+ – [C2H5] 
Diazepam 285 [M + H]+ 257 [M + H]+ – [CO] 
Methadone 310 [M + H]+ 265 [M + H]+ – [NH(CH3)2] 
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Simple molecular ion spectra were recorded for the illicit drugs as they all produced an 
easily interpreted protonated molecular ion [M+H+]. Table 2.3 summarises the parent 
and product ion transitions that were recorded for each of the drugs. 
The tandem MS signals for each analyte were generally due to loss of distinct 
groups from each structure.  The parent molecules of both morphine and temazepam 
undergo loss of a water moiety, (18 mass units), resulting in product ions of m/z 268 and 
m/z 283, respectively.  The molecular ion of EDDP loses an ethyl group or 29 mass 
units to form a product ion at m/z 249.  In the case of MDMA and methadone the 
product ions 163 and 265 are formed by loss of a methylamine and dimethylamine, 
respectively.  The heptagonal ring of diazepam undergoes a contraction to hexagonal, 
losing the carbonyl group and 28 mass units producing a product ion at m/z 257.  
Cocaine and its two metabolites, benzoylecgonine and cocaethylene undergo a similar 
transition by losing a benzoic acid group for their structures.  The product ion of LSD is 
formed when the CON(C2H5)2 branch of the molecule is removed during fragmentation 
yielding m/z 223 in the tandem MS spectrum.  A dimethoxyphenyl moiety is lost from 
the structure of papaverine and corresponds to a product ion at m/z 202, 138 mass units 
less than the precursor.  Finally, heroin loses 102 mass units, which is thought to be due 
to loss of both acetyl groups (CH3O) and a subsequent dehydration reaction.  Due to the 
nature of the analytes of choice, analysis could be carried out in positive MS mode only.  
In some cases the fragment ion appeared at a higher intensity than the parent ion in 
single MS mode.  This occurred in particular for methadone and MDMA where peaks at 
265 and 163 respectively, were integrated under single MS conditions instead of the 
parent ion in order to achieve the greatest sensitivity.  This phenomenon can be 
explained due to collisionally induced fragmentation of the parent ions in single MS 
mode. 
 
2.3.2 Liquid chromatography of illicit drugs: 
The gradient and set of chromatographic conditions described above were previously 
applied to the analysis of pharmaceutical residues in aqueous and solid environmental 
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matrices with successful results.12  Consequently this seemed a suitable starting point for 
the separation of the twelve illicit drugs.  Ammonium acetate was added to the mobile 
phase mixture to aid in the ionisation process.  The system was then applied to the 
separation of the thirteen illicit drugs.  Extracted ion chromatograms illustrating the 
separation of a 1 mg/L standard solution of the twelve target analytes are shown in 
Figure 2.2.   
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Figure 2.2: Separation of a 1 mg/L standard solution of 12 illicit drugs in milli-Q water.  
Chromatograms marked with * denotes analytes represented by their fragment ion in 
single MS mode.  
 
To assess the performance of the separation, resolution data was calculated for each of 
the analytes.  Resolution was calculated using Eqn. 2.1 and the results are shown in 
Table 2.4.   
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All values were 1.5 and above which indicates complete separation of analytes and is the 
desired result according to the literature.13  An overall run time of one hour for the entire 
separation and re-equilibration was deemed satisfactory. 
 
Table 2.4: Resolution data for twelve separated drugs of abuse. 
Drug Retention time (min) Resolution 
Morphine/Benzoylecgonine 16.0/16.4 2.7 
Benzoylecgonine/MDMA 16.4/17.4 2.2 
MDMA/Cocaine 17.4/26.9 16.2 
Cocaine/Heroin 26.9/27.7 2.7 
Heroin/LSD 27.7/28.7 2.5 
LSD/Cocaethylene 28.7/29.2 2.1 
Cocaethylene/Papaverine 29.2/31.8 5.8 
Papaverine/EDDP 31.8/32.9 2.5 
EDDP/Temazepam 32.9/33.7 3.9 
Temazepam/Methadone 33.7/35.4 2.4 
Methadone/Diazepam 35.4/36.4 3.8 
 
2.3.3 Solid phase extraction (SPE): 
A study of four commercially available SPE cartridges was carried out to assess the 
affinity of the illicit drugs for a range of sorbents.  The sorbents chosen for the study 
were Varian HF Bond Elut certify II 3 mL cartridges, Phenomenex Strata X 3 mL 
cartridges, Phenomenex Strata XC 1 mL cartridges and finally Waters Oasis MCX 6 mL 
cartridges.  The Strata X tubes contained a purely reversed-phase polymeric sorbent of 
modified styrene divinylbenzene for the extraction of polar and aromatic analytes due to 
pi-pi interactions and hydrogen bonding.  The Strata XC tubes consist of a mixed mode 
phase for extraction of basic compounds consisting of the polymeric sorbent described 
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above surface modified with sulfonic acid groups for cation exchange.  This type of 
phase was chosen as most of the illicit drugs are basic in nature.  Similarly, the Oasis 
MCX phase facilitates cation exchange with a hydrophilic-hydrophobic balanced 
polymer backbone and sulfonic acid groups present to provide dual mode extraction.  
Finally, the Bond Elut Certify II tubes also contain a mixed mode sorbent, consisting of 
a non-polar C8 silica backbone bonded to octyl and quaternary amine groups suited to 
anion exchange.  Details on the size and format of the sorbents as well as the procedures 
used to carry out the extractions are given in Table 2.5. 
The SPE optimisation experiments were carried out using 50 mL of ultra pure 
water spiked to a concentration of 1 µg/L of illicits and set to the required pH using 
dilute glacial acetic acid or ammonium hydroxide and were performed in duplicate.  
After loading and elution, the samples were dried down under N2 and reconstituted in 
100 µL of 90 : 10 10 mM ammonium acetate : acetonitrile.  The SPE method 
preconcentration factor was 500 resulting in a final concentration of drugs in the extracts 
of 0.5 mg/L.  The resulting peak heights were compared to those of a 1 mg/L standard 
solution of the analytes to calculate recoveries from each type of cartridge.  The results 
of the SPE study are presented in Table 2.6.  
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Table 2.5: Specifications and procedures employed for 5 SPE cartridges. 
Name Barrel 
Volume 
Sorbent 
mass 
Functional group Sample 
pH 
Conditioning 
solvent 
Wash solvent Elution solvent 
Oasis 
HLB 
6 mL 200 mg Hydrophilic-lipophilic, 
reversed-phase sorbent  
pH 5.5 6 mL methanol 
6 mL ultra pure 
water 
1 mL ultra pure 
water 
50/50 ethyl 
acetate/acetone 
Oasis 
MCX 
6 mL 150 mg Mixed-mode: cation-
exchange and reversed-
phase sorbent 
pH 3.5 6 mL methanol 
6 mL ultra pure 
water 
1 mL 2% acetic 
acid 
5% ammonium 
hydroxide in methanol 
Strata X 3 mL 200 mg Polymeric sorbent, 33 
µm 
pH 9.5 3 mL methanol 
3 mL ultra pure 
water 
1 mL 5% 
methanol in 
ultra pure water 
50/50 ethyl 
acetate/acetone 
Strata XC 1 mL 30 mg Mixed-mode: 
polymeric sorbent, 33 
µm bonded to strong 
cation exchanger 
pH 3.5 1 mL methanol 
1 mL 2% acetic 
acid 
1 mL 2% acetic 
acid 
5% ammonium 
hydroxide in methanol 
Bond 
Elut 
Certify II 
3 mL 200 mg Mixed-mode: octyl and 
quaternary amine  
pH 3.5 3 mL methanol 
3 mL 2% acetic 
acid 
1 mL 2% acetic 
acid 
78/20/2 CH2Cl2/ 
isopropanol/ammoniu
m hydroxide 
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Table 2.5: Relative recoveries of illicit drugs using four different SPE sorbents for the 
extraction of twelve illicit drugs and compared to a 1 mg/L standard in ultra pure water. 
Drug pKa Bond Elut Strata X Strata XC Oasis 
MCX 
Morphine 
 27 ± 4 111 ± 19 110 ± 18 97 ± 11 
Benzoylecgonine 11.2014 79 ± 2 120 ± 12 110 ± 19 116 ± 18 
MDMA 9.9015 69 ± 2 44 ± 8 58 ± 6 41 ± 4 
Cocaine 8.6016 64 ± 9 36 ± 15 85 ± 15 76 ± 41 
Heroin 
 36 ± 13 30 ± 4 23 ± 2 5 ± 1 
LSD 
 91 ± 7 78 ± 2 15 ± 5 32 ± 1 
Cocaethylene 
 65 ± 10 59 ± 12 80 ± 8 60 ± 2 
Papaverine 8.0717 59 ± 11 78 ± 1 87 ± 23 63 ± 1 
Temazepam 1.6018 119 ± 8 108 91 ± 7 93 ± 1 
EDDP 
 39 ± 11 6 ± 2 50 ± 21 22 ± 2 
Diazepam 3.4619 71 ± 3 92 ± 4 110 ± 41 99 ± 26 
Methadone 9.1020 50 ± 10 ND* 58 ± 36 39 ± 21 
 
Analytes were most likely retained due to hydrophobic interactions with the polymeric 
sorbents and ion exchange in the case of the mixed-mode sorbents. In general the mixed-
mode sorbents, the Bond Elut, Strata XC and Oasis MCX gave the most consistently 
high recoveries with seven of the target analytes out of the twelve having relative 
recoveries greater or equal to 60%. Due to the cationic nature of the ion exchanging 
groups in the Bond Elut sorbent which were not suited to the mainly basic illicits, the 
main retention mechanism was thought to be non-polar interactions.  Recoveries of 
heroin were low in all cases.  The Strata XC cartridges demonstrated good affinity for 
the illicits, however the 1 mL barrel volume resulted in extended loading times that 
lengthened the preconcentration process.  The Bond Elut and Oasis MCX cartridges 
were deemed suitable for preconcentration of illicit drug traces however Oasis MCX 
 117 
were chosen for further analysis due to the mixed mode cation exchange reversed-phase 
sorbent being most suited to the basic nature of the illicits.   
The entire extraction method including the optimised SPE procedure was then 
applied to the separation of twelve illicit drugs.  Amphetamine was discarded as a target 
analyte as it was undetected from the SPE study.  A complete separation of the twelve 
target analytes in a spiked hair sample (600 pg/mg) extracted under optimised conditions 
is shown in Figure 2.3. 
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Figure 2.3: Separation of a hair sample spiked with 12 illicit drugs to a concentration of 
600 pg/mg, extracted and separated using the 45 minute gradient on Waters Sunfire 
column at a flow rate of 0.2 mL/min with ESI-MS detection.  The analytes are in order 
of retention time and are as follows: morphine, benzoylecgonine, MDMA, cocaine, 
heroin, LSD, cocaethylene, papaverine, EDDP, temazepam, methadone and diazepam. 
 
2.3.4 Method validation: 
The method validation data for all twelve illicit drugs are listed in Table 2.6.  Standard 
curves were plotted for spiked hair samples in the range of 50-1000 pg/mg.  Curves 
contained at least n=5 data points, a trend line was fitted and linearity was examined 
based on correlation coefficients (R2).  Acceptable results (R2 ≥ 0.95) were achieved in 
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all cases except for MDMA which had an R2 value of 0.9280.  Correlation coefficients 
of 0.9737 and 0.9762 for cocaine and diazepam respectively were also disappointing.  
Overall benzoylecgonine, LSD, temazepam, papaverine, methadone and cocaethlyene 
exhibited the best linear responses of R2 ≥0.99 over n≥6 data points.   
 Limits of quantification and detection were calculated at four different low to 
mid range concentrations.  All analytes reported LODs of <30 pg/mg except for MDMA 
and temazepam.  Cocaine, benzoylecgonine and cocaethylene all reported very low 
LODs <10 pg/mg.  These values for cocaine and benzoylecgonine were quite similar to 
those obtained in a study by Scheidweiler et al. in 2003.9  Detection limits for 
methadone and its metabolite EDDP were much lower than those reported by Lucas et 
al. in 2000 using an SPME clean-up step with GC-MS.21  One study in 2004 which 
involved the analysis of a range of drugs such as benzodiazepines and illicit stimulants 
reported excellent LODs for cocaine and benzoylecgonine and amphetamine, 
demonstrating that it is possible to sensitively detect amphetamine along with other 
illicits.  The method employed an 18 hour incubation in a methanol/acetonitrile 
extraction medium.22  
 Absolute recoveries of the drugs from hair were acceptable with all values ≥60%.   
  Method precision was acceptable with almost all recoveries varying by less than 20% 
for n=2/n=3 replicates of the complete extraction method.  Recoveries greater than 
100% were reported for both morphine and papaverine with relatively low variation 
between samples.  This indicates enhancement from interfering compounds in the hair 
matrix, because a blank extract was analysed so that any traces of drugs in the sample 
could be corrected for.  Scheidweiler et al. also reported enhancement of morphine 
signals in their publication which employed a similar analysis procedure.9  These results 
indicate that perhaps different strand and sections of hair contain varying amounts of 
interfering matrix components and could lead to false positive results.  False positives 
and interferences due to methanolic extraction have previously been reported during hair 
analysis.23-25 
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 An investigation of instrument precision showed a variation in peak height of 
<6% in all but two cases, (temazepam and morphine).  Finally percentage ion 
suppression values were calculated for each of the illicits.  The values reported were 
surprisingly high particularly for morphine, MDMA, EDDP and LSD.  The suppression 
values were calculated for three replicate sample extractions and the level of variation 
between samples was quite high, almost 30% variation between samples in three cases.  
This could be explained by different matrix components being extracted from each of 
the samples or by the fact that the samples were not agitated while being extracted 
leading to non-uniform extraction.  In future a method of agitation, such as sonication, 
during incubation to ensure reproducible extraction of each sample may be useful.  In all 
cases ion suppression was reported.  Ion suppression was reported by Scheidweiler et al. 
for cocaine and cocaethylene using a similar extraction method in 2004, however other 
drugs such as benzoylecgonine and morphine demonstrated signal enhancement.9 
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Table 2.7: Method validation data for twelve illicit drugs in hair. 
Analyte 
Instrument  
precision (% 
RSD) 
Correlation  
coefficient (R2) 
LOD in 
hair 
 (pg/mg) 
LOQ in hair  
(pg/mg) 
Absolute %  
recovery in 
hair 
% MS ion  
suppression in 
hair 
Morphine 6.5 0.9951 26 87 129 ± 2 56 ± 7 
Benzoylecgonine 2.3 0.9957 7 23 91 ± 3 13 ± 6 
MDMA 5.3 <0.9500 58 193 61 ± 1 67 ± 7 
Cocaine 4.6 0.9737 3 9 101 ± 18 36 ± 29 
Heroin 5.6 0.9876 29 98 76 ± 16 34 ± 29 
LSD 5.2 0.9925 22 73 85 ± 2 56 ± 12 
Cocaethylene 2.8 0.991 3 10 89 ± 10 40 ± 28 
Papaverine 3.9 0.9944 20 68 129 ± 7 63 ± 7 
EDDP 1.3 0.9868 23 76 60 ± 7 54 ± 16 
Temazepam 7.9 0.9989 35 115 92 ± 13 21 ± 10 
Methadone 5.6 0.9958 26 85 81 ± 21 50 ± 9 
Diazepam 4.7 0.9762 10 34 86 ± 16 20 ± 21 
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2.3.5 Application of optimised method to analysis of possibly contaminated hair:  
A hair sample from a recreational drug user was obtained and extracted using the 
optimised extraction and clean-up method. The sample was analysed by LC-MS/MS. 
Traces of cocaine were identified in the hair sample and its presence was confirmed 
monitoring the product ion of cocaine in MS2 mode, see Figure 2.4.  The correlation 
between the cocaine mass spectrum in the contaminated sample and the mass spectrum 
of a 1 mg/L standard is illustrated in Figures 2.4 and 2.5. The fragment ion of the 
cocaine at m/z 182 can be clearly observed in the MS2 spectrum of both figures and is 
formed due to loss of 122 mass units from both the cocaine molecule.  The amount of 
cocaine present was determined to be 128 pg/mg from the cocaine calibration curve.   
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Figure 2.4: Extracted ion chromatogram of cocaine in hair at m/z = 304 and its fragment 
ion at m/z = 182 with corresponding mass spectra in MS1 and MS2 modes for 
confirmation of result. 
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Cocaine MS1 spectrum Cocaine MS2 spectrum
 
Figure 2.5: Single and tandem mode mass spectra for injection of a 1 mg/L standard of 
cocaine in ultra pure water, taken from peak apex. 
 
2.4 Conclusions: 
A multi-residue method for the separation and detection of twelve illicit drugs in hair 
samples was developed.  The twelve drugs were separated in 45 minutes with excellent 
resolution between peaks.  A number of commercially available SPE sorbents were 
investigated as preconcentration techniques for the illicit analytes.  A mixed-mode 
sorbent was chosen as the optimum and was applied to the preconcentration of the 
illicits from hair extracts.  Method validation data was compiled and limits of detection 
were comparable to those in other publications.  A hair sample from a known drug user 
was analysed using the optimised method and traces of cocaine in the sample were 
quantified.  Future work would involve examining a larger number of analytes using the 
optimised method.  An experiment should be conducted to determine if 100 % of the 
analytes were extracted during methanol incubation and more hair samples are needed 
for further quantification of illicits.  The purchase of deuterated standards can reduced 
the matrix effect offer a more accurate approach to quantification.   
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Chapter 3.0: Characterisation of a Half-metre Monolithic Column as a 
High Efficiency Stationary Phase for HPLC 
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3.1 Introduction: 
The demand for more efficient separations in recent years has seen the rise of a new 
generation of LC. With UPLC, reducing particle size has been the primary approach to 
shortening analysis time while maintaining column performance in recent years despite 
the expensive equipment and extremely high backpressures.1  More recently, the 
combination of 2 µm particles with high flow rates and elevated column temperatures, as 
high as 90 oC, has been demonstrated.  This technique is known as high-temperature 
UPLC (HT-UPLC).  The viscosity of the mobile phase is reduced due to the elevated 
temperatures therefore allowing high flow rates to be employed without loss of 
efficiency.2, 3  However, elevated backpressures of up to 1000 bar are observed with 
UPLC techniques even with the use of high temperatures.3 
 Monolithic silica columns can provide efficient separations at high flow rates due 
to there bimodal pore structure of macropores and mesopores.  The structure of the 
skeleton and pore sizes in monolithic silica rods can be controlled and optimised during 
manufacture and the macroporous structure results in a highly permeable separation bed 
which is advantageous in fast HPLC.4  The smaller mesopore structure supplies the 
surface area (300 m2/g) required for kinetic processes of the separation to occur and 
results in faster mass transfer rates which maintains high efficiency at high flow rates.5  
With particle packed columns this is not possible as the smaller particles employed to 
achieve improved mass transfer result in higher backpressures.4  In 2000, Merck 
released the first commercially available monolithic column which had macro-pores of 
approximately 2 µm and meso-pores of approximately 13 nm in diameter.5  Silica 
monoliths have been primarily employed in fast HPLC separations due to their total 
porosity being up to 20 % greater than particulate columns and their efficiency of 
separation comparable to that of a 3.5 µm particulate column.6 
 The trend towards minimising particle diameter and shortening column length 
concentrates on reducing analysis time.  However, complex sample types may require a 
lengthier and, as a result of high generated pressures, a more permeable stationary phase 
bed with high theoretical plate numbers in order to resolve all components of the 
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mixture.5  A new approach to maintaining high plate numbers is to increase the length of 
the column by manufacturing or by coupling columns in series based on high porosity 
monolithic columns.  In 2001, it was suggested that monolithic columns were the ideal 
candidates to be connected in series for high efficiency separations of complex 
mixtures.5  Several papers demonstrating high efficiency separations using coupled 
Chromolith RP-18e monolithic columns (10 cm x 0.46 cm) have been published since.  
The number of coupled columns ranged from six to fourteen with plate numbers over 
100,000 reported for a wide range of samples separated such as drugs and complex 
isomeric mixtures.7, 8, 6  Pellicular particles and traditional 5 µm particle packed columns 
have also been investigated in long column format resulting in very high plate counts of 
180,000 at elevated temperatures.9, 10  The performance of these long columns has been 
assessed in a number of ways.  Ikegami et al. evaluated the performance of different 
numbers of coupled monoliths based on band broadening and extra-column effects.11  
Gray et al. investigated multiple monoliths in series and in parallel as a method of 
improving peak capacity and loading capacity.12 
Since 2000, monolithic columns have been characterised using van Deemter 
plots as with particulate columns despite the obvious differences in internal structure.4  
Both the A and C terms in the van Deemter equation rely heavily on particle size, 
however this problem has been addressed by assigning a particle size to monoliths by 
comparing macropore diameter to inter-particle spaces in conventional columns.13  The 
van Deemter plots reported for long monoliths have emphasised their excellent 
efficiency at high linear velocities and illustrated their advantages over particle-packed 
beds.6, 14  Bones et al. demonstrated the benefits of even two coupled Phenomenex Onyx 
monoliths (100 x 3.0 mm) over a 1.8 µm particulate column using van Deemter and 
kinetic plots.  Smaller plate height was observed for the particle-packed column, 
however the 20 cm monolith excelled in plate number at considerably lower 
backpressure and was therefore better suited to separation of a complex mixture of 
drugs.14  More recently, peak capacity values were calculated for ten monoliths in series 
(one metre total length) with excellent results of up to 244 peaks per hour and 90,000 
 129 
plates.15  The study was carried out at pressures associated with a conventional LC 
separation and both studies by this group employed mass spectrometric detection with 
ESI as an interface.14, 15 
 In this work a half metre monolithic column composed of five 10 cm monolithic 
rods connected in series is introduced as a highly efficient separation phase for complex 
environmental samples.  The monolithic column was characterised using van Deemter 
plot experiments and compared to a conventional particulate column to illustrate the 
advantages of high plate number and low plate height at reduced backpressures.  The 
performance of the coupled monolith was investigated at a range of temperatures and by 
calculation of peak capacity values.  The increased loading capacity of coupled 
monoliths was also demonstrated.  
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3.2 Experimental: 
 
3.2.1 Reagents and preparation of glassware and standards: 
All solvents used including acetonitrile and methanol were HPLC grade or better. 
Acetonitrile and methanol were obtained from Labscan (Dublin, Ireland).  Acetone, 
dichloromethane, dichlorodimethylsilane and ethyl acetate were purchased from Aldrich 
(Gillingham, UK) as was the mobile phase additive ammonium acetate.  Ammonium 
hydroxide (LC-MS additive grade) was purchased from Fluka (Steinheim, Germany).  
Reagent water was obtained from a Millipore Milli-Q water purification unit (Millipore, 
Bedford, MA, USA) and was 18.2 MΩ/cm or better.  
All pharmaceuticals purchased were ≥97% purity.  Paracetamol, salicylic acid, 
propranolol hydrochloride, clofibric acid, ketoprofen, diclofenac sodium salt, 
bezafibrate, warfarin, flurbiprofen, indomethacin, ibuprofen sodium salt, meclofenamic 
acid sodium salt, atenolol, salbutamol, sulfamethoxazole, sulfapyridine, sulfamethazine 
sodium salt, carbamazepine, nimesulide, (±)-metoprolol (±)-tartrate salt, mefenamic 
acid, salbutamol, erythromycin, doxazosin mesylate, phenazone, nifedipine, budesonide, 
simvastatin, tamoxifen, sertraline hydrochloride, citalopram hydrobromide, 3,4,4_-
trichlorocarbanilide, amitriptyline hydrochloride, nortriptyline hydrochloride, 
cimetidine, ranitidine hydrochloride, tramadol hydrochloride, chloramphenicol, and 
clotrimazole were all obtained from Sigma-Aldrich (Steinheim, Germany).  
Trimethoprim, caffeine, S(±)-2-(6-methoxy-2-naphthyl)-propionic acid and irgasan were 
ordered from Fluka (Buchs, Switzerland).  Cocaine hydrochloride, morphine sulfate salt 
pentahydrate, methadone hydrochloride and heroin were purchased under license from 
Sigma-Aldrich (St. Louis, MO, USA).  Benzoylecgonine hydrate, cocaethylene, D-
amphetamine sulfate salt, temazepam, diazepam, papaverine hydrochloride, 3,4-
methylenedioxymethamphetamine hydrochloride (MDMA) and 2-ethylidine-
1,5dimethyl-3,3-diphenylpyrrolidine perchlorate were purchased under license from 
Sigma-Aldrich (Poole, UK). 
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All glassware utilised in the preparation of pharmaceutical and illicit drug stocks 
and standards were all silanised prior to the preparation to prevent the drugs from 
adhering to glass surfaces.  This was carried out by rinsing the glassware with 10% 
dichlorodimethylsilane in dichloromethane.  This was followed by rinsing with 
dichloromethane and rinsing with methanol twice each.  Stock solutions of 
pharmaceuticals were prepared in methanol to a concentration of 1000 mg/L and were 
stored in a fridge at 4 oC.  Working standards were prepared freshly before analysis in 
ultra pure water. 
 
3.2.2 Liquid chromatography-UV detection: 
For column characterisation and van Deemter plot experiments, liquid chromatography 
was carried out on two systems.  The first was an Agilent 1200 series high performance 
liquid chromatograph with a vacuum degasser, quaternary pump, ALS autosampler, 
thermostatted column compartment and variable wavelength detector.  Data analysis was 
performed using Agilent Chemstation programme, version B.02.01 (Agilent 
Technologies, USA).  The second system was an Agilent 1100 series high performance 
liquid chromatograph with a vacuum degasser, binary pump, ALS autosampler, and 
diode array detector.  Agilent chemstation version A.09.03 (Agilent Technologies, USA) 
was employed for data analysis and system control.  For the temperature study a 
SparkHolland MISTRAL heater was employed to ensure that a precise column 
temperature was reached before analysis. 
Separations were performed using a Waters Sunfire 150 x 2.1 mm i.d. 3.5 µm 
column and five Phenomenex Onyx Monolithic 100 x 3.0 mm i.d. columns.  The five 
monolithic columns were coupled in sequence using peek tubing and ferules to give a 
half-metre column.  For characterisation experiments, an isocratic mobile phase was 
employed of 70 : 30 10mM ammonium acetate acetonitrile for separation of 10 mg/L 
solutions of diclofenac, cocaine and metoprolol.  For the separation of mixed drug 
standards, linear and multi-step gradients were employed for both columns with mobile 
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phases of (A) 90 : 10 and (B) 20 : 80 10 mM ammonium acetate acetonitrile.  A flow 
rate of 0.2 mL/min and injection volume of 10 µL were utilised.  
 
3.3 Results and Discussion: 
 
3.3.1 Characterisation of half-metre monolith and comparison to 3.5 µm particulate 
column: 
The efficiency of the columns was characterised using van Deemter curves.  Diclofenac, 
a common anti-inflammatory and analgesic, was chosen as a test analyte for the study.  
The separations were carried out isocratically as already described with UV detection at 
225 nm.  A 10 mg/L working standard of the drug was prepared from a 1000 ppm stock 
solution.  Injection volume was 10 µL and flow rates from 0.4 mL/min to 0.01 mL/min 
were employed throughout the study.  
The first experiment compared the separation efficiency of a single monolith 
with that of five monoliths in series and the Waters Sunfire particle column.  The 
experiments were all carried out at 20 oC and a 10 µL volume of the diclofenac standard 
was injected at a range of flow rates.  The retention time, peak width, dead volume and 
pressure were recorded at each flow rate.  Each measurement was carried out in 
duplicate and average values were calculated.  Flow rates up to only 0.26 mL/min were 
applicable with the 3.5 µm Sunfire column due to excessive backpressures of over 3200 
psi.  The monolithic columns were investigated up to 0.4 mL/min, however further 
increases in flow rate could have been investigated due to much lower backpressures of 
525 psi on one monolith and 1710 psi on the coupled monoliths at 0.4 mL/min.  
Figure 3.1 and 3.2 below depict the van Deemter curves obtained for the three 
columns investigated in terms of plate height (HETP), plate number per column 
(N/column) and linear velocity (υ).  From Figure 3.1, the Sunfire column produced 
higher linear velocities overall, these were accompanied by an increase in plate height 
due to poor mass transfer rates.  A higher optimum linear velocity was observed for the 
the monolithic columns than the Sunfire column at much lower backpressures.  A plate 
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height of 26.19 µm at a linear velocity of 0.306 was recorded for the Sunfire.  The five 
coupled monoliths were slightly better with HETP = 25.90 at υ = 0.316 while a single 
monolith gave the most efficient result with HETP = 19.68 µm at υ = 0.689.  This result 
was achieved at a flow rate of 0.24 mL/min, six times higher than the flow rate on the 
Sunfire of 0.04 mL/min.  This illustrates the obvious advantage monoliths have over 
particle columns of equal if not improved efficiency at higher flow rates.  Higher flow 
rates should result in decreased mass transfer; however the porous structure of the 
monolith allows for faster rates of mass transfer and therefore provides excellent 
efficiency despite the higher flow. 
Figure 3.2 illustrates the beneficial effect of coupling monoliths in series.  The 
0.5 m monolith produced considerably higher numbers of theoretical plates (19304 
plates) than both the single monolith (5081 plates) and Sunfire column (5728 plates).  
The single monolith produced much the same number of plates as the Sunfire which 
corresponds to earlier statements made that the efficiency of monoliths is about that of a 
3.5 µm particle-packed column.6   
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Figure 3.1: Graph of plate height (HETP) against linear velocity (υ) for the single 
monolith (○), the five coupled monoliths (∆), and the Sunfire column (□). 
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Figure 3.2: Graph of number of theoretical plates per column (N/column) against linear 
velocity (υ) for the single monolith (○), the five coupled monoliths (∆), and the Sunfire 
column (□). 
 
Figure 3.3 highlights the low operating backpressures generated by monolithic columns.  
The five monoliths in series generated 1710 psi while the Sunfire column generated 
almost double, 3278 psi.  In addition, the long monolith produced more than three times 
the number of theoretical plates per column than the Sunfire at half the operating 
pressure.  The single monolith as expected exhibited the lowest backpressures but was 
comparable to the Sunfire in the number of plates provided.  These plots demonstrate 
that the main advantage of long coupled monoliths over standard particulate columns, 
are the low operating pressures at high flow rates with excellent numbers of theoretical 
plates and hence improved separation efficiency. 
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Figure 3.3: Graph of number of backpressure (psi) against linear velocity (υ) for the 
single monolith (○), the five coupled monoliths (∆), and the Sunfire column (□). 
 
3.3.2 Investigation of effect of temperature on efficiency of 0.5 m coupled monolithic 
column: 
Recently increasing temperature has been employed in UPLC as a way of increasing 
efficiency.2, 3  With fast mass transfer rates already a characteristic of monolithic 
separations, in theory increased temperatures could result in even better efficiency.  
Increased temperatures would reduce the mobile phase viscosity allowing for faster 
interactions between mobile and stationary phase hence reduces Cm.   
Experiments were carried out using the five coupled monoliths over a range of 
temperatures with an identical isocratic system as employed before.  From the product 
information, the monolith was stable up to 45 oC so experiments were conducted at 10, 
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15, 20 and 45 oC.  Linear velocities were plotted against plate height (H), plate number 
per column and backpressure (psi) to illustrate the improved performance of the half 
metre column at elevated temperatures.  Figure 3.4, 3.5 and 3.6 illustrate the advantages 
of employing high temperature separations over those at ambient conditions.  The 
number of theoretical plates for the 0.5 m monolithic column increased from 14522 at 10 
oC to 23486 at 45 oC with a decrease in plate height of approximately 13 µm and a 
reduction in backpressure of over 1000 psi.  The slopes of the van Deemter plots 
indicate that there was only marginal loss of efficiency at higher linear velocities with a 
plate count of almost 24,000. Particularly in Figure 3.4, as the linear velocity increased 
and hence the flow rate increased, the expected increase in plate height did not occur to a 
great extent.  Therefore this column shows promise for application to very complex 
sample types such as soil or sludge.  
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Figure 3.4: Plot of linear velocity (υ) versus plate height (HETP) generated on five 
coupled monoliths at 10 oC (○), 15 oC (□), 20 oC (□) and 45 oC (x).  
 138 
10000
14000
18000
22000
26000
0 0.5 1 1.5
Linear Velocity (mm/s)
N
o
.
 
o
f p
la
te
s 
pe
r 
co
lu
m
n
 
Figure 3.5: Plot of linear velocity (υ) versus number of theoretical plates per column 
(N/column) generated on five coupled monoliths at 10 oC (○), 15 oC (□), 20 oC (□) and 
45 oC (x).  
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Figure 3.6: Plot of linear velocity (υ) versus backpressure (psi) generated on five 
coupled monoliths at 10 oC (○), 15 oC (□), 20 oC (□) and 45 oC (x).  
 
When a comparison was made by plotting the monolith data at 45 oC against the Sunfire 
data at ambient temperatures, the advantages of coupled monoliths were obvious as 
illustrated in Figure 3.7, 3.8 and 3.9.  The Sunfire column reached its optimum 
efficiency at a plate height of 26.19 µm and then steadily loses efficiency as linear 
velocity increases.  This optimum plate height was at a flow rate of only 0.04 mL/min 
which is impractical due to long analysis times.  Therefore, to increase analysis time 
efficiency has to be sacrificed.  The monolith however, reached a minimum plate height 
of 21.29 at a flow rate of 0.16 mL/min, four times that of the Sunfire.  Also the plate 
height did not increase as steeply after this minimum as it does for the Sunfire.  This 
illustrates that higher flow rates can be used without a significant loss of efficiency.  
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Figure 3.7: Plot of linear velocity (υ) versus plate height (HETP) for the five coupled 
monoliths at 45 oC (□) and the Sunfire particulate column at ambient temperature (□).  
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Figure 3.8: Plot of linear velocity (υ) versus number of theoretical plates per column 
(N/column) for the five coupled monoliths at 45 oC (□) and the Sunfire particulate 
column at ambient temperature (□).  
 141 
0
500
1000
1500
2000
2500
3000
3500
0 0.5 1 1.5 2
Linear Velocity (mm/s)
Pr
e
ss
u
re
 
(ps
i)
 
Figure 3.9: Plot of linear velocity (υ) versus backpressures (psi) for the five coupled 
monoliths at 45 oC (□) and the Sunfire particulate column at ambient temperature (□).  
 
3.3.3Peak capacity study: 
Calculating the number of peaks that can be separated in a specific time period is an 
excellent way of assessing the performance of a column.  Giddings first proposed a 
formula for calculating peak capacity.16  Neue et al. developed an equation that could be 
applied to linear gradient chromatography and it is this equation (shown below) that was 
used to calculate peak capacity in this study.17  Peak capacity has previously been used 
to determine the performance of monolithic columns with good results when compared 
to particle columns and at high flow rates.15  
W
t
P gc += 1     (Eqn. 3.1) 
A working standard containing approximately fifty PPCPs in ultra pure water was 
injected at a volume of 20 µL and detected at a wavelength of 230 nm.  An identical 
gradient was employed for separations with both the long monolith and the Sunfire 
columns.  The gradient run time was ninety minutes over which the concentration of 
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mobile phase B (20 : 80 10 mM ammonium acetate : acetonitrile) increased from 0 to 
100%.  From the resulting chromatograms twenty peaks were selected and divided into 
the gradient run time, the average of these figures was then taken and the peak capacity 
per hour was also reported.  Table 3.1 contains the data obtained from the peak capacity 
study.  
 
Table 3.1: Peak capacity values calculated for half-metre monolith and Sunfire columns  
 Flow Ratea Backpressureb Deadtimec Linear Velocityd 
 Pc Pc/hr Pc Pc/hr Pc Pc/hr Pc Pc/hr 
Monolith 104 69 86 57 108 72 132 88 
Sunfire 103 69 50 33 50 33 93 62 
a
 Flow rate was 0.2 mL/min for both columns with backpressures of 34 bar for the 
monolith and 146 bar for the Sunfire. 
b
 Flow rates were 0.18 mL/min and 0.04 mL/min for the monolith and Sunfire columns 
respectively resulting in backpressures of ~ 30-31 bar (570 psi). 
c
 Flow rates were 0.28 mL/min and 0.04 mL/min for the monolith and Sunfire columns 
respectively resulting in dead times of 9.94 and 9.73 minutes respectively. 
d
 Flow rates were 0.36 mL/min and 0.16 mL/min for the monolith and Sunfire columns 
respectively resulting in linear velocities of 1.07 and 1.04 mm/s respectively. 
 
Peak capacity (Pc) studies have been carried out on monolithic capillary columns with 
impressive results.18  Luo et al. reported peak capacities greater than 1000 at 345 bar on 
a 70 cm monolithic capillary column.  More recently, Bones et al. investigated ten 
coupled monolithic columns (100.0 x 3.0 mm I.D.) for the separation of protein digests.  
The one metre monolith reported excellent peak capacity values per hour, which 
increased with increasing flow rate.15   
 In this study peak capacity values per chromatographic run and per hour were 
compared for the half-metre monolith and the Sunfire particulate columns.  Four 
experiments were carried out each under a different set of chromatographic conditions.  
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At identical flow rate the columns reported identical peak capacities, however when 
backpressures were matched the monolith was operated a much higher backpressure 
which allowed almost twice the number of peaks to be separated within the run time.  A 
similar result was obtained when the void volumes of the columns were correlated.  For 
the t0 value of the Sunfire column to match that of the monolith, the flow rate had to be 
lowered to only 0.04 mL/min.  This resulted in only half the number of peaks being 
separated in 90 minutes than those generated on the monolithic column.  Finally linear 
velocities of mobile phase were matched and the peak capacities were again evaluated.  
Once more the monolithic column reported higher peak capacity at lower backpressure 
of only 61 bar.  Bones et al. calculated a ratio of peak capacity/hour : backpressure as an 
indication of the column providing highest efficiency separation per hour at the lowest 
pressure drop.15  This ratio was calculated for the half-metre monolithic and Sunfire 
columns at identical linear velocities, the results were 1.44 and 0.42 respectively.  The 
higher value demonstrated for the monolithic column indicates that it is an excellent 
choice for high efficiency separations at backpressures that can be achieved using 
standard HPLC instrumentation. 
 
3.3.4 Investigation of loading capacity: 
The volume of sample loaded onto columns in recent years has decreased due to shorter 
columns with smaller particles which can be easily saturated with sample.  In the case of 
trace analysis this becomes a significant problem.  A highly efficient phase which has 
the capacity to receive a wide range of injection volumes is desirable.  Due to the 
increased length and increased surface area of the monolith available for separation of 
analytes, it was expected that the long column would have an increased capacity for 
large sample volumes.  An earlier study by Gray et al. determined that increasing the 
length of a monolith increased the loading capacity while improving resolution.12 
Three test compounds metoprolol, cocaine and diclofenac were chosen for the 
experiment.  A mixed working standard at a concentration of 10 mg/L was prepared and 
was injected at volumes of 10 to 900 µL, (the maximum syringe volume on the 
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instrument).  The separations were carried out isocratically with mobile phase 70 : 30 10 
mM ammonium acetate : acetonitrile over a thirty minute runtime.  Peak height, width at 
half height and asymmetry were plotted against increasing injection volume to monitor 
changes in peak shape and the ability of the column to manage increased loading. These 
results are illustrated in Figures 3.10, 3.11 and 3.12. 
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Figure 3.10: Plot of peak height (mAU) versus injection volume (µL) for (□) = 
metoprolol, (□) = diclofenac and (□) = cocaine. 
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From Figure 3.10, peak height increased linearly with injection volume up to 900 µL for 
all three test compounds.  Correlation coefficients of r2 = 1.000, 0.9989 and 0.999 were 
obtained from graphs of peak height versus injection volume for metoprolol, diclofenac 
and cocaine respectively.  The 0.5 m monolith was capable of accepting almost 1 mL of 
sample. 
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Figure 3.11: Plot of peak width at half maximum (min) versus injection volume (µL) 
for (□) = metoprolol, (□) = diclofenac and (□) = cocaine. 
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Peak width increased from 30 µL up to 900 µL for the test compounds as expected, 
(Figure 3.11).  The peak widths recorded were width at half maximum peak height.  
Although metoprolol and cocaine exhibited some deviations at low injection volumes of 
10, 20 and 30 µL, the increase in width throughout the study was not large.  From 
Figure 3.11 width increased only minimally for metoprolol and diclofenac and remained 
constant or even slightly decreased for cocaine.  This result illustrates that despite the 
increasing injection volume, sharp peaks were being recorded.  The surface area and 
capacity of the monoliths was sufficient for the concentration of solutes within the 
injected volumes and because of this the sample plug did not disperse significantly.  If 
the column were overloaded, some solutes would be eluted more quickly due to 
saturation of stationary phase adsorption sites.  The small variation in peak width 
corresponds to the earlier linearity result, as the injection volume increased the intensity 
or peak height increased but the peak width remained relatively constant.  Overall the 
width at half maximum increased from a minimum of 0.4638 (30 µL) to a maximum of 
0.5279 min (900µL) for metaprolol corresponding to an increase of ~ 4 seconds.  The 
same increase applied for diclofenac with a minimum at 0.3075 min (10 µL) and 
maximum at 0.3769 min (900 µL).  Cocaine had an increase of ~ 2.5 seconds overall 
with minimum peak width of 0.5445 min (40 µL) and a maximum at 0.588 min (900 
µL).  
Asymmtery is calculated by bisecting a peak perpendicularly and dividing the 
right half width into the left half width.  Asymmetry due to tailing is caused by 
alternative retention mechanisms taking place within the column leading to the tail of 
peak being drawn out.  Tailing results in an asymmetry factor greater than one.  Fronting 
is the second type of asymmetry which is more relevant to this study.  It is mainly 
caused by overloading the column with sample.  Fronting results in an asymmetry value 
less than unity.19  Figure 3.12 depicts the graph of peak asymmetry against injection 
volume for the three test compounds.  Diclofenac maintained a high level of symmetry 
up to 100 µL with a fronting value of 0.883, after which the symmetry of the peaks 
decreased with increasing injection volume.  Metoprolol and cocaine both exhibited 
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signs of asymmetry at low injection volumes and these values decreased rapidly until 
after 100 µL when they began to even out.  According to the graph minimal peak tailing 
was occurring throughout the separation.  
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Figure 3.12: Plot of peak asymmetry versus injection volume (µL) for (□) = metoprolol, 
(□) = diclofenac and (□) = cocaine. 
 
To determine the effect of increased sample loading on the efficiency of the column, the 
number of theoretical plates per column was calculated for each analyte using Eqn. 3.2 
and plotted against injection volume.  
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Figure 3.13 demonstrates that only about a 10 % loss in efficiency was observed for 
each analyte at an injection volume of 200 µL.  This result is mirrored very well by the 
peak width plot in Figure 3.11.  The peak widths for metoprolol and diclofenac 
increased by approximately 6 % between sample volumes of 10 and 200 µL while the 
peak widths for cocaine only increased by approximately 3 % over the same range.  
Separation efficiency for diclofenac and metoprolol demonstrated quite a linear decrease 
with respect to increased sample volumes. The number of theoretical plates decreased 
initially for cocaine before levelling off and remaining quite linear. This result 
demonstrates the excellent ability of the monolithic stationary phase to effectively 
separate large volumes of solutes and emphasises the advantages in applying these 
phases to trace analysis and separation of complex sample types.   
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Figure 3.13: Plot of number of theoretical plates (N) versus injection volume (µL) for 
(□) = metoprolol, (□) = diclofenac and (□) = cocaine.  
 
The long monolith was then applied to the separation of increasing volumes of a mixed 
standard containing up to 50 pharmaceuticals and illicit drugs in ultra pure water. This 
study was carried out to demonstrate the superior loading capacity of the 0.5 m monolith 
when separating a complex mixture of analytes and also to optimise gradient conditions 
for the separation of numerous target analytes. Injections of the 0.33 mg/L standard were 
made at volumes of 10, 20, 50 and 100 µL and separated over a 110 min run time at 0.2 
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mL/min, a column temperature of 45 oC and detected at a wavelength of 230 nm. A 
gradient was employed, mobile phase B ( 20 : 80 10 mM ammonium acetate : 
acetonitrile) was increased from 0 – 100% over 90 minutes and held for 20 minutes and 
a re-equilibration time back to 100% mobile phase A ( 90 : 10 10 mM ammonium 
acetate : acetonitrile) of 30 minutes. Chromatograms obtained from the experiments are 
shown in Figures 3.14 and 3.15 below. 
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Figure 3.14: Overlaid chromatograms obtained after 10 µL (----), 20 µL (----), 50 µL (----) and 100 µL (----) injections of a 
0.33 mg/L standard of 51 pharmaceuticals and illicit drugs in ultra pure water. 
 
 152 
The chromatogram in Figure 3.14 illustrates the excellent separation power of the 
coupled monoliths.  Increases in peak height relative to the increase in injection volume 
can be seen from the overlay of the signals.  An expansion of a section of the four 
chromatograms and identification of some pharmaceuticals can be seen in Figure 3.15.  
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Figure 3.15: Expansion of overlaid chromatograms in figure. Peak 1 = sulfamethazine, 
2 = trimethoprim, 3 = naproxen, 4 = ketoprofen, 5 = methadone and 6 = bezafibrate.  
 
Alternative gradient conditions were investigated for the separation of 51 
pharmaceuticals on the half-metre monolith in order to optimise the separation 
conditions before application to any real samples.  These gradients included shorter 
linear gradients and stepwise gradients over 75-140 minute time periods.  A flow rate of 
0.3 mL/min was also employed with these condensed gradients in an effort to shorten 
the run time.  However the shorter linear gradients resulted in unresolved peaks and 
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stepwise gradients did not improve the separation significantly.  The original linear 
gradient over 110 minutes at 0.2 mL/min was chosen for further work. 
 
3.4 Conclusion: 
Five monolithic columns were coupled in series and characterised using van Deemter 
experiments.  The exceptional numbers of theoretical plates and low plate heights were 
illustrated by comparison of the long monolithic column to a conventional particulate 
stationary phase.  Column efficiency was investigated at a range of temperatures and it 
was found that an 18% increase in theoretical plates could be achieved at 45 oC while 
operating at even lower backpressures.  Peak and loading capacity of the half-metre 
monolith were also investigated.  The monolith demonstrated excellent loading capacity, 
with only 10% loss of efficiency with a 200 µL injection.  The optimised method was 
then successfully applied to the separation of 51 pharmaceuticals.  High efficiency 
separations were possible at flow rates that are applicable to MS detection.  With 
coupling to a mass selective detector, this column could be applied to screening for a 
large number of forensically and environmentally relevant analytes.   
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Chapter 4.0: Application of a Half-metre Monolithic Column to the 
LC-MS/MS Analysis of Complex Environmental and Biological 
Matrices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 156 
4.1 Introduction: 
Analysis of environmental and biological matrices is of utmost importance today in 
order for scientists to better understand the occurrence, fate and effects of PPCPs in our 
environment.  LC-MS/MS has grown as a tool for biological and environmental 
monitoring in recent years.  Atmospheric pressure interface technologies such as ESI are 
perfectly suited to the analysis of polar compounds e.g. pharmaceuticals.  Matrix effects 
are the pitfall of LC-MS/MS analysis and reduce linearity, accuracy and precision of the 
analytical method.1  Ion suppression or enhancement in MS detection can be caused by 
co-elution of matrix components which have similar m/z values to analytes or, and more 
commonly, signal suppression or enhancement occurs due to interactions between 
matrix components and analytes within the ion source.2   
In the case of pharmaceuticals in aqueous environmental samples, signal 
suppression has been thoroughly investigated and it is now common practice to report 
matrix effects along with other method validation data.3-7  Matrix effects have also been 
quantified for biological matrices such as urine and a number of different preparation 
techniques have been investigated.8-10  A limited number of publications have described 
matrix effects in the extracts of solid environmental matrices, however it is a well known 
fact that the inhomogeneity and high load of organic material in solid samples leads to 
increased matrix effects despite exhaustive clean-up procedures.11-13  Pfeifer et al. 
demonstrated that antibiotics analysed using ESI was more sensitive to matrix effects 
than when detected using APCI.11  Barron et al. demonstrated higher suppression effects 
for a range of pharmaceuticals in sludge than in soil extracts, while Stoob et al. reported 
very high levels of suppression for sulphonamides in soil.12, 13 
There are several generally accepted techniques for the improvement of matrix 
effects in LC-MS/MS analysis.  The traditional method of standard addition is laborious 
and time consuming, as is preparing external calibration standards in a suitable 
replacement matrices.2, 14-16  New and improved sample separation techniques such as 
IP-LC using volatile ion-pairing agents have also been devised as a solution to the 
suppression problem with good results.17  A study in 2005 found that reducing flow rates 
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greatly reduced matrix effects in LC-MS of trace organics in wastewater.6  However, the 
most common method of quantifying analytes affected by matrix components in both 
environmental and biological samples, is the addition of structurally similar compound 
or isotopically labelled compounds to act as internal standards.9, 18-22  A number of 
studies have compared the different matrix correction techniques and while isotopically 
labelled standards are expensive, they are considered to provide the most accurate 
solution to ion suppression and enhancement.23, 24  As is obvious from this discussion, 
analytical techniques for the determination of PPCPs in environmental and biological 
samples generally involve time-consuming sample preparation and method development 
prior to analysis. 
As mentioned above, thorough optimisation of the chromatographic separation 
can help to reduce matrix effects.2, 25  An important aspect of separation development is 
the selection of a suitable column length and stationary phase.  Monolithic stationary 
phases have previously been applied to high efficiency separations of protein digests in 
capillary column format26, determination of pharmaceuticals in wastewater27 and 
analysis of antibiotics in bodily fluids.28  Samanidou et al. analysed urine samples which 
had been simply precipitated and filtered before direct injection onto the monolithic 
column.  When compared to the performance of a conventional particulate column, the 
efficiency of the monolith was excellent with almost twice the number of theoretical 
plates at the same linear velocity.28  Direct injection of urine samples was also carried 
out by Dams et al. for the detection of opiates and cocaine.  This technique reported 
little matrix effects and shortened analysis time considerably due to lack of sample 
clean-up step.9 
In this work, matrix effects in LC-MS/MS analysis of the solid environmental 
matrices soil and sludge were evaluated using a half-metre monolithic column and a 
conventional particulate column.  Alternative sample preparation techniques were 
employed for each sample type.  It is theorised that the longer stationary phase of the 
monolith serves to more efficiently separate matrix components and analytes within the 
column and therefore reduce matrix effects.  The long monolith was also applied to the 
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analysis of urine by direct injection after only minimal sample pre-treatment and 
suppression effects were also quantified.  Finally, a screening method for approximately 
40 PPCPs was applied to urine samples and a number of compounds were detected. 
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4.2 Experimental: 
 
4.2.1 Reagents and preparation of glassware and standards: 
All solvents used including acetonitrile and methanol were HPLC grade or better. 
Acetonitrile and methanol were obtained from Labscan (Dublin, Ireland). Acetone, 
dichloromethane, dichlorodimethylsilane and ethyl acetate were purchased from Aldrich 
(Gillingham, UK) as was the mobile phase additive ammonium acetate. Ammonium 
hydroxide (LC-MS additive grade) was purchased from Fluka (Steinheim, Germany). 
Reagent water was obtained from a Millipore Milli-Q water purification unit (Millipore, 
Bedford, MA, USA) and was 18.2 MΩ/cm or better.  
All pharmaceuticals purchased were ≥97% purity. Propranolol hydrochloride, 
ketoprofen, bezafibrate, indomethacin, atenolol, salbutamol, sulfamethoxazole, 
sulfapyridine, sulfamethazine sodium salt, carbamazepine, (±)-metoprolol (±)-tartrate 
salt, erythromycin, doxazosin mesylate, phenazone, nifedipine, budesonide, simvastatin, 
tamoxifen, sertraline hydrochloride, citalopram hydrobromide, amitriptyline 
hydrochloride, nortriptyline hydrochloride, cimetidine, ranitidine hydrochloride, 
tramadol hydrochloride, chloramphenicol, metformin, and clotrimazole were all 
obtained from Sigma-Aldrich (Steinheim, Germany). Trimethoprim, caffeine and 
ciprofloxacin were ordered from Fluka (Buchs, Switzerland). Cocaine hydrochloride, 
morphine sulfate salt pentahydrate, methadone hydrochloride and heroin were purchased 
under license from Sigma-Aldrich (St. Louis, MO, USA). Benzoylecgonine hydrate, 
cocaethylene, temazepam, diazepam, papaverine hydrochloride, 3,4-
methylenedioxymethamphetamine hydrochloride (MDMA), ketamine hydrochloride, 
lysergic acid diethylamide (LSD) and 2-ethylidine-1,5dimethyl-3,3-diphenylpyrrolidine 
perchlorate (EDDP) were purchased under license from Sigma-Aldrich (Poole, UK). 
All glassware utilised in the preparation of pharmaceutical and illicit drug stocks 
and standards was silanised prior to the preparation to prevent the drugs from adhering 
to glass surfaces. This was carried out by rinsing the glassware with 10% 
dichlorodimethylsilane in dichloromethane. This was followed by rinsing with 
dichloromethane and rinsing with methanol twice each. Stock solutions of 
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pharmaceuticals were prepared in methanol to a concentration of 1000 mg/L and were 
stored in a fridge at 4 oC. Working standards were prepared freshly before analysis in 
ultra pure water. Structural information of each pharmaceutical is given in Table 4.1, the 
illicit drugs are not included as they have previously been described. 
 
4.2.2 Sample collection and preparation: 
Samples of digested sludge were taken from two different wastewater treatment 
facilities. After collection these samples were frozen until required for analysis. The 
sampling site from which the sludge was obtained serves a population of approximately 
1.7 million and had a wastewater throughput of 5 x 108 L per day. The sample was a 
thermally treated granular sludge with ≥90% dried solid matter and is one of two 
biosolid fertilisers employed at the plant. The sludge sample was freeze dried to remove 
excess moisture and ground up with a mortar and pestle resulting in a low density, 
flocculent sample.  
 Soil grab samples were obtained from farmland in Ireland. The samples were 
allowed to air dry in a fridge for a week before being ground up in a mortar and pestle. 
The resulting mass was passed through a 100 µm sieve to ensure a homogenous particle 
size and comprehensive extraction of the organic sample matrix. 
 Urine samples were collected from volunteers and stored at 4 oC in the fridge 
until analysis.  For the peptide study a MassPREP digestion standard of bovine serum 
albumin was obtained from Waters Corporation (Dublin, Ireland).  The standard had 
been prepared by digesting bovine serum albumin using trypsin.  The standard was 
stored at room temperature in a sealed packet until ready for analysis as specified.   
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Table 4.1: Structural information for each target pharmaceutical 
Name Structure Name Structure 
Amitriptyline 
N CH3
CH3
 
Atenolol 
NH2
O
OH
N
H
CH3
CH3
O
 
Bezafibrate 
NHCH2CH2
O
Cl OC
CH3
CH3
OH
 
Budesonide 
O
CH3
OH
H
CH3 O
HH
O
CH2CH2CH3
CH2OHO
 
Caffeine 
N
N
N
NO
O
CH3
CH3
CH3
 
Carbamazepine 
N
NH2O
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Chloramphenicol 
N
H
Cl
Cl
OHOHO2N
OH H
 
Cimetidine 
N
H
N
CH3
S
N
NH
N
H
CH3
CN
 
Ciprofloxacin 
N
NH
N
F
O
OH
O
 
Citalopram 
O
N
CH3
CH3
F
CN
 
Clotrimazole 
N
N
Cl
 
Doxazosin 
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O
N
N
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O
CH3
CH3
NH2
N
O
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Erythromycin 
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Indomethacin 
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Ketamine 
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Ketoprofen 
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CH3O
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Metformin 
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H
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Metoprolol O CH3
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Nifedipine 
N
H
CH3 CH3
CH3O CH3O
O O
NO2
 
Nortriptyline 
N
H
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Phenazone 
CH3 N
N
CH3
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Propranolol 
O
OH
N
H
CH3
CH3
 
Ranitidine 
O
N S
N
H
N
N
H
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Salbutamol 
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CH3CH3
 
Sertraline H
H
NHCH3
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Simvastatin 
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Sulfamethazine CH3
CH3NH
S
NH2
O O
 
Sulfamethoxazole 
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O
N
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O
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Sulfapyridine 
N N
H
S
NH2
OO
 
Tamoxifen 
O CH2CH2
CH2CH3
N
CH3
CH3
 
Tramadol O
OH
N
 
Trimethoprim 
N
NNH2
NH2
OMe
OMe
OMe
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4.2.3 Extraction procedures: 
 In the case of the soil and sludge extraction, pressurised liquid extraction (PLE) was 
employed.  Depending on the type of experiment, 2.7 g or 5 g of soil or 1 g of sludge 
were weighed out and mixed with white quartz sand (analytical grade) and transferred 
directly to the stainless steel extraction cell (33 cm3).  The sample was spiked with a 
working standard of pharmaceuticals in milli-Q water at this time if required.  Any 
remaining empty space in the cell was filled with sand and the cell was tightly sealed.  
Extraction was carried out in the Dionex ASE-200 (Dionex Corporation, Sunnyvale, 
CA, USA).  The extraction solvent was 50 : 50 v/v methanol : milli-Q water and the 
resulting extract of approximately 50 mL was collected in brown glass collection vials.  
Extraction method parameters were previously optimised.12  Operating temperature and 
pressure were 60 oC and 1,500 p.s.i. respectively, heating and static periods were five 
minutes each and the flush volume was 33 cm3 over one minute.12 
 After extraction, soil samples were simply exaporated to dryness under a 
nitrogen stream at 50 oC and reconstituted in 1 mL of 90 : 10 v/v 10 mM ammonium 
acetate in water : MeCN or a 1 mg/L standard solution of pharmaceuticals in ultra pure 
water where required.  Sludge extracts, however, due to a higher organic load, required a 
clean-up/preconcentration step.  The extracts were diluted to a 1 L using milli-Q water 
and the sample solutions were adjusted to approximately pH5.  This was done using 2% 
acetic acid solution. Solid phase extraction was performed on Waters Oasis HLB 6 mL 
cartridges (Waters Ireland, Dublin, Ireland).  The cartridges were conditioned with 6 mL 
of methanol and 6 mL of milli-Q water prior to loading.  The samples were then left to 
extract on the cartridges overnight.  The sorbents were washed with 1 mL milli-Q water 
and allowed to dry for 30 minutes after loading.  The target analytes were eluted in 10 
mL of 50 : 50 ethylacetate : acetone and collected in 12 mL glass vials.  The eluates 
were then dried down under nitrogen at 50 oC and reconstituted in 1 mL of 90 : 10 v/v 
10 mM ammonium acetate in water : MeCN or a 1 mg/L standard solution of 
pharmaceuticals in milli-Q water where required.  For study of suppression effects in 
ESI-MS detection of pharmaceuticals in soil and sludge, an unspiked sample was 
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extracted using the described method, the extract was evaporated to dryness and 
reconstituted in 1 mL of a 1 mg/L standard solution of pharmaceuticals in milli-Q water. 
 Urine samples were collected from volunteers in Sterilin 50 mL centrifuge tubes 
(Bibby Sterilin Ltd, Stone, Staffs, UK) and were immediately stored in the fridge (≤4 
oC) until analysis. 1 – 1.5 mL aliquots of sample were transferred to Sterilin 1.5 mL 
centrifuge tubes (Bibby Sterilin Ltd, Stone, Staffs, UK) and centrifuged at 10,000 rpm 
for 10 minutes to remove any precipitated matter. The pH of the sample was then 
measured to ensure it was in the range pH 2-7 so as not to damage the monolithic 
column. If needed the pH was adjusted using acetic acid and ammonia solutions. Urine 
samples were then analysed neat or were spiked by evaporating 1 mL of a 1 mg/L 
standard solution of pharmaceuticals to dryness under nitrogen and reconstituting the 
residue in 1 mL of neat urine sample.  No clean-up or preconcentration procedure was 
required prior to analysis of the urine samples. 
The peptide sample was reconstituted in 100 µL of 0.1% formic acid in milli-Q water 
and vortexed.  A 10 µL injection of the protein digest was analysed on the half-metre 
monolith using UV detection at 214 nm tandem.  
 
4.2.4 Liquid chromatography-mass spectrometry: 
Liquid chromatography was carried out using five Phenomenex Onyx Monolithic 100 x 
3.0 mm i.d. columns.  The five monolithic columns were coupled in sequence using 
peek tubing and ferules resulting in a total column length of approximately 50 cm or 0.5 
m.  Previously optimized gradient conditions were 100 % 90 : 10 10 mM ammonium 
acetate acetonitrile linearly increasing organic content to 100 % 20 : 80 10 mM 
ammonium acetate acetonitrile over 90 minutes and held constant over 20 minutes. Re-
equilibration time was 20 minutes.  Separations were carried out at a flow rate of 0.2 
mL/min using an injection volume of 10 µL at an optimised column temperature of 45 
oC.  For suppression studies the monolithic column was compared to a Waters Sunfire 
150 x 2.1 mm i.d. 3.5 µm column.  Separations were carried out on the Sunfire using an 
 168 
identical method to the monolithic column except for column temperature which was 
ambient.  
LC-UV, LC-MS and LC-MS/MS analysis was carried out using an Agilent 1100 
series high performance liquid chromatograph with a vacuum degasser, binary pump, 
ALS autosampler, and diode array detector.  This LC was coupled to a Bruker Daltonics 
Esquire~LC ESI-ion trap mass spectrometer.  Detection was carried out in single and 
tandem MS modes.  Agilent chemstation version A.09.03 (Agilent Technologies, USA) 
and Bruker Daltonics esquire control version 4.0 (Bruker Daltonics, UK) were employed 
to control the system and data analysis was performed using Bruker Daltonics Data 
Analysis 3.0 (Bruker Daltonics, UK).   
In order to tune the mass spectrometer and determine the parent and precursor 
ions for each drug, individual 10 mg/L solutions of each drug made up in 100% 
methanol were infused directly into the mass spectrometer.  This was carried out using a 
Cole-Palmer syringe pump and a Hamilton micro-syringe.  Once the molecular ion was 
identified, it was fragmented to obtain the product ion for each drug in tandem MS 
mode.  During analysis definitive identification of drug residues was obtained by 
identifying the individual transitions between parent and product ions in tandem MS 
mode.  Quantitative measurements were achieved by integrating the most intense peak 
exhibited for each illicit drug.  The optimised MS conditions are listed in Table 4.2. 
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Table 4.2: ESI-MS parameters employed for analysis. 
Parameter Positive Mode 
Capillary Voltage 4500 
End Plate Offset (V) -561 
Skimmer 1 (V) 28.1 
Skimmer 2 (V) 6.7 
Cap. Exit Offset (V) 63.7 
Octopole (V) 2.51 
Octopole RF (Vpp) 155.3 
Octopole Delta (V) 1.98 
Lens 1 -2.4; -37.8 
Trap Drive 34.7 
Dry Gas Flow (N2; L/min) 8 
Nebulizer Pressure (psi) 50 
Dry Gas Temp. (oC) 300 
 
4.3 Results and Discussion: 
 
4.3.1 Mass spectromety and tandem mass spectrometry detection: 
Standard solutions containing ~1 mg/L of all analytes in methanol were infused directly 
into the electrospray source at a flow rate ~300 µL/hr in positive ionisation mode to 
determine precursor and product ions. A large proportion of the target analytes listed in 
Table 4.3 were previously investigated in our laboratory.12, 29, 30 In agreement with these 
studies, simple pseudo molecular ion [M + H]+ spectra were recorded for the majority of 
pharmaceuticals in single MS mode, e.g. atenolol, caffeine, trimethoprim and 
metoprolol.  Clotrimazole pseudo molecular ions however displayed no signal of 
significant intensity. An intense signal at m/z 277 indicated fragmentation and the loss 
of an imidazole group under MS1 conditions which most likely arose from collisionally 
induced dissociation (CID).  
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Table 4.3: Proposed precursor and product ions for target analytes in positive ion mode 
MS. 
Analyte m/z Precursor ion m/z Product ion 
Amitriptyline 278 [M + H]+ 233 [M + H]+ – [NH(CH3)2] 
Atenolol 267 [M + H]+ 190 [M + H]+ – [H2O]-[C3H7]-[NH2] 
Benzoylecgonine 290 [M + H]+ 168 [M + H]+ – [C6H5COOH] 
Bezafibrate 362 [M + H]+ 316 [M + H]+ – [HCOOH] 
Budesonide 431 [M + H]+ 413 [M + H]+ – [H2O] 
Caffeine 195 [M + H]+ 138 [M + H]+ – [CONCH3] 
Carbamazepine 237 [M + H]+ 194 [M + H]+ – [CONH] 
Chloramphenicol 345 [M + Na]+ 275 [M + Na]+ – [NO2H] 
Cimetidine 253 
275 
[M + H]+ 
[M + Na]+ 
211 [M + H]+ – [NH2-CN] 
Ciprofloxacin 332 [M + H]+ 314 
288 
[M + H]+ – [H2O] 
[M + H]+ – [CO2] 
Citalopram 325 [M + H]+ 262 [M + H]+ – [F]-[NH(CH3)2] 
Clotrimazole 277 [M – 
C3H3N2H]+ 
165 [M – C3H3N2H] – [C6H5Cl] 
Cocaethlyene 318 [M + H]+ 196 [M + H]+ – [C6H5COOH] 
Cocaine 304 [M + H]+ 182 [M + H]+ – [C6H5COOH] 
Diazepam 285 [M + H]+ 257 [M + H]+ – [CO] 
Doxazosin 452 [M + H]+ 344 [M + H]+ – [C6H4O2] 
EDDP 278 [M + H]+ 249 [M + H]+ – [C2H5] 
Erythromycin 734 [M + H]+ 576 [M + H]+ – 
[C5H4O(CH3)2(OH)(OCH3)] 
Heroin 370 [M + H]+ 268 [M + H]+ – –[CH3CO]-[CH3CO2] 
Indomethacin 358 [M + H]+ 174 [M + H]+ – [C6H4Cl-CONHCH2CH3] 
Ketamine 238 [M + H]+ 220 [M + H]+ – [H2O] 
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Table 4.3 Contd. 
Ketoprofen 255 [M + H]+ 209 [M + H]+ – [HCOOH] 
LSD 324 [M + H]+ 223 [M + H]+ – [CO-N(C2H5)2] 
MDMA 194 [M + H]+ 163 [M + H]+ – [NH2CH3] 
Metformin 130 [M + H]+ –  
Methadone 310 [M + H]+ 265 [M + H]+ – [NH(CH3)2] 
Metoprolol 268 [M + H]+ 116 [M + H]+ – [C8H8OHOCH3] 
Morphine 286 [M + H]+ 268 [M + H]+ – [H2O] 
Nifedipine 345 [M + H]+ –  
Nortriptyline 264 [M + H]+ 233 [M + H]+ – [NH2CH3] 
Papaverine 340 [M + H]+ 202 [M + H]+ –[C6H4(OCH3)2] 
Phenazone 189 [M + H]+ –  
Propranolol 260 [M + H]+ 116 [M + H]+ – [C6H4-C4H3-OH] 
Ranitidine 315 [M + H]+ 270 [M + H]+ – [NH(CH3)2] 
Salbutamol 240 [M + H]+ 166 [M + H]+ – [NH2-C(CH3)3] 
Sertraline 275 [M – 
NH2CH3]+ 
–  
Simvastatin 441 [M + Na]+ –  
Sulfamethazine 279 [M + H]+ 156 [M + H]+ – [NH2-C4HN2-(CH3)2] 
Sulfamethoxazole 254 [M + H]+ 156 [M + H]+ – [NH2-C3HNO-CH3] 
Sulfapyridine 250 [M + H]+ –  
Tamoxifen 372 [M + H]+ 327 [M + H]+ – [NH-(CH3)2] 
Temazepam 301 [M + H]+ 283 [M + H]+ – [H2O] 
Tramadol 264 [M + H]+ –  
Trimethoprim 291 [M + H]+ 123 [M + H]+ – [C6H3-(OCH3)3] 
 
Other more recently obtained pharmaceuticals were also infused and their base peak and 
fragment ions elucidated. Again, in most cases, the pseudo molecular ion was observed, 
e.g. doxazosin, tamoxifen and ranitidine, however some other base peak ions were also 
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observed. For example, the sodiated adducts [M + Na]+ of chloramphenicol, cimetidine 
and simvastatin were recorded at m/z 345, 275 and 441, respectively. Sodiated or 
potassiated adducts generally arise due to impurities in solvents used for mobile phase 
preparation.  Sertraline fragmented under MS1 conditions, losing a methylamine group 
[M – NH2CH3]+ to give a base peak at m/z 275. For simvastatin and chloramphenicol, 
the sodiated ion exhibited an intense signal, whilst for cimetidine a pseudo molecular ion 
was also present at a higher intensity and was the primary ion used in detection.  
Generally the ionisation mode used for monitoring an analyte can be predicted by its 
acidic or basic nature. It is unusual therefore that acidic drugs e.g. bezafibrate, 
ketoprofen, nifedipine, phenazone and temazepam, which have pKa values of 3.6, 4.4, 
1.0, 1.45 and 1.6, respectively can be successfully monitored in positive mode.12 
 The majority of the MS2 mode transitions involved the loss of easily identifiable 
groups from the pseudo molecular ion. One of the most common moieties to be lost was 
those containing amine, methyl amine and dimethyl amines e.g. amphetamine, atenolol, 
ranitidine, salbutamol and tamoxifen.  Substituted benzene rings are also often cleaved 
from the molecular ion during fragmentation e.g. trimethoprim, propranolol, doxazosin 
and clotrimazole.  Some similarities in fragmentation patterns were observed for related 
drug molecules.  The antidepressants amitriptyline and nortriptyline both undergo 
cleavage of an amine side-chain resulting in a shared fragment ion at m/z 233. As 
previously discussed, cocaine and its two metabolites, benzoylecgonine and 
cocaethylene all underwent a cleavage of a benzoic acid group from the 7-membered 
ring.  Metoprolol and propranolol also exhibited similar fragmentation pathways which 
lead to a shared product ion at m/z 116.  The sulfonamide antibiotics sulfamethazine and 
sulfamethoxazole both underwent fragmentation leading to the formation of a common 
product ion at m/z 156.  A third sulfonamide sulfapyridine, despite having structural 
features in common with sulfamethazine and sulfamethoxazole e.g. sulphur dioxide 
group, had no fragment ion and was monitored wholly in single MS mode.  As can be 
seen in Table 4.3 fragment ions were not observed for all analytes e.g. tramadol, 
simvastatin, sertraline, sulfapyridine and phenazone.  For this reason the sensitivity of 
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the method for these analytes was limited to single mode MS monitoring using 
molecular ions.  For calculations of analyte recovery and percentage suppression of 
pharmaceuticals, the most intense signal observed for each of the target analytes was 
integrated. The molecular ion was predominantly chosen, however in some cases 
collisionally induced dissociation of molecular ions to a fragment ion led to a more 
intense peak being observed for the fragment ion in single MS mode. This phenomenon 
occurred in particular for the illicit drugs such as MDMA and methadone whose 
fragment ions were observed as the base peak in single mode MS, not their molecular 
ions. In these cases the fragment ion was integrated instead of the molecular ion. 
 
4.3.2 Liquid chromatography-mass spectrometry of PPCPs in soil and sludge: 
A soil sample was prepared by extracting 5 g spiked with 1 mL of a 1 mg/L standard of 
pharmaceuticals in milli-Q water using 50 : 50 v/v methanol : milli-Q water as described 
above.  The extracts which had a final spiking concentration of 0.2 mg/Kg were 
analysed by LC-MS using the half-metre monolithic column.  The extraction procedure 
was very simple with no clean-up or preconcentration step required. A list of single 
mode MS extracted ion chromatograms for each of the target analytes are shown in 
Figure 4.1.  A number of the pharmaceuticals were not detected in the spiked soil 
sample e.g. amphetamine, doxazosin, budesonide, citalopram, sertraline, papaverine and 
ranitidine.  This could be due to formation of adducts between the compound and a 
matrix component resulting in a signal at a different mass being detected.  Bezafibrate 
appeared to elute very close to a large peak most likely a background signal and so 
exhibited a very weak signal in single MS mode and is not displayed in Figure 4.1. 
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Atenolol m/z = 267
Caffeine
Trimethoprim
Metoprolol
propranolol
Carbamazepine
Clotrimazole
Ketoprofen
Sulfamethoxazole
Salbutamol
Sulfamethazine
Phenazone
Nifedipine
Simvastatin
Amitriptyline
Tamoxifen
m/z = 195
m/z = 291
m/z = 268
m/z = 260
m/z = 237
m/z = 277
m/z = 255
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m/z = 189
m/z = 345
m/z = 441
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m/z = 278
Chloramphenicol
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Figure 4.1: Extracted ion chromatograms for 34 pharmaceuticals spiked into soil sample 
at a concentration of 0.2 mg/Kg.  Chromatograms marked with * not subject to tandem 
MS fragmentation. 
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Tramadol m/z = 264Nortriptyline
Morphine
MDMA
Benzoyecgonine
Ketamine
Heroin
Cocaine
Cocaethylene
LSD
EDDP
Methadone
Temazepam
Cimetidine
Sulfapyridine
Diazepam
Indomethacin
m/z = 286
m/z = 163
m/z = 290
m/z = 238
m/z = 370
m/z = 304
m/z = 318
m/z = 324
m/z = 278
m/z = 265
m/z = 301
m/z = 285
m/z = 358
m/z = 250
m/z = 253
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(ar
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Retention Time (min)
*
  
Figure 4.1 Contd.: Extracted ion chromatograms for 34 pharmaceuticals spiked into soil 
sample at a concentration of 0.2 mg/Kg.  Chromatograms marked with * not subject to 
tandem MS fragmentation. 
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Table 4.4: Chromatographic data calculated for each of the analytes in Figure 4.1. 
Name Retention time 
 (min) 
Width  
(min) 
Resolution (Rs) Capacity  
factor (k) 
Sulfamethoxazole 24.6 0.8   0.6 
Salbutamol 25.8 1.8 0.9 0.7 
Atenolol 27.8 2.9 0.9 0.8 
caffeine 27.9 1.4 0.0 0.8 
Sulfapyridine 29.3 1.25 1.1 0.9 
Cimetidine 30.2 1.3 0.7 0.9 
Benzoyecgonine 33 1.8 1.8 1.1 
Morphine 33.4 2 0.2 1.1 
Sulfamethazine 33.5 1.6 0.1 1.1 
Phenzone 36.4 1.6 1.8 1.3 
Trimethoprim 40 2 2.0 1.5 
Ketoprofen 40.8 1.5 0.5 1.5 
MDMA 43.3 3.6 1.0 1.7 
Chloramphenicol 45.7 1.6 0.9 1.8 
Metoprolol 48.6 3.8 1.1 2.0 
Tramadol 51.1 2.6 0.8 2.2 
Indomethacin 53.4 1.5 1.1 2.3 
Carbamazepine 55.7 1.4 1.6 2.4 
LSD 58.1 3 1.1 2.6 
Cocaine 58.4 2.9 0.1 2.6 
Heroin 58.8 1.8 0.2 2.6 
Propranolol 62.5 5 1.1 2.8 
Ketamine 64 1.6 0.5 2.9 
Cocaethylene 64.3 4 0.1 2.9 
Temazepam 65.1 1.5 0.3 3.0 
Nifedipine 66.8 0.9 1.4 3.1 
Diazepam 72.5 1.5 4.8 3.4 
EDDP 73.9 3.1 0.6 3.5 
Nortriptyline 78.2 3.2 1.4 3.7 
Methadone 81.3 3.4 0.9 3.9 
Amitriptyline 87.1 4.3 1.5 4.3 
Clotrimazole 88 1.2 0.3 4.3 
Tamoxifen 90.9 1.2 2.4 4.5 
Simvastatin 97 1.4 4.7 4.9 
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Table 4.4 displays chromatographic information describing the separation of the 34 
analytes listed in Figure 4.1.  Resolution and capacity factor (α) were calculated using 
Eqn. 2.1 and Eqn. 4.1, respectively.   
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From Table 4.4 it is obvious that not all pharmaceuticals were completely 
resolved from each other particularly in the case of caffeine and atenolol, morphine and 
benzoylecgonine and cocaine and heroin.  Analytes that are not adequately separated 
from one another and elute at the same retention time can result in suppression of signals 
during ESI-MS detection.  However, many of the target analytes were adequately 
resolved with values reported greater than 1.0 e.g. indomethacin and carbamazepine, 
amitriptyline and methadone and clotrimazole and tamoxifen. The low resolution values 
were mimicked by low relative retention for these groups of analytes also indicating 
incomplete separation.  Capacity factors (k) of 2-10 are desirable,31 however a number 
of the analytes showed little or no affinity for the monolithic stationary phase e.g. 
sulfamethoxazole, salbutamol, cimetidine and sulfapyridine, reporting k values of less 
than one.  Due to the length of the stationary phase even the low affinity analytes 
appeared at retention times of between 24 and 45 minutes and were in many cases well 
resolved from each other.  Later eluting compounds were well retained by the 
monolithic bed but not so much so as to over extend retention times and broaden peaks.  
As gradient and mobile phase conditions had been optimised previously (Chapter two) 
as well as column efficiency, this separation was deemed adequate taking into account 
the number of analytes and the selectivity of the detection method.  
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4.3.3 Matrix effects in soil and sludge: 
A UV chromatogram of the separation blank sludge extract on the half-metre monolith is 
depicted in Figure 4.2.  This figure illustrates the complexity and abundance of the 
matrix components present in the sample and highlights the excellent ability of the long 
column to separate them. 
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Figure 4.2: Separation of blank sludge extract on 0.5 m monolithic column at 254 nm. 
Time axis offset by 10 minutes. 
 
Two blank sample extracts were prepared as described using 2.7 g of soil and 1 g 
of sludge.  Post extraction, the samples were spiked with 1 mL of a 1 mg/L standard of 
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pharmaceuticals in milli-Q water.  The degree of analyte signal suppression in both soil 
and sludge was determined by comparing these sample extracts spiked with post 
extraction with a 1 mg/L standard as previously described.12  The pharmaceuticals 
spiked into the sample post extraction underwent none of the extraction procedures and 
so should report 100% recovery.  Any reduction in signal intensity must therefore be due 
to matrix components within the sample or coeluting pharmaceuticals which cause 
analyte suppression.  To further demonstrate the applicability of the monolithic column 
to the analysis of complex samples, the extracts were analysed on a Waters Sunfire 150 
x 2.1 mm i.d. 3.5 µm column under the same chromatographic and gradient conditions.  
Suppression is calculated as the percentage loss of analyte recovery.  Relative 
suppression of all analytes on both columns was calculated as a ratio of their respective 
absolute suppression percentages with a relative suppression of less than one indicating 
lower levels of suppression on the monolithic column.  The results of the suppression 
studies in soil are presented in Table 4.5 and the results of the suppression study in 
digested sludges are presented in Table 4.6. 
 
Table 4.5: Percentage recovery and suppression for 41 pharmaceuticals in soil. 
Calculated by comparing a soil extract spiked post extraction with a 1 mg/L standard 
solution in milli-Q water.  The shaded cells indicate those that exhibited less suppression 
on the monolithic column. 
  
% MS suppression 
 in soil 
Relative 
Suppression 
Name Sunfire Monolith  
Metformin 53 ± 24 4 ± 14 0.1 
Salbutamol -14 ± 2 -2 ± 9 0.1 
Sulfamethoxazole -2 ± 1 8 ± 24 4.5 
Atenolol 4 ± 2 5 ± 3 1.4 
Caffeine 10 ± 8 19 ± 19 1.9 
Sulfapyridine 10 ± 1 8 ± 9 0.9 
Cimetidine 15 ± 1 3 ± 7 0.2 
Sulfamethazine 12 ± 2 11 ± 5 0.9 
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Table 4.5 Contd. 
Morphine 17 ± 0 -1 ± 2 0.1 
Benzoylecgonine -9 ± 3 -5 ± 7 0.5 
Ranitidine 26 ± 2 11 ± 4 0.4 
Phenazone 10 ± 3 1 ± 6 0.1 
MDMA 2 ± 3 -33 ± 28 17.8 
Trimethoprim 12 ± 1 1 ± 7 0.1 
Metoprolol 9 ± 5 6 ± 4 0.7 
Ketoprofen 16 ± 4 14 ± 9 0.8 
Tramadol 1 ± 9 1 ± 15  
Chloramphenicol -70 ± 108 8 ± 16 0.1 
Bezafibrate 35 ± 5 18 ± 15 0.5 
Cocaine 31 ± 7 24 ± 0 0.8 
Heroin 38 ± 4 19 ± 0 0.5 
Propranolol 20 ± 1 15 ± 8 0.7 
LSD 11 ± 2 -1 ± 3 0.1 
Indomethacin 15 ± 6 6 ± 8 0.4 
Carbamazepine 14 ± 3 7 ± 7 0.5 
Cocaethylene 17 ± 9 7 ± 0 0.4 
Ketamine 13 ± 5 -3 ± 1 0.2 
Citalopram 25 ± 1 23 ± 1 0.9 
Papaverine 17 ± 1 12 ± 2 0.7 
EDDP 11 ± 0 6 ± 2 0.5 
Doxazosin 34 ± 4 38 ± 2 1.1 
Temazepam 18 ± 3 17 ± 3 1.0 
Nortriptyline 42 ± 4 43 ± 0 1.0 
Nifedipine 3 ± 31 14 ± 4 5.5 
Budesonide 20 ± 20     
Methadone 19 ± 3 17 ± 7 0.9 
Amitriptyline 40 ± 1 41 ± 2 1.0 
Diazepam 12 ± 9 9 ± 4 0.8 
Sertraline 66 ± 2 63 ± 2 0.9 
Clotrimazole 73 ± 0 67 ± 2 0.9 
Tamoxifen 72 ± 1 56 ± 6 0.8 
Simvastatin 62 ± 0 58 ± 4 0.9 
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Overall the monolith was by far the better phase for separating complex samples with an 
average suppression value for the monolith being 15% and 19% for the sunfire.  In 
general the effect of the soil matrix was quite low for the monolithic column with 
percentage suppression equal to or below 10% for half the target analytes.  This was true 
for only nine of the pharmaceuticals when separated on the Sunfire.  Of the 41 drugs 
compared in the study levels of suppression were lower for 32 drugs on the monolith, six 
analytes exhibited lower levels of ion suppression on the Sunfire column and 3 of the 
analytes were equally affected in both experiments.  Erythromycin, ciprofloxacin and 
amphetamine were not detected in the study perhaps due to complete suppression of the 
signal, however erythromycin was not present during the analysis of a drug standard 
suggesting that it was not included in preparation or had degraded.  Amphetamine was 
visible in the separation of a standard solution of the pharmaceuticals but exhibited a 
very weak signal.  This was not uncommon for the stimulant which was detected with 
difficulty during the hair study carried out in Chapter one.  The Sunfire reported 
reasonable recovery of budesonide, whilst no data was recorded for the drug when using 
the monolith.  This corresponded to the absence of budesonide from the extracted ion 
chromatograms of the spiked soil sample separated on the monolith presented in Figure 
4.1.   
High levels of suppression were spread throughout the separation though most of 
the highly affected analytes eluted near the end of the run time e.g. amitriptyline, 
sertraline, clotrimazole, tamoxifen and simvastatin.  This phenomenon could be 
explained by the high levels of organic matrix components eluting simultaneously due to 
higher organic content in the mobile phase.12  Suppression values reported as negatives 
indicate some enhancement of signals and in these cases the superior result was 
determined as being that closest to 0% suppression. This is exemplified by 
benzoylecgonine with % suppression of 109% and 105% on the Sunfire and monolith, 
respectively.  The monolith was determined to be superior as the result was closest to 
0% suppression.  Results were in some cases completely dissimilar.  On the monolith a 
high level of error (± 28) was reported for MDMA and the suppression result indicated 
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huge enhancement of the peak.  The Sunfire however, reported excellent results for this 
particular analyte with % suppression of only 2% and standard deviation of the same. 
Chloramphenicol exhibited enhancement on the Sunfire while low levels of suppression 
were reported by the monolith.  Conversely, many results were quite consistent between 
columns with suppression values for the monolith considerably lower, e.g. sulfapyridine, 
cimetidine, phenazone, trimethoprim, ketoprofen.  
 
Table 4.6: Percentage recovery and suppression for 37 pharmaceuticals in digested 
sludge. Calculated by comparing a digested sludge extract spiked post extraction with a 
1 mg/L standard solution in milli-Q water.  Cells marked n/a (not applicable) indicate 
that values could not be calculated.  The cell marked * indicates that no error could be 
calculated and the value is based on one analysis alone.  The shaded cells indicate those 
that exhibited less suppression on the monolithic column. 
  
% MS Suppression 
 in sludge 
Relative 
Suppression 
Name Sunfire Monolith  
Metformin 73 ± 4 81 ± 3 1.1 
Salbutamol 8 ± 4 19 ± 2 2.3 
Sulfamethoxazole 47 ± 1 53 ± 2 1.1 
Atenolol 12 ± 2 19 ± 1 1.6 
Caffeine 7 ± 1 21 ± 18 2.9 
Sulfapyridine 55 ± 2 54 ± 3 1.0 
Cimetidine 42 ± 1 40 ± 2 1.0 
Sulfamethazine 70 ± 1 54 ± 2 0.8 
Morphine 68 ± 2 27 ± 10 0.4 
Benzoylecgonine 19 ± 4 24 ± 5 1.3 
Ranitidine  n/a   n/a  n/a  
Phenazone 16 ± 3 15 ± 7 1.0 
MDMA 63 ± 3 37 ± 7 0.6 
Trimethoprim 45 ± 2 44 ± 5 1.0 
Metoprolol 63 ± 1 53 ± 7 0.8 
Ketoprofen 63 ± 3 44 ± 0 0.7 
Tramadol 42 ± 1 31 ± 2 0.7 
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Table 4.6 Contd. 
Chloramphenicol   n/a  n/a    n/a 
Bezafibrate 57 ± 4 33 ± 15 0.6 
Cocaine 47 ± 1 53 ± 1 1.1 
Heroin 39 ± 1 56 ± 6 1.4 
Propranolol 58 ± 1 47 ± 3 0.8 
LSD 67 ± 1 52 ± 2 0.8 
Indomethacin 60*  60 ± 13 1.0 
Carbamazepine 59 ± 8 54 ± 14 0.9 
Cocaethylene 50 ± 2 51 ± 3 1.0 
Ketamine 33 ± 3 33 ± 3 1.0 
Citalopram 73 ± 1 53 ± 1 0.7 
Papaverine 54 ± 1 49 ± 2 0.9 
EDDP 58 ± 1 50 ± 1 0.9 
Doxazosin 46 ± 2 42 ± 3 0.9 
Temazepam 58 ± 5 54 ± 7 0.9 
Nortriptyline 60 ± <1 47 ± 2 0.8 
Nifedipine   n/a   n/a   n/a 
Budesonide 23 ± 15   n/a   n/a 
Methadone 68 ± <1 42 ± 1 0.6 
Amitriptyline 56 ± 1 47 ± 13 0.8 
Diazepam 50 ± 4 49 ± 3 1.0 
Sertraline   n/a 13 ± 4   n/a 
Clotrimazole 78 ± 1 57 ± 8 0.7 
Tamoxifen 39 ± <1 46 ± 2 1.2 
Simvastatin 69 ± 2 45 ± 20 0.7 
 
Ion suppression was much more significant for pharmaceuticals in sludge extracts.  The 
average level of matrix induced ion suppression for the target analytes on the monolith 
and Sunfire columns were 43% ± 14 and 50% ± 19 respectively.  Only 37 
pharmaceuticals were compared in the sludge suppression study as ranitidine, 
chloramphenicol and nifedipine were undetected by both columns whilst budesonide and 
sertraline were undetected by the monolith and Sunfire columns, respectively.  Signals 
corresponding to chloramphenicol and nifedipine were low intensity peaks, a fact that is 
illustrated in Figure 4.1.  Ranitidine, which was also a weak responder, was undetected 
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in the spiked soil sample.  It is most likely that the complexity of the sludge matrix is the 
reason for the loss of these signals.   
 Overall the monolith reported lower levels of ion suppression for a total of 25 
pharmaceuticals out of 37 with two drugs being equally quenched by matrix components 
on both columns.  As with suppression levels in soil, ion suppression in sludge increased 
as the separation progressed perhaps due to higher acetonitrile content eluting much of 
the digested sludge organic matter. However, high levels of suppression were present 
throughout the separation, with metformin, sulfamethazine, sulfamethoxazole and 
morphine reporting very low recoveries in the early stages.  Polar matrix components 
with little or no affinity for the hydrophobic stationary phases could be the cause of such 
results.  The sludge matrix obviously contains a wide range of organic compounds 
ranging from polar to non-polar eluting throughout the run-time and affecting all target 
analytes.  The superior performance of the monolithic column is particularly prevalent 
when noting the number of analytes with percentage suppression greater than 60%.  
Only two analytes separated on the monolithic phase were suppressed to this extent 
whilst 13 analytes were on the Sunfire column.  The ability of the half-metre monolith to 
reduce suppression effects caused by complex matrices such as soil and sludge can be 
attributed to its increased capacity to separate all sample components (including matrix 
species) over a greater temporal concentration.  This was previously optimised in 
Chapter two.  The sheer length of the stationary bed may result in more efficient 
separation of the organic matrix leading to less interferents co-eluting or interacting with 
the pharmaceuticals. 
 
4.3.4 Analysis of neat urine on half-metre monolith by LC-UV-MS/MS: 
The half-metre monolith was applied to the direct analysis of PPCPs in undiluted urine 
samples using a greatly simplified sample clean-up procedure with no need for 
preconcentration.  Initially a preconcentration step was included in sample preparation; 
however this resulted in not only concentration of any drug residues within the sample 
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but also preconcentration of the matrix components and hence resulted in a much higher 
background signal and a less sensitive method.   
 Neat urine samples were prepared as described earlier, by centrifuging and 
adjusting the pH.  A direct injection of 10 µL was made onto the half-metre monolithic 
column and analysed under identical chromatographic conditions as the soil and digested 
sludge.  The separation of a neat urine sample on the 0.5 M monolith using UV detection 
at 230 nm is depicted in Figure 4.3.  From the UV chromatogram, it is clear that a large 
number of unretained species are eluted near the start of the separation which are 
unresolved.  The inset of Figure 4.3 shows an expansion of a later section of the 
separation which illustrates the excellent ability of the monolith to separate complex 
sample matrix components. 
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Figure 4.3: UV chromatogram of neat urine sample separated on the half-metre 
monolith at 230 nm. Inset: Expansion of 30 minute period of the separation, illustrating 
individual matrix components separated on long monolith. 
 
The unretained species would most likely be polar and ionic species with a high affinity 
for the polar mobile phase.  Uric acid is formed due to the breakdown of food in the 
body and is excreted in our urine.  It has a molecular mass of 168 g/mol and has 
previously been detected in a range of biological samples by LC-MS using 
predominantly negative ion mode at m/z 167.32  It has been reported that the purine 
metabolite is usually determined in negative ion mode due to better sensitivity; however 
a molecular ion is also present in positive mode at m/z 169 and a sodiated adduct at m/z 
191.32  A large peak was present at m/z 169 in three of the neat urine samples analysed 
(Figure 4.4) with smaller peaks present at m/z 191.  A fragment ion of uric acid due to 
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the loss of 43 mass units (m/z 126) has previously been used in its identification using 
negative ion mode.33  However, a peak at m/z 127 was present in positive ion mode 
analysis of the three neat urine samples which could be due to loss of the same moiety.  
The presence of the fragment ion in the single mode mass spectrum could be a result of 
collisionally induced dissociation of the parent ion in single MS mode.  This is 
illustrated by the signal at m/z 126/127 that can be seen in the mass spectrum of uric 
acid in Figure 4.4.   
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Figure 4.4: Overlaid peaks at m/z 169 thought to be uric acid in three neat urine 
samples.  Inset: MS1 spectrum at m/z 169. 
 
Two other common components of urine, creatine and creatinine which are broken down 
in the body to form uric acid have been observed at m/z 132 and m/z 114.34  Signals 
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were present at these masses in all three neat urine samples analysed and could 
theoretically represent creatine and its metabolite creatinine (Figures 4.5 and 4.6). 
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Figure 4.5: Overlaid peaks at m/z 114 thought to be creatinine in three neat urine 
samples.  Inset: MS1 spectrum at m/z 114. 
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Figure 4.6: Overlaid peaks at m/z 132 thought to be creatine in three neat urine samples.  
Inset: MS1 spectrum at m/z 132. 
 
Creatinine, creatine and uric acid are all absorbent in the UV range and had similar 
retention times to the large signal at the beginning of the UV chromatogram in Figure 
4.3 indicating they could be elements of the weakly retained urine matrix.  These 
substances are just a few of the many which could be eluted quickly from the monolithic 
column.  Other unretained components could include urea, carbohydartes or ions such as 
chloride, potassium and calcium. 
Figure 4.7 presents the base peak chromatogram of second neat urine sample 
separated on the monolithic column.  This diagram illustrates the high efficiency 
separation of all ionisable groups present in the urine sample.  
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Figure 4.7: Base peak chromatogram of neat urine sample analysed on the half –metre 
monolith. 
 
4.3.5 Liquid chromatography-mass spectrometry of PPCPs in urine and ion suppression 
study: 
Spiked urine samples were prepared by drying down 1 mL of a 1 mg/L standard solution 
of PPCP’s in milli-Q water and reconstituting in 1 mL of neat urine sample.  The 
complete separation of 38 illicit drugs and PPCP’s spiked into urine is shown in Figure 
4.8. 
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Figure 4.8: Extracted ion chromatograms of 38 illicit drugs and PPCP’s spiked into 
urine at a concentration of 1 µg/mL.  The axis is offset by 4 minutes.  The analytes are in 
order of retention time and are as follows: salbutamol, atenolol, caffeine, sulfapyridine, 
cimetidine, morphine, benzoylecgonine, sulfamethazine, ranitidine, phenazone, 
trimethoprim, ketoprofen, MDMA, bezafibrate, metoprolol, tramadol, indomethacin, 
carbamazepine, cocaine, LSD, heroin, propranolol, papaverine, cocaethylene, ketamine, 
doxazosin, temazepam, nifedipine, citalopram, diazepam, EDDP, nortriptyline, 
methadone, amitriptyline, sertraline, clotrimazole, tamoxifen and simvastatin. 
 
As with the soil and sludge samples, budesonide, erythromycin and ciprofloxacin were 
undetected during the separation of spiked urine.  Chloramphenicol, which also 
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exhibited weak signals in spiked soil samples and disappeared completely in the sludge 
matrix, was also absent from the spiked urine sample.  More unusual was the absence of 
metformin and sulfamethoxazole were easily identified in previous complex samples.  
Both of these drugs elute at the beginning of the separation with retention times in a 1 
mg/L standard of 21.5 and 23.6 minutes respectively.  Due to their short residence time 
on the column they could have been subject to complete ion suppression by the 
abundance of weakly retained matrix compounds.  Due to the high concentration of 
sodium and potassium ions present on urine, sodiated and potassiated adducts of these 
two drugs were investigated as possible ions for their detection. However, no ions were 
present for either species at the [M + Na]+ or [M + K]+ mass.   
The effects of ion suppression in urine were studied by analysing a spiked urine 
sample already described and comparing the resultant peak heights to those in a 1 mg/L 
standard of the 38 illicit drugs and PPCP’s.  The results of the suppression study are 
presented in Table 4.7.  
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Table 4.7: Percentage relative recovery and percentage suppression values for 38 illicit 
drugs and PPCP’s spiked into undiluted urine at concentration of 1 µg/mL.  Values 
calculated by comparing spiked urine sample with a 1 mg/L standard solution in milli-Q 
water. 
Name 
% Suppression 
 of pharmaceuticals 
in urine 
Name 
% Suppression 
 of pharmaceuticals 
in urine 
Salbutamol 27 ± 5 LSD 1 ± 5 
Atenolol 26± 5 Heroin 8 ± 5 
Caffeine 46 ± 8 Propranolol -7 ± 1 
Sulfapyridine 28 ± 4 Papaverine -8 ± 2 
Cimetidine 42 ± 2 Cocaethylene -3 ± 5 
Benzoylecgonine 16 ± 1 Ketamine -11 ± 19 
Sulfamethazine 26 ± 1 Doxazsoin 7 ± <1 
Morphine 11 ± 2 Temazepam 12 ± 3 
Ranitidine 9 ± 3 Nifedipine -18 ± 24 
Phenazone 7 ± <1 Citalopram -7 ± 6 
Trimethoprim 10 ± 2 Diazepam 1 ± 3 
Ketoprofen 4 ± 19 EDDP -7 ± 5 
MDMA -18 ± 40 Nortriptyline 1 ± <1 
Bezafibrate 36 ± <1 Methadone -2 ± 1 
Metoprolol 8 ± 5 Amitriptyline -3 ± 12 
Tramadol -3 ± 2 Sertraline 8 ± 5 
Indomethacin 33 ± 1 Clotrimazole 4 ± 13 
Carbamazepine 10 ± 2 Tamoxifen 48 ± 5 
Cocaine <1 ± 4 Simvastatin 3 ± 17 
 
Overall the suppression effects in undiluted urine were quite low with 28 out of 38 target 
analytes reporting recoveries ≥80%.  However, some analytes were strongly suppressed 
e.g. caffeine, cimetidine and tamoxifen reported ion suppression of 46, 42 and 48 %, 
respectively.  Suppression in urine was generally less than that in soil and sludge with an 
average ion suppression value of 11% ± 22.  The lower suppression value in urine may 
be due to less organic matter eluting late in the separation.  These compounds are 
thought to be responsible for much of the signal interferences in environmental samples 
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such as soil and sludge.  Conversely the higher suppression values in urine were noted at 
the beginning of the separation due to unretained polar and ionic species.  The second 
half of the separation was relatively suppression free with only two analytes reporting 
recoveries <90% from 55 minutes onwards.  The retention time of the analytes was also 
monitored during the suppression study in order to highlight any retention shifts that 
occurred due to endogenous compounds.  All target analytes reported changes in 
retention time compared to retention time in a standard of ≤0.2 minutes except for 5 
analytes.  Consequently these included some of the most severely suppressed analytes 
e.g. cimetidine and atenolol. 
 
4.3.6 Application of half-metre monolith to screening of drugs in urine: 
Samples were injected as described before with no dilution or preparation apart from 
centrifugation.  The urine was centrifuged to remove any precipitants and the pH was 
checked to ensure it adhered to the operating guidelines of the monolith.  1 mL aliquots 
of neat urine were transferred to HPLC vials and 10 µL injections were made for LC-
MS analysis.  Three different urine samples were analysed in this way, one urine sample 
assumed to be blank containing no pharmaceutical residues, one from a recreational drug 
user and one from the sufferer of a kidney infection.  The blank sample contained no 
therapeutic or illicit drugs but traces of caffeine were detected in the sample despite high 
levels of ion suppression being reported for caffeine in the earlier study.  The extracted 
ion chromatograms of the parent and product ions for caffeine are shown in Figure 4.9.  
The signal for the fragment ion of caffeine at m/z 138 was quite weak but the MS2 
spectrum confirmed its presence.  It should be noted that only 10 µL of urine was 
injected for this analysis. However, as discussed in Chapter 3 of this work, the half-
metre monolithic column had a high sample loading capacity with only 10 % loss of 
efficiency at an injection volume of 200 µL.  The urine sample matrix would obviously 
decrease the loading capacity of the column however; it would be possible to increase 
the injection volume to a certain extent if better sensitivity was required.  
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Figure 4.9: Detection of caffeine in undiluted urine sample using half-metre monolith.  
Inset illustrates the proposed fragment ion at m/z 138 and shows MS1 and MS2 spectra 
for both the parent and product ions.  
 
The second urine sample contained traces of the cocaine metabolite benzoylecgonine.  
There were no traces of cocaine itself or the product of cocaine and ethanol consumption 
cocaethylene which was also included in the study.  However, this was not thought to be 
unusual as studies have shown that cocaine has a very short half-life and is rapidly 
converted to benzoylecgonine and a range of seven other metabolites once ingested.35  In 
studies of urinary excretion levels, benzoylecgonine was shown to be present at the 
highest concentration and was present in urine samples collected several days after 
consumption of the cocaine. Conversely the majority of cocaine was excreted within the 
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first two hours due to its extremely short half-life within the body.36  The urine sample in 
question was collected up to 24 hours or more after consumption of cocaine; therefore 
the detection of benzoylecgonine is not surprising.  The presence of the benzoylecgonine 
in the urine is illustrated in Figure 4.10.  This result demonstrates that benzoylecgonine 
is a good indicator of cocaine usage that allows for wider collection period for the 
specimen. 
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Figure 4.10: Detection of benzoylecgonine in undiluted urine sample using the half-
metre monolith.  Inset illustrates the proposed fragment ion at m/z 168 and shows MS1 
and MS2 spectra for both the parent and product ions.  Time offset for better view of 
fragment ion. 
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Lastly, the urine of a volunteer who had suffered a kidney infection was analysed and 
two antibiotics used to treat the condition were detected.  Trimethoprim and 
ciprofloxacin were both found in the urine sample and the results of the study are shown 
in Figures 4.11 and 4.12 respectively.  The signals for both analytes were very intense, 
in the 106 – 10 7 intensity range. 
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Figure 4.11: Detection of trimethoprim in undiluted urine sample using the half-metre 
monolith.  Inset illustrates the proposed fragment ion at m/z 123 and shows MS1 and 
MS2 spectra for both the parent and product ions. 
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Figure 4.12: Detection of ciprofloxacin in undiluted urine sample using the half-metre 
monolith.  Inset illustrates the proposed fragment ions at m/z 314 and m/z 288 in the 
MS1 spectrum due to CID. 
 
Ciprofloxacin was undetected by LC-MS/MS when separating a mixed 1 mg/L standard 
solution of all the illicit drugs and PPCP’s. It was also absent during analysis of the 
spiked urine sample.  When preparing the ciprofloxacin stock solution in methanol at a 
concentration of 1000 ppm, there were issues with solubility of the antibiotic.  This may 
have caused its absence and could have been due to the fact that pure ciprofloxacin had 
been purchased from Sigma Aldrich and not ciprofloxacin hydrochloride.  The analyte 
may have precipitated out of solution or may have been suppressed due to the sheer 
number of other pharmaceuticals present in solution.   
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Therefore there was no standard retention time available to match with the peak found in 
the real sample of urine.  To remedy this, two fragment ions of ciprofloxacin instead of 
just one were monitored in tandem MS mode.  Also a 10 mg/L standard solution of 
ciprofloxacin in milli-Q water was analysed by LC-UV under optimized conditions at 
280 nm37 to confirm the detection of ciprofloxacin at 37.7 minutes.   
The fragment ions of ciprofloxacin that were monitored were at masses of m/z 314 and 
288.  These ions were present at a much higher intensity in single MS mode than in 
tandem MS mode due to collisionally induced dissociation (CID).  In Figure 4.12 only 
the single mode mass spectrum is presented as it clearly illustrates the presence of both 
product ions.  The average retention time recorded for the ciprofloxacin peak was 38.84 
minutes.  This result confirmed the presence of ciprofloxacin in the urine sample and 
distinguished it as the second larger peak in the spectrum (Figure 4.12) and not the 
smaller sharper peak present at approximately 30 minutes.  The slight variation in 
retention times between the standard and urine analysis can most likely be explained by 
the instrument variation as the retention time test was carried out on an alternative 
HPLC system to other analyses or could be an effect of matrix components. 
Ciprofloxacin and trimethoprim were also detected in the UV spectrum during 
the analysis of the urine sample.  The ciprofloxacin and trimethoprim peaks can be 
clearly seen in the UV spectrum overlaid with the extracted ion chromatograms from 
mass spectrometric detection in Figure 4.13. 
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Figure 4.13: UV chromatogram of neat urine at 230 nm overlaid with extracted ion 
chromatograms for ciprofloxacin and trimethoprim at m/z 332 and m/z 291, 
respectively. 
 
In previous studies of antibiotics in urine, a substantial amount of preparation has been 
required including SPE.38  In some cases UV detection could not be used despite the 
sample clean-up.  However, in these studies, only trace amounts of the pharmaceuticals 
were present in the samples.  The concentrations of analytes separated in these studies 
are quite high and so future work might include validation of the separation method and 
calculation of detection limits. 
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4.4 Conclusions: 
This work has demonstrated that long monolithic columns are an efficient stationary 
phases for application to LC-MS/MS analysis of PPCPs in environmental and biological 
matrices.  Matrix effects, though not eliminated were considerably lower for analytes 
separated on the monolith than on a more conventional particle HPLC phase.  Coupled 
monoliths could also reduce the amount of time spent on sample pretreatment by 
allowing direct injection of biological samples.  Urine samples were screened for a large 
number of pharmaceutical analytes and several were identified.  Future work may 
include validation of the multi-residue method for quantification of a large number of 
environmentally and forensically relevant compounds without sample preparation. 
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Final Conclusions: 
It is clear from this study that PPCPs are present in quite substantial concentrations in 
many environmental matrices.  Further research is needed to determine other 
pharmaceutical residues that have not yet been investigated.  Although not covered 
under this work, techniques for removal of PPCPs from WWTPs and drinking water are 
also receiving a lot of attention.  These techniques need to be thoroughly monitored to 
ensure that the relevant compounds are being eliminated.  Persistence of pharmaceutical 
compounds in the environment is a major issue and more focus is needed in this area to 
determine the long term effects of non-degrading medicinal drugs.  Biological analysis is 
important to determine the effects of these pollutants on animal and human life and to 
monitor the metabolites also being excreted into the environment.  LC-MS/MS is the 
technique of choice, however matrix effects and laborious sample preparation processes 
continue to limit its applicability to all samples. 
 Monolithic stationary phases have been characterised as highly efficient 
separation media for HPLC analysis.  Multi-residue analytical techniques are becoming 
more popular due to the comprehensive approach and determination of several 
therapeutic families of compounds in one run.  Monolithic stationary phases have yet to 
be applied to multi-residue analysis of PPCPs in solid environmental and biological 
matrices.  The reduction in ion suppression illustrated in this study may allow for less 
time spent on sample preparation. 
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